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GENERAL INTRODUCTION 
 
Alzheimer’s disease (AD) is a neurodegenerative disorder that affects the elderly. One 
of the main characteristics of AD is the presence of extracellular protein deposits, 
consisting of amyloid-β (Aβ), a peptide produced by the proteolytic processing of the 
amyloid-β precursor protein APP. Although APP is an important protein since its 
pathological processing is directly linked to AD, the normal physiological role of APP 
is still elusive. In this thesis, we used the Xenopus intermediate pituitary cell to study 
APP and a related protein, the amyloid-β precursor-like protein APLP2. Furthermore, 
stable Xenopus transgenesis was employed in order to gain more insight into the 
physiological roles of APP and APLP2. The following provides an introduction to the 
topics dealt with in this thesis. 
 
Alzheimer’s disease 
The neurodegenerative disorder AD was first described by Alois Alzheimer in 1907 
[1]. The prevalence of AD increases with age, affecting 10-20% of the population 
above 85 years [2,3]. AD can be determined only post-mortem by the presence of two 
morphological features, namely neurofibrilary tangles and neuritic plaques. The major 
constituent of the neurofibrilary tangles is a hyperphosphorylated form of the protein 
Tau. Tau is a multifunctional microtubule-associated protein that plays an essential 
role in the assembly and stabilization of microtubules [4]. Furthermore, tau has been 
reported to be involved in neurite outgrowth [5] and signal transduction [6]. The 
mechanisms that cause the hyperphosphorylation of Tau in AD patients however 
remain unclear. The second hallmark of AD is the occurrence of neuritic plaques, 
which are extracellular protein deposits that mainly consist of the 40-42 amino acid 
peptide Aβ [7]. The mechanisms that cause the formation of Aβ in AD patients 
remain elusive and it is not clear whether the generation of Aβ is part of normal 
physiology. Furthermore, it is still unclear if the neurofibrilary tangles and neuritic 
plaques observed in the brains of AD patients are a cause or a consequence of this 
neurodegenerative disorder. 
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Genetic aspects of AD 
Although the majority (>80%) of AD patients exhibit the first clinical symptoms at 
the age of >70, occasionally the conditions develop before the age of 60. This has led 
to the discrimination of two types of AD: early-onset familial AD and late onset AD. 
As implicated by the definition of early-onset familial AD, it encloses a genetic 
component. Three genes have been directly linked to familial AD, namely the APP 
gene itself (located on chromosome 21), the presenilin 1 gene (PS1; chromosome 14) 
and the presenilin 2 gene (PS2; chromosome 1). Although the first mutations linked to 
AD were found in the APP gene [8-11], they are estimated to account for only ~5% of 
all the familial AD cases [12]. The majority of mutations are found in the PS1 and, to 
a lesser extent, PS2 genes [12-16]. To date, a total of 16 rare, autosomal dominant 
mutations have been found in the APP gene, 140 in the PS1 gene and 10 in the PS2 
gene [17]. All these mutations are assumed to cause an increase in the formation of 
Aβ, since mutations in the APP gene are located in the region encoding Aβ, while the 
presenilins are involved in the processing of APP to Aβ.  
In the same year that the first early-onset familial AD mutation was found, a genetic 
linkage of late onset AD was found on chromosome 19 [18]. Two years later, a 
polymorphism was found in the gene encoding apolipoprotein E in the same 
chromosomal region associated with an increased risk for late-onset AD [19,20]. 
Apoliprotein E is involved in cholesterol metabolism [21] and the gene encodes three 
different isoforms that differ only in two amino acid positions (ApoE2, ApoE3 and 
ApoE4). Individuals carrying the ApoE4 allele were found to have an increased risk of 
developing AD [20], although the presence of this allele is only a risk factor and in 
itself not sufficient to cause AD. 
Besides these four well-established genetic risk factors, a number of other genes have 
been implicated in the pathology of AD. All of these genes encode proteins that are 
somehow involved in the processing of APP to Aβ, or in the degradation of Aβ 
species. These studies have recently been reviewed by Tanzi and Bertram [17]. 
 
The APP superfamily 
APP has been identified in many vertebrate species, including human [22], mouse 
[23], rat [24], Xenopus [25] and zebrafish [26]. Furthermore, two proteins closely 
related to APP occur: the amyloid-β precursor-like proteins APLP1 and APLP2. 
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Whereas APP has been described in a number of vertebrate species, APLP1 and -2 
have thus far been identified only in mammals [27-31]. Invertebrates contain a single 
APP protein, designated APL-1 in C.elegans [32] and APPL in Drosophila [33]. 
These invertebrate proteins are thought to represent the ancestral forms of the APP 
superfamily members known in vertebrates. 
Both APP and the APLPs are type I transmembrane proteins that consist of a signal 
peptide sequence, a large amino-terminal luminal/extracellular domain, a membrane-
spanning region and a highly conserved short cytoplasmic tail (Figure 1). The luminal 
portions of all superfamily members contain conserved zinc-binding [34], heparin-
binding [35] and collagen-binding domains [36]. Other domains, such as a second 
heparin-binding domain [37], a copper-binding region [38,39], a Kunitz protease 
inhibitor (KPI) domain [40,41] and a chondroitin sulphate glycosaminoglycan 
attachment site [41-44] are present only in APP and APLP2, and not in APLP1. 
Furthermore, eleven conserved cysteine residues are present in the N-terminal domain 
of all superfamily members. The cytoplasmic tails are highly conserved between all 
members and contain a GTP-binding protein (G0) binding site [45] and the NPxY-
motif implicated in clathrin-coated vesicle targeting [46]. Finally, APP contains two 
features that are not present in the other family members, namely a growth-promoting 
region [47,48] and the amyloid-β sequence that is involved in the pathology of AD.  
In human, the gene encoding APP consists of 18 exons, of which exons 7 and 8 are 
alternatively spliced, resulting in three major APP isoforms of 695, 751 and 770 
amino acid residues [22,49,50]. In addition, another APP isoform that lacks exon 15 
(designated L-APP) has been described [44]. The APP protein is ubiquitously 
expressed, although the distribution of the different isoforms varies between tissues. 
In mammals, the APP695 protein, lacking the alternatively spliced KPI domain 
(encoded by exon 7), is mainly expressed in neuronal tissues [24,51,52], whereas the 
two other forms of APP (APP751/770) are predominantly expressed in non-neuronal 
tissues [53-57]. The L-APP variant shows a ubiquitous expression pattern in rats, 
including brain but not in neurons [55]. The human APLP2 gene has first been 
described in 1994 [58] and is assigned to chromosome 11 [59]. Like APP, the APLP2 
gene consists of 18 exons and the APLP2 protein is ubiquitously expressed.  
General Introduction 
11 
Alternative splicing of exon 7 (encoding the KPI domain) and exon 14 results in four 
different APLP2 isoforms. Compared to APP, the tissue-distribution of these four 
isoforms is different in that the APLP2 forms containing the KPI domain are 
predominantly expressed in both neuronal and non-neuronal tissues [41]. The gene 
encoding APLP1 has been assigned to chromosome 19 [31] and comprises 17 exons, 
that have not been found to be alternatively spliced. In comparison to APP and 
APLP2, the exon encoding the KPI domain is lacking in the APLP1 gene. Whereas 
APP and APLP2 share a ubiquitous expression pattern, APLP1 is expressed only in 
neuronal tissues [60]. 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
During trafficking through the secretory pathway, the APP superfamily members are 
subject to a number of post-translational modifications. Mammalian APP has been 
found to undergo both N- and O-linked glycosylation [61-64] and tyrosine sulphation 
[64]. Like APP, mammalian APLP1 and -2 are also both N- and O-glycosylated 
[65,66]. Furthermore, some isoforms of APP and APLP2 contain a chondroitin 
sulphate glycosaminoglycan attachment site [42,44]. Besides glycosylation, the APP 
superfamily members can undergo phosphorylation. The mammalian APP sequence 
contains several potential phosphorylation sites that have been shown to be 
phosphorylated in transfected cell lines [67-71]. Similar to APP, conserved potential 
phosphorylation sites have also been reported to be phosphorylated in APLP1 and -2 
[72]. These post-translational modifications have been implicated to be somehow 
Figure 1 The APP superfamily 
Schematic representation of the members of the APP superfamily. Depicted are the predicted
signal peptide (SP), the large N-terminal domain, the transmembrane region (TM) and the
cytoplasmic tail (CT). The various domains are presented as gray boxes. For APLP1 and -2,
the percentages of amino acid sequence identity between these domains and those of APP
are indicated. For APP, alternatively spliced exons 7 (encoding the KPI domain) and 8 are
depicted below the molecule, and for APLP2, exons 7 and 14 are shown. 
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involved in the trafficking, targeting and processing of these proteins and have 
therefore been directly or indirectly associated with the proper physiological 
functioning of these molecules [63,65,73-80]. 
 
Proteolytic processing of APP and APLPs 
Following their maturation (i.e. glycosylation and phosphorylation), the APP 
superfamily members can be proteolytically processed by a group of enzymes called 
secretases. Pathological processing of APP to the neurotoxic peptide Aβ involves 
cleavages by β- and γ-secretase, whereas the processing of APP by α-secretase 
prevents the formation of Aβ and is thought to represent the physiological cleavage 
(Figure 2A) [81]. The α-secretase cleavage of APP yields a large N-terminal fragment 
called APPsα, that is secreted into the extracellular space [82,83], and a membrane-
associated C-terminal fragment called C83. The β-secretase cleavage of APP also 
results in a secreted N-terminal fragment (APPsβ) and a membrane-tethered fragment 
termed C99. Both C83 and C99 may be substrates for further processing by the γ-
secretase enzyme, resulting in the release of the cytoplasmic domain, also known as 
the APP intracellular domain AICD. Besides AICD, the processing of C83 by γ-
secretase results in a fragment called p3, while γ-cleavage of C99 yields the Aβ-
peptide that is involved in AD (Figure 2A). While α- and β-secretase cleavage of the 
APP molecule take place at a single site, the intra-membranous cleavage by γ-
secretase can occur at several residues (Figure 2B). The two main γ-cleavage sites are 
after valine residue 636 (numbering according to the APP695 isoform) resulting in an 
Aβ species of 40 amino acids (Aβ40), and alanine residue 638, yielding Aβ42. 
Whereas Aβ40 represents the more soluble form of Aβ, Aβ42 is more prone to form 
fibrils and therefore plays a key role in plaque formation [84]. Moreover, γ-secretase 
cleavages of APP at other positions have been reported, resulting in Aβ forms of 34, 
36, 37, 38 or 39 amino acid residues [85], although their levels are low relative to the 
40- and 42- peptide forms. Besides the well-established α-, β- and γ-cleavages, 
proteolytic processing of APP at a number of other positions has also been reported. 
The so-called δ-cleavage of APP at position Thr584 has thus far been described only 
in hippocampal neurons [86]. More recently, ε- and ζ-cleavages, occurring at 
positions Leu645 and Val642, respectively, have been reported and, like γ-secretase 
cleavage, shown to be presenilin-dependent [87,88]. The latter two also result in 
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AICD-like fragments that might have different properties compared to the AICD 
fragments generated by regular γ-secretase cleavage [89]. 
 
 A 
  
 
 
 
 
 
 
 
 
 
 
 B 
 
 
 
 
 
 
 
 
 
 
 
The proteolytic processing of APLP1 and APLP2 has been studied to a much less 
degree than that of APP, presumably since these two proteins do not contain the Aβ 
sequence. Large secretory fragments corresponding to α- and β-secretase processing 
products of both APLP1 [66] and APLP2 [90] have been detected in media of 
transfected cells. Furthermore, C-terminal fragments of both APLP1 and -2 resulting 
    
 
 
 
 
 
   
Figure 2 Proteolytic processing of APP 
A) Processing of APP by α-secretase results in a large secreted N-terminal domain, APPsα, 
and a C-terminal fragment called C83, that can subsequently be processed by γ-secretase 
within its membrane yielding p3 and the APP intracellular domain AICD. Pathological
processing of APP by β-secretase yields APPsβ and a C-terminal fragment C99 which can be 
further processed by γ-secretase to Aβ and AICD. SP: signal peptide, TM: transmembrane 
region, CT: cytoplasmic tail. 
B) Amino acid sequence of the region within APP that is proteolytically processed by the
secretase enzymes. Arrows indicate the sites of α-, β-, γ-, δ-, ε- and ζ-cleavages. The amino 
acid residues that are located within the transmembrane region are underlined. 
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from α-, β-, γ- and ε-like cleavages have been reported [91-93]. The C-terminal 
fragments of the APP superfamily members may be substrates for caspase cleavage 
[94-96], yielding small neurotoxic peptides of ~ 31 amino acids [95,97]. 
 
Secretases 
Since the enzymes involved in the proteolytic processing of APP are directly or 
indirectly responsible for the amount of Aβ generated, they might provide therapeutic 
targets and have therefore been subject to extensive research over the last decade. 
This has led to the identification of the genes encoding the secretase cleavage 
enzymes. The α-secretase cleavage of APP resembles that of a number of other 
integral membrane proteins, for instance of the growth factors TGF-α and TNF-α 
[98]. Like for APP, the processing of these factors consists of a constitutive 
component and a regulated component that can be activated by protein kinase C 
[73,99,100]. It is therefore likely that the α-secretase processing of APP involves 
more than one protein. Proteases with proposed α-secretase function belong to the 
ADAM (a disintegrin and metalloproteinase) family of proteins that includes ADAM9 
[101], ADAM10 [102] and ADAM17, also known as TACE [103]. Since α-secretase 
cleavage of APP prevents the formation of Aβ, increasing the activity of these 
enzymes might be a therapeutic strategy in the treatment of AD [104]. 
Independent research from four groups has led to the identification of a single enzyme 
responsible for the processing of APP at the β-secretase site, namely the beta-site APP 
cleaving enzyme BACE1 [105-108]. Studies using mice lacking the gene encoding 
BACE1 confirmed that this enzyme is really involved in the β-secretase cleavage of 
APP in vivo [109] and, more recently, also in that of APLP2 [110]. Besides BACE1, a 
related aspartyl protease called BACE2 has been implicated in the proteolytic 
processing of APP in vitro, although for this enzyme, the cleavage site within the APP 
molecule is not clear.  
Whereas some studies report BACE2 cleavage of APP at the β-secretase cleavage site 
[111,112], others have found that BACE2 cleaves APP adjacent to the α-secretase 
cleavage site [113,114]. A direct comparative analysis of BACE1 and -2 implicated 
an involvement of BACE1, but not of BACE2, in the β-secretase cleavage of APP and 
thus in the formation of Aβ [115]. 
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The enzyme responsible for the γ-cleavage of APP has received most attention, 
presumably since it is involved in the final step of Aβ formation. For a long time, the 
only proteins known to be directly involved in γ-secretase cleavage of APP were the 
two homologous presenilins PS1 and PS2, also known for their genetic linkage to 
numerous familial AD cases [15]. The presenilins are eight-membrane-spanning 
proteins that resemble aspartyl proteases [116]. Targeted disruption of the PS1 gene in 
mice led to a severe reduction in the amount of Aβ [117]. Furthermore, in mice 
lacking both PS1 and PS2, the generation of Aβ was completely abolished [118,119]. 
Despite the direct involvement of presenilins in γ-secretase cleavage, evidence was 
emerging that these proteins could not be solely responsible for the γ-secretase 
cleavage of APP [118,120]. Subsequently, three other essential components of the γ-
secretase complex have indeed been identified, namely the type I integral membrane 
glycoprotein nicastrin, the predicted seven-transmembrane protein APH-1 and the 
small double membrane-spanning protein PEN-2 [121-124]. These four proteins are 
assembled into the active γ-secretase complex in a 1:1:1:1 ratio and in a highly 
regulated manner (reviewed by Periz and Fortini [125]). Besides APP, at least 15 
other proteins are processed by the γ-secretase complex, including APLP1 and -2 [91] 
and the developmentally important protein Notch [126]. Since there are two 
presenilins and three APH-1 variants, six separate γ-secretase complexes can occur 
depending on the tissue distribution and expression of the individual subunits [127]. 
Furthermore, the composition of the various γ-secretase complexes is thought to 
determine the specificity for their substrates [128]. Together, the secretases are key 
players in the processing of APP to Aβ and agents that regulate the activity of these 
enzymes might therefore be interesting targets for drug development. However, some 
caution is required, since proteolytic processing of APP also occurs under normal 
physiological conditions. Thus, affecting this processing may also cause abnormal 
functioning of APP. Furthermore, APP is not the only protein that is proteolytically 
processed by these enzymes, increasing the risk of side effects when inhibiting or 
increasing their activity [129]. 
 
Functions proposed for APP and APLPs 
Although the pathways involved in the pathological processing of APP to Aβ are well 
established, the normal physiological role of APP (and that of APLP1 and -2) still 
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remains poorly understood, despite research for over more than 15 years. Initially, 
roles as a cell-surface receptor [22] or in cell adhesion [24] have been attributed to 
APP. Furthermore, APP has been shown to have neuroprotective [130,131] and 
synaptic functions [132]. More recently, APP was suggested to function as a cargo 
receptor in kinesin-mediated axonal transport [133] and shown to be transported in 
membranous axonal organelles that also contain BACE1 and PS1 [134]. The latter 
finding however is contradicted by a recent publication in which PS1 and BACE1 
were found not to be cotransported with APP in the sciatic nerves of mice [135]. 
Finally, several functions for the fragments derived from the proteolytic processing of 
APP have been reported. The large secreted N-terminal domains generated by the α/β-
secretase cleavages have been shown to act as a growth factor (reviewed by Mattson 
[54]), whereas the AICD fragment generated by γ/ε-secretase cleavage is thought to 
be involved in transcriptional regulation by forming a transcriptionally active complex 
with Fe65 and the histon acetyltransferase Tip60 [136]. 
For its proper functioning, the interaction of APP with other proteins might be 
required. Especially the C-terminal region of APP harbors a number of binding sites 
for other proteins. In particular, APP has been found to interact with X11, Fe65, 
mDab, c-Abl-1, Shc, JIP-1, Numb and Grb2 (reviewed by Russo et al. [80]). These 
interactions may be involved in either the physiological or the pathological 
functioning of APP. For instance, X11 stabilizes APP, preventing processing by β- 
and γ-secretase [137], whereas the interaction of APP with Fe65 regulates Aβ 
formation, its transcriptional activities or even cell movement [79,136,138]. Some of 
these interactions occur only when the C-terminal fragments of APP have been 
phosphorylated [79,139], emphasizing the importance of this post-translational 
modification for the functioning of APP. 
The physiological roles of APLP1 and -2 remain also elusive. Besides structural 
homology, members of the APP superfamily might share similar functions. 
Analogous to APP, the APLPs have also been implicated to function as a cargo 
receptor in kinesin-mediated transport [140]. Furthermore, the large N-terminal 
domains of APLP1 and –2 have been found to be secreted [66,90] and, for APLP2, to 
stimulate neurite outgrowth [141]. The intracellular domains of APLP1 and -2 are also 
thought to be involved in transcriptional regulation [91]. For APLP2, a role has been 
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proposed in chromosome replication and/or segregation, a function that has not been 
attributed to APP and APLP1 [142].  
The generation of mice lacking either one or more of the APP superfamily members 
has supported the hypothesis that APP and the APLPs serve essential but partially 
redundant functions [143,144]. Mice lacking either APP, APLP1 or APLP2 were 
viable and showed only minor abnormalities [143-146]. In contrast to the minor 
phenotype observed in single knock-outs, APP-/- APLP2-/- and APLP1-/- APLP2-/- 
double mutants showed perinatal lethality, suggesting functional redundancy. 
Surprisingly, APP-/- APLP1-/- double knock-out mice are viable, indicating a key 
physiological role for APLP2 [143,144]. More recently, mice lacking all three APP 
superfamily members have been generated and these mice die shortly after birth 
[147]. These results indicate that APP and APLP1 and -2 have overlapping 
physiological roles. Nevertheless, more extensive research is required to elucidate the 
normal functions of APP and APLPs, which in turn might provide new insights into 
the role of APP in the pathology of AD. 
 
The South-African claw-toed frog Xenopus laevis 
To investigate the roles of proteins with unknown function, animal models are often 
used to perform studies close to the in vivo situation. The mouse, and the invertebrate 
nematode C .elegans and fruit fly Drosophila melanogaster have been used 
extensively to study molecular and cell-biological mechanisms in a physiological 
context. During the last decades, the South-African claw-toed frog Xenopus laevis has 
become an attractive animal model. Relative to the other organisms used, this 
amphibian has a number of advantages. Xenopus laevis is a vertebrate that is readily 
maintained in the laboratory and can be induced to ovulate at any time of the year, 
allowing the generation of hundreds of embryos in one day by performing in vitro 
fertilization. Xenopus embryos efficiently translate injected mRNAs, are transparent, 
develop externally in a simple salt solution and their embryonic development is well 
characterized [148]. Furthermore, most anatomical and functional features as well as 
amino acid sequences are highly conserved between Xenopus and mammals. For 
instance, the overall amino acid sequence identity of Xenopus and human APP is 
87%. Together, these characteristics allow to extrapolate results from Xenopus studies 
to mammalian systems and make Xenopus an attractive vertebrate model organism to 
study APP and related proteins.  
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Background adaptation of Xenopus 
Besides the above-mentioned properties, Xenopus has one other remarkable feature, 
namely the ability to adapt its skin color to its background. This process of 
background adaptation is regulated by the melanotrope cells of the intermediate 
pituitary gland. When light enters the eye, it is processed via the hypothalamus to the 
intermediate pituitary melanotrope cells that are innervated by neurons of 
hypothalamic origin. When the animals are placed on a black background, the 
melanotrope cells become highly active in producing the prohormone 
proopiomelanocortin (POMC). One of the processing products of POMC is the α-
melanophore stimulating hormone (α-MSH) that is secreted by the melanotrope cells 
and causes dispersion of the pigment melanin in the skin melanophores, causing the 
animal to become black. When the animal is placed on a white background, the 
melanotrope cells are virtually inactive and the animals become white (reviewed by 
Jenks et al. [149]). The activation of the melanotrope cells upon black-background 
adaptation is accompanied by an increase in cell size and a highly developed 
biosynthetic machinery (reviewed by Roubos [150]). In the active melanotrope cells 
of black-adapted animals, the levels of POMC are ~20/30-fold higher compared to 
those in white-adapted animals. Coordinately expressed with POMC are a number of 
other proteins, such as the POMC-processing enzymes prohormone convertase 2 
(PC2), carboxypeptidase H, the putative ER-to-Golgi cargo receptors p24α3, p24β1, 
p24γ3 and p24δ2 and the V-ATPase accessory subunit Ac45 [151,152]. All of these 
proteins are somehow involved in the biosynthesis, processing or transport of POMC, 
indicating that the melanotrope cell is a highly specialized cell destined to produce 
and process high amounts of this prohormone. These features combined with the fact 
that the melanotrope cell can be physiologically activated or inactivated by simply 
changing the background of the animal make this cell an attractive model system to 
study proteins that are operational in the secretory pathway.  
 
Xenopus transgenesis 
To study the function of proteins close to the in vivo situation, transgenic animals can 
be generated that express wild-type or mutant forms of the protein of interest in a 
tissue-specific manner. In 1996, Kroll and Amaya first described the generation of 
transgenic Xenopus [153]. Later, the technique was simplified by Sparrow et al. [154]. 
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Briefly, Xenopus sperm nuclei are mixed with a linear DNA fragment, containing a 
(tissue-specific) gene promoter sequence, the coding sequence of the gene of interest 
and a poly-adenylation signal. This nuclei-sperm suspension is injected into 
unfertilized eggs, after which fertilization and integration of the transgene into the 
Xenopus genome occurs. Using various gene promoters, the transgene of interest (e.g. 
APP or APLP2) can be targeted to any desired cell- or tissue type, for instance 
specifically to the intermediate pituitary melanotrope cell using the POMC gene 
promoter [155], to neuronal cells using the neural β-tubulin gene promoter [153], to 
muscle cells using the cardiac actin gene promoter [153,154] or to all cells using the 
elongation factor 1α gene promoter [156]. By fusing the protein of interest to the 
jellyfish reporter green fluorescent protein GFP, transgenic animals can be easily 
identified using a fluorescence microscope. The percentage of transgenic animals 
varies between ~1 and 50%, mainly depending on the gene promoter used and the 
quality of the eggs. 
 
Aim and outline of this thesis 
Despite research for several decades, the normal physiological roles of APP and 
APLP2 are still not fully understood. The aim of this thesis was to increase the 
knowledge on APP and APLP2 using the Xenopus intermediate pituitary melanotrope 
cell as a model, including in combination with the Xenopus transgenesis procedure. In 
chapter two, we describe the identification and expression of the first non-
mammalian APLP2 protein in Xenopus and perform a phylogenetic analysis of the 
APP superfamily that has led to a new insight into the evolution of this superfamily. 
Chapter three focuses on the expression and the biosynthesis of endogenous APP in 
the Xenopus melanotrope cells. We describe the biosynthesis of two pools of APP, 
only one of which is induced (threefold) upon black-background adaptation of the 
animal. These results suggest that APP is somehow involved in the biosynthetic 
machinery of these cells. In chapter four, we study the biosynthesis and expression 
of APLP2 in Xenopus intermediate pituitary and found that, unlike for APP, only one 
pool of APLP2 occurs. This pool is not induced upon black-background adaptation, 
indicating that although closely related, APP and APLP2 have distinct roles in these 
cells. Chapters five and six describe the efforts made to target GFP-fusion proteins 
of wild-type and mutant APP and APLP2 specifically to the intermediate pituitary 
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cells or to other cell types using stable Xenopus transgenesis. Unfortunately, transgene 
expression of APP and APLP2 in Xenopus neuroendocrine/neuronal cells was not 
successful. One explanation for these results may be the presence of an interfering 
DNA element within the 3’-end of Xenopus APP cDNA that acts as a strong neural-
specific promoter. The identification and characterization of this putative DNA-
promoter element are presented in chapter six. Finally, in chapter seven we discuss 
the results described in this thesis and propose a model for the roles of APP and 
APLP2 in Xenopus intermediate pituitary cells. 
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ABSTRACT 
The Alzheimer’s disease-linked amyloid-β precursor protein APP belongs to a 
superfamily of proteins, which also comprises the amyloid-β precursor-like proteins 
APLP1 and APLP2. Whereas APP has been identified in both lower and higher 
vertebrates, thus far, APLP1 and -2 have been characterized only in human and 
rodents. Here we identify the first non-mammalian APLP2 protein in the South-
African claw-toed frog Xenopus laevis. The identity between the Xenopus and 
mammalian APLP2 proteins is ~75%, with the highest degree of conservation in a 
number of amino-terminal regions, the transmembrane domain and the cytoplasmic 
tail. Furthermore, amino acid residues known to be phosphorylated and glycosylated 
in mammalian APLP2 are conserved in Xenopus. The availability of the Xenopus 
APLP2 protein sequence allowed a phylogenetic analysis of APP superfamily 
members that suggested the occurrence of APP and preAPLP lineages with their 
separation predating the mammalian-amphibian split. Like in mammals, Xenopus 
APLP2 mRNA was ubiquitously expressed and alternatively spliced forms were 
detected. However, the expression ratios between the mRNA forms in the various 
tissues examined were different between Xenopus and mammals, most prominent for 
the alternatively spliced forms containing the Kunitz protease inhibitor-coding region 
that were less abundantly expressed than the corresponding mammalian forms. Thus, 
the identification of APLP2 in Xenopus has revealed evolutionarily conserved regions 
that may help to delineate functionally important domains and its overall high degree 
of conservation suggests an important role for this APP-superfamily member. 
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INTRODUCTION 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized 
by two morphological features in the brain, namely amyloid plaques and 
neurofibrillary tangles. The intracellular neurofibrillary tangles consist of a 
hyperphosphorylated form of the microtubule-associated protein tau. Amyloid plaques 
are extracellular protein deposits, mainly consisting of amyloid-β, a neurotoxic 
peptide produced by proteolytic processing of the amyloid-β precursor protein APP 
[1]. APP belongs to a superfamily of proteins [2] that includes the mammalian 
amyloid-β precursor-like proteins APLP1 and APLP2 [3-7], Drosophila APP-like 
APPL [8] and C.elegans APP-like APL-1 [9]. Since APPL and APL-1 represent the 
only members of the APP superfamily in Drososphila and C.elegans, respectively, the 
genes encoding these proteins are likely to be ancestral to the APP gene superfamily 
members found in vertebrates. APP has been identified in many vertebrate species, 
including zebrafish (Danio rerio) [10] and the South-African claw-toed frog Xenopus 
laevis [11,12]. In contrast, APLP1 and -2 have thus far been described in only human 
and rodents. 
APP and the APLPs are type-I transmembrane proteins containing a signal peptide, a 
large amino-terminal luminal / extracellular part, a transmembrane domain, and a 
short cytoplasmic tail. The luminal portions of all superfamily members contain 
conserved zinc-binding [13,14], heparin-binding [14] and collagen-binding domains 
[15]. Furthermore, a GTP-binding protein (G0) binding site [16] and  the NPXY-
sequence responsible for clathrin-coated vesicle targeting [17] are present within the 
cytoplasmic tail of all family members. Other domains, such as a second heparin-
binding domain [18], a copper-binding region [19,20], a Kunitz protease inhibitor 
(KPI) domain [21,22] and a chondroitin sulphate attachment site [21,23-25] are found 
in APP and APLP2, but not APLP1. Besides structural similarity, APP and APLP2 
also share a similar ubiquitous expression pattern [3,5], while APLP1 is expressed 
only in neuronal tissues [26]. 
The human APLP2 gene has first been identified in 1994 [27] and is currently 
assigned to chromosome 11q24 [28]. Due to alternative splicing, four forms of 
mammalian APLP2 mRNA have been described [3,21]. During APLP2 gene 
transcription, exon 7 (encoding the 56-amino acid KPI domain also alternatively 
spliced in APP) and exon 14 (encoding a 12 amino-acid domain involved in the 
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attachment of a chondroitin sulfate glycosaminoglycan side chain) are alternatively 
spliced [29]. While forms of APP mRNA lacking the KPI domain are expressed 
predominantly in neuronal cells [30-32], the KPI-deficient APLP2 mRNA forms 
display low expression levels in all tissues examined [21]. 
Despite extensive research over several decades, the physiological roles of APP, 
APLP1 and APLP2 still remain elusive. APP has been implicated to play a role in 
cell-cell adhesion [32], neurite outgrowth [33] and kinesin-mediated vesicular 
transport [34] or may function as a heparan sulfate proteoglycan core protein [35]. 
Furthermore, following its translocation to the nucleus, the carboxy-terminal fragment 
of APP, which is produced after cleavage by the enzyme γ-secretase, has been found 
to play a role in the regulation of transcriptional processes [36]. Similar findings have 
been reported for the carboxy-terminal fragments of both APLP1 and –2 [37]. The 
physiological roles of APLP1 and -2 have been less extensively studied, probably 
because they appear not to be involved in amyloidogenesis. Nevertheless, a role for 
APLP2 has been proposed in chromosome replication and/or segregation, a function 
that has not been attributed to the other members of the APP superfamily [27,38]. 
However, since APP and APLP2 are structurally related, it is conceivable that they 
also share similar roles. This is further supported by the finding that both APP-/- and 
APLP2-/- knock-out mice are viable, while APP-/- and APLP2-/- double mutants show 
perinatal lethality, suggesting functional redundancy [39]. Also APLP1-/- / APLP2-/- 
double mutants die within the first day of birth, while APP-/- / APLP1-/- mice are 
viable, indicating a key physiological role for APLP2 [40]. 
Since the identification of evolutionarily conserved regions may help to establish 
functionally important domains within a protein, we here identify the first non-
mammalian APLP2 protein in the amphibian Xenopus laevis and present a 
phylogenetic analysis of the APP superfamily that now thus includes Xenopus 
APLP2. Furthermore, we analyze alternative splicing and the tissue distribution of 
Xenopus APLP2 mRNA. 
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MATERIALS AND METHODS 
Animals 
South-African claw-toed frogs Xenopus laevis were bred and reared at the Central Animal 
Facility of the University of Nijmegen. 
 
Rapid amplification of 5’-cDNA ends 
To generate a pool of adaptor-ligated double-stranded cDNAs, total Xenopus brain RNA was 
isolated using a total RNA isolation kit (Promega). Subsequently, polyA+ RNA was isolated 
(polyA+ RNA isolation kit, Promega) and 1 µg polyA+ RNA was used to generate the pool, 
according to the protocol of the manufacturer (Clontech, MarathonTM cDNA amplification 
kit). 5’-RACE was performed using adaptor primer 5’-CCATCCTAATACGACTCACTATAGGGC-
3’ and gene-specific reverse primer 5’-CAGCAAGTACGTGGTGGTAATGACGG-3’ (obtained from 
an EST database sequence presumably corresponding to a partial Xenopus APLP2 cDNA; 
http://xenopus.nibb.ac.jp). The exon 7 sequence of Xenopus APLP2 was obtained by PCR 
analysis of Xenopus stomach cDNA. PCR products were subcloned into pGemTeasy vector 
and inserts were sequenced from both strands (ABI prism, Perkin Elmer) with SP6 and M13- 
sequencing and various internal primers.  
 
Phylogenetic analysis 
For phylogenetic analysis, amino acid sequences of several known APP superfamily members 
were used. Sequences were obtained from the Swiss-Prot database. Accession numbers were: 
human APP (HsAPP), #P05067; murine APP (MmAPP), #P12023; chicken APP (GgAPP), 
#Q9DJG7; Xenopus laevis APP gene A (XlAPPA), #Q98SG0 and gene B (XlAPPB), 
#Q98SF9; zebra fish APP (DrAPP), #Q90W28; Fugu rubripes APP (FrAPP), #O93279; 
Tetraodon fluviatilis APP (TfAPP), #O73683; electric ray APP (NjAPP), #O57394; human 
APLP1 (HsAPLP1), #P51693; murine APLP1 (MmAPLP1), #Q03157; human APLP2 
(HsAPLP2), #Q06481; murine APLP2 (MmAPLP2), #Q61482; Caenorhabditis elegans APL-
1 (CeAPL1), #Q10651; Drosophila melanogaster APPL (DmAPPL), #P14599. Phylogenetic 
trees were constructed using a variety of Maximum Likelihood (ML) and Bayesian methods. 
Program PROTML from the MOLPHY package (version 2.3b3) [41] was used for standard 
ML calculations. Since the number of Operational Taxonomic Units (OTUs) in the dataset 
exceeded the program's ability to perform an exhaustive tree search, the star-decomposition 
option with the JTT scoring matrix [42] was used. The Tree-Puzzle program, version 5.1, was 
employed to perform quartet puzzling tree reconstruction [43-45]. The program was run with 
exact parameter estimation and with eight gamma rate categories. All other program options 
were left at the default setting. Finally, for Bayesian analysis MrBayes version 3.0B4 was 
used [46,47]. The program was run with 4 chains over 1,000,000 generations, and the sample 
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frequency was 100; the first 100,000 generations were discarded (burn-in). The rate variation 
method used was the "invgamma" model (i.e. proportion of the sites are invariant, while the 
rates for the remaining sites are drawn from a gamma distribution). 
 
RT-PCR analysis 
For RT-PCR analysis, total RNA from different Xenopus tissues was isolated using the Trizol 
method (standard procedure, Gibco BRL). About ~ 1 µg total RNA from various tissues was 
incubated with 5 mU pd(N)6 for 10 min at 70°C and RNA was reverse transcribed using 100 
U SuperscriptTM II (Gibco BRL) in 10 mM dithiothreitol, 0.5 mM dNTPs and 40 U RNase 
inhibitor (Promega) for 60 min at 37°C. To examine Xenopus APLP2 cDNA for alternatively 
spliced forms, two different primer sets spanning intron-exon boundaries were used. Forward 
primer 5’-GATGAAGTTGTAGAAGACCGTGACTATTA-3’ and reverse primer 5’- 
GTGGTGCCGAACCTCTAGTTG-3’ were used to examine the presence of exon 7; to study the 
presence of exon 14, forward primer 5’-AGAGTCCCAGGGCGATGTAA-3’ and reverse primer 5’-
CCACTGACTCTCTCTGCATTGAA-3’ were used. As a control, Xenopus GAPDH cDNA was 
amplified (forward primer 5’-GCCGTGTATGTGGTGGAATCT-3’ and reverse primer 5’-
AAGTTGTCGTTGATGACCTTTGC-3’). Amplification was performed at 94°C for 1 min, 58°C for 
1 min and 72°C for 1 min, 30 cycles, and an additional extension step for 10 min at 72°C. 
PCR products were analyzed on a 1.4 % agarose gel. 
 
 
RESULTS AND DISCUSSION 
 
Isolation and sequence analysis of Xenopus APLP2-A and –B cDNAs 
To isolate APLP2 cDNA of the South African claw-toed frog Xenopus laevis, a 
Xenopus brain cDNA pool was generated to perform rapid amplification of 5’-cDNA 
ends (5’-RACE). This analysis resulted in the identification of two full-length, 
structurally different gene transcripts encoding proteins with a predicted molecular 
mass of 85.2 kDa, representing the Xenopus orthologue of mammalian APLP2. The 
two gene transcripts have probably been the result of a gene duplication event, since 
Xenopus laevis is a tetraploid animal with a duplicated genome [48]. For several other 
Xenopus transcripts, including APP [12], the existence of two gene transcripts has 
been described [49-53]. The nucleotide sequences of the Xenopus APLP2 gene A and 
–B transcripts were determined and comparison of the two sequences showed a 94.1% 
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identity within the coding regions. The degree of sequence identity between the 
Xenopus APLP2-A and APLP2-B proteins was 94% (Figure 1A). 
 
Phylogenetic analysis of the APP superfamily 
To reveal the evolutionary history of the APP superfamily, we used Maximum 
Likelihood and Bayesian methods to construct a phylogenetic tree of the members of 
the APP superfamily that now includes Xenopus APLP2 (X-APLP2) as the first non-
mammalian APLP2 protein. Using the C.elegans APL-1 and Drosophila APPL 
sequences as outgroups, we were able to assign a root to the remainder of the 
phylogeny. In the resulting three trees, the APP and APLP1/2 families were found as 
sister groups (Figure 2), presumably resulting from an early gene duplication. A 
subsequent gene duplication in the preAPLP family may have resulted in the 
appearance of the APLP1 and APLP2 gene families. The fact that both mammals and 
Xenopus contain APP and APLP2 proteins suggests that the first gene duplication 
giving rise to the APP and preAPLP lineages predated the mammalian-amphibian 
split. This finding is different from that of Coulson et al. [2] who concluded that the 
first gene duplication event would have led to the generation of APLP1 and 
preAPP/APLP2 lineages (rather than to the APP and preAPLP  separation  as  found  
by  our analysis), and the second duplication event would have caused the splitting of 
the APP and APLP2 families. However, Coulson et al. [2] used the parsimony, 
neighbor-joining and Kitch methods, which are now considered to be less rigorous 
and statistically sound than the calculation methods we employed. Thus, our results 
indicate that the APLP1 gene diverged from the APLP2 gene and did not arise from 
the first gene duplication event during the evolution of the APP superfamily. 
Interestingly, APLP1 has been identified only in mammals, is expressed exclusively 
in the brain and further displays a number of structural features not present in the 
other members of the APP superfamily, such as the absence of the exon encoding the 
KPI domain and the lack of a second heparin-binding domain [3,4,13,26]. 
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Figure 1 Amino acid sequence comparison between the Xenopus and
mammalian APLP2 proteins  
A) Alignment of the amino acid sequences of Xenopus APLP2-A/B,  and human, mouse
and rat APLP2 proteins. The one-letter amino acid notation is used. Residues identical
among all four species are white on a black background, while residues conserved in
three species are black on a dark gray background. Conservative amino acid changes
are depicted in black on a light gray background. The predicted signal peptide sequences
are represented by a dotted line, while the transmembrane domains are indicated by a
bold line. Domains encoded by alternatively spliced exons, the most N-terminal being a
Kunitz type protease inhibitor KPI domain, are indicated by a dashed line. Amino acid
residues known to be phosphorylated in mammalian APLP2 are indicated by asterisks
and putative N-linked glycosylation sites by a dot. The human (#Q06481), mouse
(#Q61482) and rat (#P15943) APLP2 sequences were obtained from the Swiss-Prot
database.  
B) Schematic overview of the degree of amino acid sequence identity between regions
within Xenopus and human APLP2 proteins. The percentages of sequence identities
within regions between Xenopus APLP2-A and human APLP2 are depicted. SP, signal
peptide (amino acid residues 1-20); ZBD, zinc-binding domain (residues 186-193); CBD,
collagen-binding domain (residues 504-536). The transmembrane region (residues 682-
704) and the cytoplasmic tail (residues 705-761) are indicated by TM and CT,
respectively. The various domains are presented as gray boxes. Alternatively spliced
exons 7 (KPI domain, residues 291-346) and 14 (residues 602-613) are depicted below
the schematic drawing. 
A 
B 
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Comparative analysis of the Xenopus and mammalian APLP2 proteins 
Comparing the amino acid sequences of the two X-APLP2 proteins with the human, 
mouse and rat APLP2 protein sequences showed an overall sequence identity of 74-
75%, with a number of regions even more conserved (Figure 1A and B). All twelve 
cysteine residues in the amino-terminal part of APLP2 are present in X-APLP2. The 
zinc-binding domain consensus (GxExVCCP [13]) in the N-terminal part of APLP2 is 
conserved between Xenopus and mammals (residues 187-194 in X-APLP2-A). The 
three histidine residues essential for copper binding in both human APP and APLP2 
[20] are conserved in X-APLP2-B (H153, H155 and H157), while in X-APLP2-A two of 
the three residues (H155 and H157) are present. Both human APP and APLP2 contain 
two heparin-binding domains [13] with a consensus motif BBxB [54], in which B 
represents a basic residue. The two motifs are present in X-APLP2-A (K107KGK110 
and H384HNR387) and X-APLP2-B (K107RGK110 and H383HNR386). X-APLP2 also 
contains the KPI domain [21], including all six cysteine residues. The region 
important for collagen binding [15] is 94% conserved between Xenopus and 
mammalian APLP2 (residues 505-537), and X-APLP2 also contains serine residue 
S615, essential for chondroitin sulfate glycosaminoglycan modification in murine 
APLP2 [24]. Furthermore, the transmembrane domains and the cytoplasmic tails of 
the Xenopus and mammalian proteins are 91% and 100% identical, respectively, 
including the GYENPTY sequence that is present in all APP superfamily members 
and is involved in intracellular routing of the proteins [17]. 
Human APLP2 is known to undergo N- and O-linked glycosylation, although the 
exact locations of the glycosylated amino acid residues have not been identified [55]. 
Two N-linked glycosylation consensus sites (N269 and N523 in X-APLP2-A) are 
conserved in X-APLP2. In mammals, APLP2 is phosphorylated by protein kinase C 
(T723; [56]) and cdc2 kinase (T736; [56]), and both threonine residues are also present 
in X-APLP2. Thus, all important domains and residues known to be post-
translationally modified have been conserved between Xenopus and mammalian 
APLP2. 
Overall, the high degree of conservation of APLP2 may help the identification of 
functionally important domains within this APP superfamily member. 
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Figure 2  
Phylogenetic analysis of the 
APP superfamily  
Amino acid phylogenetic trees 
were calculated using Maximum 
Likelihood and Bayesian 
methods: A) PROTML, B) Tree-
Puzzle and C) MrBayes. The 
trees all display the same 
topology. The lengths of the 
branches in trees A) and B) are 
representative for evolutionary 
distance.  
Species abbreviations: Ce, 
Caenorhabditis elegans; Dm: 
Drosophila melanogaster; Dr, 
Danio rerio; Fr, Fugu rubripes; 
Gg, Gallus gallus; Hs, Homo 
sapiens; Mm, Mus musculus; Nj, 
Narke japonica; Tf, Tetraodon 
fluviatilis; Xl, Xenopus laevis. 
B 
A 
C 
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Expression pattern of Xenopus APLP2 mRNA 
The expression pattern of Xenopus APLP2 mRNA and the presence of alternatively 
spliced mRNA forms in various Xenopus tissues were studied using RT-PCR. Since 
exon 7 (encoding the KPI domain) and exon 14 (encoding a region involved in the 
attachment of a chondroitin sulfate glycosaminoglycan side chain) are alternatively 
spliced in rat APLP2 pre-mRNA [21], analysis was performed with primers 
corresponding to regions flanking these alternatively spliced exons. Expression of 
APLP2 mRNA was detected in both neuronal and peripheral tissues of Xenopus 
(Figure 3). The presence of a 414-bp PCR product indicates the occurence of the 
alternatively spliced exon 7, while a 246-bp PCR product indicates the absence of 
exon 7. In all of the Xenopus tissues examined, mRNA forms lacking exon 7 were 
present. In intestine and stomach, and to a lesser extent in brain, liver and lung, 
APLP2 mRNA forms containing exon 7 were also detectable (Figure 3, upper panel). 
In a similar way, the alternative splicing of exon 14 was studied, showing 297-bp and 
261-bp PCR products for mRNA forms containing or lacking exon 14, respectively. 
The presence of exon 14 disrupts the consensus sequence for chondroitin sulfate 
glycosaminoglycan side chain attachment (ENEGSGMAEQ in human APLP2), 
thereby preventing this post-translational modification [24,29]. The mRNA forms 
containing exon 14 are predominantly expressed in Xenopus brain, intestine, ovary 
and stomach. The mRNA forms lacking exon 14 were more abundant in testis, liver, 
heart, spleen and kidney than in oocytes, lung and muscle, where an equal distribution 
of forms containing or lacking exon 14 was found (Figure 3, middle panel). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Expression and alternative splicing of APLP2 mRNA in various
Xenopus tissues 
Presence or absence of alternatively spliced exons 7 (upper panel) and 14 (middle
panel) were analyzed via RT-PCR, using primers spanning intron-exon boundaries. 
Analysis of GAPDH mRNA expression served as a control. 
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In all rat tissues examined, the forms of APLP2 mRNA containing exon 7, encoding 
the KPI domain, are predominantly present [21]. In contrast, our data show that in 
Xenopus the various tissues contained only a relatively low amount of such 
transcripts. Interestingly, for Xenopus APP mRNA the tissue distributions of the two 
forms (with or without exon 7) do overlap with those of the mammalian APP mRNA 
forms [12]. In both Xenopus and rat, the APLP2 mRNA forms containing exon 14 are 
most abundant in neuronal tissues. Also in peripheral tissues, the tissue distribution of 
these mRNA forms is comparable between Xenopus and rat, except for the high levels 
of mRNA forms containing exon 14 in Xenopus stomach, intestine and ovary. Taken 
together, the expression analyses show that Xenopus and mammalian APP/APLP2 
mRNAs are similarly spliced and that the tissue distributions of the various 
APP/APLP2 mRNA forms are remarkably conserved among these vertebrate species, 
except for the distributions of the APLP2 mRNAs containing or lacking exon 7 
[12,21]. 
In conclusion, our results show that Xenopus APLP2 is ubiquitously expressed and 
highly similar to its mammalian orthologues. This high degree of conservation points 
to an important role for this protein and the availability of the Xenopus APLP2 protein 
sequence may help to identify potentially important functional domains. Furthermore, 
and in contrast to what has been previously reported [2], our phylogenetic analysis 
indicated that during evolution of the APP superfamily, a gene duplication event has 
resulted in APP and preAPLP lineages, whereby the splitting has occurred before the 
separation of mammals and amphibians. 
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ABSTRACT 
The amyloid-β precursor protein APP is linked to Alzheimer's disease, namely 
through its pathological proteolytic processing in the secretory pathway. Nevertheless, 
surprisingly little is known about the biosynthesis of endogenous APP. We therefore 
decided to investigate the intracellular fate of newly synthesized APP in a 
physiologically inducible neuroendocrine cell, namely in the Xenopus intermediate 
pituitary melanotrope cell. We found that the level of both APP-mRNA and -protein 
was about three-fold induced in the activated cells of black-adapted animals. 
Intriguingly, two pools of the APP-protein were found, only one of which was up-
regulated. This induced pool became readily N- and subsequently O-glycosylated, and 
was eventually proteolytically processed by an α-secretase-like cleavage event 
resulting in a secreted N-terminal and a cell-associated C-terminal APP-fragment. 
Conversely, only the other (noninduced, nonglycosylated and uncleaved) pool became 
phosphorylated. Thus, we report on the biosynthesis of APP in a physiological context 
and illuminate the occurrence of two pools of APP, one of which is linked to 
neuroendocrine cell activation.  
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INTRODUCTION 
The type I transmembrane amyloid-β precursor protein APP has been identified in a 
number of mammalian and non-mammalian species, including the South-African 
claw-toed frog Xenopus laevis [1]. The protein sequence of APP is highly conserved 
throughout vertebrate evolution (e.g. 87% amino acid sequence identity between 
human and Xenopus APP;[2], pointing to an important physiological role for this 
protein. Functions attributed to APP range from a cargo receptor in axonal transport 
for the intact protein [3] to roles for the cleavage fragments derived from APP, such 
as its secreted N-terminal domain that may act as a growth factor [4] and the so-called 
APP intracellular domain AICD that is thought to be involved in transcriptional 
regulation [5].  
APP is associated with Alzheimer’s disease (AD), an age-related neurodegenerative 
disorder. A major constituent of the senile plaques found in AD-brains, the neurotoxic 
peptide amyloid-β (Aβ), is produced by pathological processing of APP, involving 
cleavages by enzymes named β- and γ-secretase. The third secretase enzyme family 
member, α-secretase, cleaves APP within the Aβ-sequence resulting in a large N-
terminal fragment which is secreted (sAPPα) and a membrane-associated C-terminal 
fragment that can be further processed by γ-secretase, giving rise to the AICD [6]. In 
addition to its proteolytic processing, during trafficking of APP through the secretory 
pathway, a number of other post-translational modifications of the protein have been 
shown to occur, such as glycosylation and phosphorylation [7, 8].  However, the 
intracellular fate of APP has been studied mostly in transfected cells. We decided to 
explore endogenous APP in the homogeneous population of neuroendocrine 
melanotrope cells in the intermediate pituitary of Xenopus laevis. The activity of these 
cells can be physiologically manipulated through adaptation of the animal to its 
background. When adapted to a black background, the melanotrope cells are highly 
active in producing the prohormone proopiomelanocortin (POMC), while following 
adaptation to a white background, the cells become in an inactive state via their 
regulation by inhibitory neurons of hypothalamic origin [9]. During transport through 
the secretory pathway, newly synthesized POMC is post-translationally modified and 
proteolytically processed. One of the processing products is α-melanophore-
stimulating hormone (α-MSH), the hormone that stimulates the dispersion of the 
black pigment melanin in skin melanophores causing a darkening of the animal. Since 
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APP has been implicated to function as a cargo receptor in post-Golgi vesicular 
transport [3], an interesting possibility is the involvement of APP in vesicle transport 
within the secretory pathway of Xenopus intermediate pituitary cells. 
In this report, we studied the mRNA and protein levels as well as the biosynthesis and 
processing of APP in the Xenopus melanotrope cells. Interestingly, in these cells we 
find two pools of APP that differ in their induction of expression, post-translational 
modifications and proteolytic processing. 
 
 
MATERIALS AND METHODS 
Animals 
South-African claw-toed frogs Xenopus laevis were bred and reared at the Central Animal 
Facility of the Radboud University Nijmegen. Animals were adapted to a black or white 
background under constant illumination at 22°C for at least three weeks. All animal 
experiments were carried out in accordance with the European Communities Council 
Directive 86/609/EEC for animal welfare. 
  
Real-time quantitative RT-PCR analysis 
Neurointermediate lobes (NILs) and anterior lobes (ALs) of black- and white-adapted 
Xenopus pituitaries were dissected and total RNA was isolated using the Trizol method 
(Gibco, BRL; standard protocol), redissolved in 20 µl RNase-free H2O and quantified with a 
GeneQuant RNA/DNA calculator (Pharmacia). cDNA synthesis and real-time quantitative 
PCR analysis were performed as described previously [10]. To examine which of the three 
APP mRNA isoforms (corresponding to APP695, APP751 and APP770) was expressed in 
Xenopus pituitary, NIL and AL cDNA of black- and white-adapted animals was analyzed 
using forward primer 5’-CCCGAGGAACCCTATGAAGAAG-3’ and reverse primer 5’-
GTTGTTGCCTTTGCTTTGCA-3’, giving rise to products of 361, 529 and 586 bp for APP695, 
APP751 and APP770, respectively. The mRNA form encoding APP695 was found to be the 
predominant form (>90%) expressed in the two pituitary lobes. For RQ-PCR analysis, 
forward primer 5’-GAAGAAGAAGCAATACACAACTATCCAT-3’ and reverse primer 5’-
CGAGCGGTGAAGCAGGTT-3’ were used to amplify APP cDNA and forward primer 5’-
GCCGTGTATGTGGTGGAATCT-3’ and reverse primer 5’-AAGTTGTCGTTGATGACCTTTGC-3’ for 
GAPDH cDNA-synthesis. 
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Antibodies 
Polyclonal anti-APP antibodies C87 and J58 were generated by immunizing rabbits with 
synthetic peptides corresponding to the most C-terminal 12 amino acids of Xenopus APP 
(NPTYKFFEQMQN) and amino acid residues DSEYRHDAAYEV (C-terminal region of 
Xenopus sAPPα), respectively, and coupled to keyhole limpet haemocyanin. Polyclonal anti-
APP antibody XA12 was generated by immunizing rabbits with recombinant His-tagged 
protein XA12, representing amino acid residues 32-194 of the N-terminal domain of Xenopus 
APP695 (numbering according to Van den Hurk et al. [2]). Since besides APP no additional 
products were detected during western blot as well as immunoprecipitation analysis using the 
three anti-APP antibodies XA12, J58 and C87, these antibodies are specific for APP. 
Polyclonal antibody ST62 directed against the precursor form of Xenopus POMC [11], 
monoclonal antibody 22C11, raised against the extracellular domain of APP [12] and 
monoclonal anti-tubulin antibody E7 [13] have been described previously. Affinity-purified 
antibodies were prepared using antigen-sepharose 4B columns according to standard 
protocols [14]. 
 
Western blot analysis 
For western blot analysis, tissues were lysed in lysis buffer (50 mM Hepes pH 7.3, 140 mM 
NaCl, 0.1 % Triton, 0.1 % deoxycholate, 0.5 % NP-40, 5 mM EDTA, 1 mM 
phenylmethylsulfonylfluoride (PMSF) and 1 mM soybean trypsin inhibitor) and lysates were 
centrifuged for 7 min at 13000 rpm and at 4°C. Supernatants were taken and proteins were 
denatured in Laemmli sample buffer at 95°C for 5 min, separated on either a 10% or a 12.5% 
SDS-PAGE gel and transferred onto nitrocellulose membranes (Protran, Schleicher and 
Schuell). For the separation of small-sized proteins (5-25 kDa range), a 15% Tris-Tricine gel 
was used. Blots were incubated with affinity-purified anti-APP antibody C87 (the anti-APP 
antibodies XA12 and J58 did not work) or anti-tubulin antibody E7. For quantification, 
detection was performed with a BioChemi imaging system and signals were analyzed using 
the LabWorks 4.0 program (UVP BioImaging systems, Cambridge, UK). 
 
Metabolic cell labeling and immunoprecipitation analysis 
For metabolic cell labeling, NILs of black-adapted Xenopus were dissected and incubated in 
Ringer’s medium (112 mM NaCl, 2 mM KCl, 2 mM CaCl2, 15 mM Hepes pH 7.4, 0.3 mg/ml 
BSA and 2 mg/ml glucose) at 22°C for 15 min. Pulse labeling of newly synthesized proteins 
was performed by incubating lobes in Ringer’s medium containing 5 mCi/ml 35S-Met/Cys 
(MP Biomedicals, Irvine, CA) for the indicated time periods at 22°C. Pulse-chase and 
immunoprecipitation analysis were performed as described previously [15]. In some 
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experiments, lobes were preincubated, pulsed and chased in the presence or absence of 1 mM 
benzyl-2-acetamido-2-deoxy-a-D-galacto-pyranoside (benz-GalNAc; Sigma, St. Louis, MO), 
preincubated and pulsed with or without 10 µg/ml tunicamycin (Sigma) or 5 µg/ml brefeldin 
A (BFA; Sigma), or chased with or without 20 µM β-secretase inhibitor II (Calbiochem, La 
Jolla, CA) or 20 µM γ-secretase inhibitor IV (Calbiochem). For the phosphorylation 
experiments, lobes were labeled in the presence of 8.5 mCi/ml 32P-labeled orthophosphate 
(Amersham Biosciences, Roosendaal, the Netherlands) and during lysis and 
immunoprecipitation, phosphatase inhibitors (1 µM ocadaic acid, 20 mM pyro-phosphate, 30 
mM NaF, 2 mM EGTA, 5 mM EDTA) were present. Radiolabeled proteins were either 
directly subjected to 12.5% SDS-PAGE or immunoprecipitated with APP-antibody XA12 
(1:200), J58 (1:200) or C87 (1:500).  
 
Statistics 
Data are presented as means ± SEM. Statistical evaluation was performed using one-way 
analysis of variance (ANOVA) followed by a students t-test. Values of p < 0.05 were 
considered statistically significant. 
 
 
RESULTS 
 
Dynamics of APP-mRNA and –protein expression in the pituitary of black- and 
white-adapted Xenopus 
Real-time quantitative RT-PCR-analysis was performed to determine the levels of 
Xenopus APP transcripts in the neurointermediate lobe (NIL) and the anterior lobe 
(AL) of the pituitary of animals adapted to a black or a white background. 
Interestingly, APP transcripts were up-regulated more than threefold in NILs of black-
adapted animals compared to white-adapted animals (3.4 ± 0.5 fold up-regulation, 
n=4), whereas the levels in the ALs were not significantly different (Figure 1A). To 
investigate whether an induction also occurred at the protein level, western blot 
analysis was performed on NIL- and AL-lysates of black and white animals, using the 
affinity-purified C-terminally directed APP-antibody C87. Our analysis revealed the 
presence of two APP proteins with estimated molecular weights of ~100 kDa and 
~110 kDa (Figure 1B). Remarkably, only the 110-kDa APP form was found to be up-
regulated in the NIL of black-adapted animals (3.0 ± 0.1 fold up-regulation, n=3). 
Again, no differences in the APP-levels were detected in the ALs. Similar results were 
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obtained using monoclonal anti-APP antibody 22C11 (data not shown). To study the 
up-regulation of APP in more detail, we adapted white animals to a black background 
for various time periods. Western blot analysis revealed that the amount of APP 
started to increase after five days of black-background adaptation until maximum 
levels were reached following three weeks of adaptation. The time course of induction 
coincided with that of POMC, the major newly synthesized protein produced in 
Xenopus intermediate pituitary cells (Figure 1C). Together, the results show that (at 
the mRNA level and for the 110-kDa protein) APP expression is up-regulated in the 
active melanotrope cells of black-adapted Xenopus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 APP-mRNA and -
protein expression in the pituitary of
black- and white-adapted Xenopus  
A) Real-time quantitative RT-PCR
analysis of APP-mRNA levels in the NIL
and AL of the pituitary of black (B)- and
white (W)-adapted animals. The values
shown are relative to the amounts of
GAPDH mRNAs. The level of APP
mRNA in the NIL of black-adapted
animals was set to 100%. The values
shown represent the mean ± SEM from
four independent experiments. A
significant difference (p<0.05) is
indicated by an asterisk.  
B) Western blot analysis of APP-protein levels in the NIL and AL of black- and white-
adapted animals, using the C-terminally directed APP-antibody C87. Proteins were
separated by SDS-PAGE. Tubulin was used to show equal protein loading. Shown is a
representative example of three independent experiments.  
C) Western blot analysis of APP- and POMC-protein levels in the NILs of fully white-
adapted animals (WA), of animals adapted from a white to a black background for the
indicated time periods, or of fully black-adapted (BA) animals. Proteins were separated by
SDS-PAGE and immunoblotted using the C-terminally directed APP-antibody C87 or the
anti-POMC antibody ST62. Tubulin was used to show equal protein loading. 
CA 
B 
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Biosynthesis and proteolytic processing of APP in Xenopus intermediate 
pituitary cells 
Since the presence of two forms of the APP-protein (100-kDa and 110-kDa) on the 
western blot suggested the occurrence of a post-translational modification of APP, a 
pulse-chase analysis involving metabolic cell labeling combined with 
immunoprecipitation of radiolabeled proteins was performed to investigate the 
biosynthesis and processing of APP. Xenopus NILs (consisting of the biosynthetically 
active intermediate pituitary melanotrope cells and the inactive hypothalamic nerve 
terminals of the pars nervosa) of black-adapted animals were radiolabeled (pulsed) 
with 35S-Met/Cys for 60 min and the labeled proteins were either directly subjected to 
SDS-PAGE or immunoprecipitated with the APP-antibody C87. The majority of the 
newly synthesized proteins produced in the Xenopus intermediate pituitary 
melanotrope cells corresponds to the 37-kDa prohormone POMC and the proform of 
its processing enzyme PC2, the 75-kDa pro-PC2 (Figure 2A, left lane). 
Immunoprecipitation analysis revealed the presence of two forms of radiolabeled APP 
with molecular weights of ~100- and ~110 kDa (Figure 2A, right lane). To study the 
biosynthesis of APP in more detail, NILs were pulsed for either 15 or 60 min, and 
subsequently chased for 0, 90 or 180 min. During the 15-min pulse incubation, APP 
was synthesized as a 100-kDa protein, while after the 60-min pulse the additional 
protein of 110 kDa was found. In all subsequent experiments, a pulse period of 60 min 
was used to obtain sufficient amounts of radiolabeled APP. Following the 60-min 
pulse and the various chase periods, the majority (~90%) of the 100-kDa APP was 
converted into the 110-kDa form, while a small amount of radiolabeled APP remained 
in the 100-kDa form, even following the 180-min chase period. After the 90- and 180-
min chases, an additional product of ~97 kDa was formed in the cells. This protein 
was recognized only by the N-terminally- but not the C-terminally-directed antibody, 
indicating that it represents an N-terminal proteolytic processing product of APP. This 
processing product was likely derived from the 110-kDa APP-form, since the gradual 
decrease in the level of the 110-kDa protein was accompanied by an increase in the 
amount of the 97-kDa product. Moreover, the amount of the 100-kDa form remained 
the same during the chase periods. The 97-kDa form of APP was released into the 
chase medium, with the secretion starting at 90 min and being nearly complete 
following the 180-min chase (Figure 2B). 
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In transfected mammalian cells, proteolytic processing of APP to a large N-terminal 
processing product has been found to occur via either β- or α-secretase [6]. The size 
difference between the resulting β- or α-derived N-terminal APP processing products 
(APPsβ and APPsα, respectively) is only 17 amino acid residues [16]. To examine 
whether in Xenopus intermediate pituitary cells the large N-terminal domain of APP 
(of  97 kDa) was produced through cleavage by the β- or the α-secretase enzyme, we 
generated an antibody (J58) that was directed to the first 12 amino acid residues of the 
17 aa-region and thus recognizes APPsα but not APPsβ. Metabolic cell labeling 
followed by immunoprecipitation analysis showed that, in contrast to the C-
terminally-directed C87 antibody, both the N-terminally-directed antibody XA12 and 
the J58 antibody were able to precipitate the 97-kDa N-terminal APP cleavage 
product from the cell lysate as well as  the chase medium (Figure 2C). Thus, in 
Xenopus intermediate pituitary cells APP is processed by an α-secretase- rather than a 
β-secretase-like enzyme. Besides sAPPα, proteolytic processing of mammalian APP 
by α-secretase results in a small C-terminal fragment called C83, which remains 
associated with the cell [17]. Attempts to immunoprecipitate the newly synthesized C-
terminal Xenopus APP-processing product were not successful. Western blot analysis 
using the C-terminally directed antibody C87 revealed the presence of a product of 
~13 kDa in NILs and ALs of both black- and white-adapted animals (Figure 2D). This 
product likely corresponds to the α-secretase C-terminal APP cleavage product C83, 
since a similarly sized immunoreactive product was produced in COS-1 cells (Figure 
2D, right lane), in which APP is known to be efficiently cleaved by the α-secretase 
enzyme [18]. The observed small change in the migrations of the Xenopus and COS-1 
products may be caused by the two amino acids that are different between the 
Xenopus and mammalian C83-sequences [2]. The levels of the Xenopus C-terminal 
APP-processing product were almost fourfold higher (3.8 ± 0.5 fold up-regulation, 
n=3) in NILs of black- compared to white-adapted animals, while in the ALs no 
significant difference in the levels was observed. The higher levels in the NILs of 
black-adapted animals indicate that the C83-product is indeed derived from the 
inducible pool of APP.  
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In Xenopus brain, APP appeared to be processed in a similar way (Figure 2D, left 
lane). No other C-terminal APP cleavage product, e.g. generated by a β- or γ-
secretase-like enzyme, was detected in the tissues examined (Figure 2D) and neither 
β- nor γ-secretase inhibitors affected the processing of newly synthesized APP (data 
not shown); unfortunately, no reliable, specific α-secretase inhibitor is presently 
Figure 2 Biosynthesis and proteolytic processing of APP in Xenopus
intermediate pituitary cells  
A) NILs from black-adapted Xenopus were pulsed in the presence of 35S-Met/Cys for 60
min. Radiolabeled proteins were extracted and either directly subjected to SDS-PAGE (tot)
or immunoprecipitated (IP) from the cell lysate with the C-terminally directed APP-antibody
C87. The radiolabeled proteins were visualized using autoradiography.  
B) NILs were pulsed and subsequently chased for the indicated time periods. Radiolabeled
proteins were immunoprecipitated from the cell lysates and chase media with the N-
terminally directed XA12 antibody or the C87 antibody. The immunoprecipitates were
resolved by SDS-PAGE gel and the radiolabeled proteins were visualized using
autoradiography.  
C) The radiolabeled proteins from the NIL cell lysates (c) and chase media (m) were
immunoprecipitated with the APP-antibodies XA12, J58 (recognizing the α- but not the β-
secretase N-terminal APP-cleavage product) and C87, resolved by SDS-PAGE and
visualized by autoradiography.  
D) Western blot analysis of APP-cleavage products in NILs and ALs of black (B)- and white
(W)-adapted animals using the APP-antibody C87. Proteins were separated on a 15% Tris-
Tricine gel. Tubulin was used to show equal protein loading. For comparison, lysates from
Xenopus brain (Br) and COS-1 cells (COS) were analyzed. Shown is a representative
example of three independent experiments. Protein molecular weight markers (Mr) are
indicated on the right. APP-CTFα: the α-secretase C-terminal cleavage fragment of APP. 
A 
C 
B
D
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available. These findings suggest that in Xenopus intermediate pituitary cells APP is 
processed by an α-secretase-like cleavage enzyme, giving rise to the end products 
sAPPα and C83. Taken together, our results suggest that newly synthesized APP is 
produced as a 100-kDa protein, of which the majority is modified to the 110-kDa 
form of APP that is subsequently cleaved by an α-secretase-like enzyme. The 
resulting 97-kDa N-terminal cleavage product is released into the extracellular space, 
while the 13-kDa C-terminal product remains associated with the cells. 
 
Post-translational modifications of newly synthesized APP in Xenopus 
intermediate pituitary cells 
We next investigated whether the conversion of the majority of newly synthesized 
Xenopus APP from a 100- to a 110-kDa product was caused by N-linked 
glycosylation. The Xenopus APP sequence contains two potential N-linked 
glycosylation sites (residues N467 and N496) that are conserved between Xenopus 
and mammals [2]. Xenopus NILs were pulse labeled in the presence or absence of 
tunicamycin, that prevents N-linked glycosylation. Tunicamycin treatment resulted in 
a shift from both the 100- and the 110-kDa form of APP to products of ~96- and 
~106-kDa, indicating that both forms of APP are N-glycosylated (Figure 3A). The 
fact that the 100-kDa N-glycosylated product was already observed following the 15-
min pulse incubation, while no unglycosylated 96-kDa product was detected (Figure 
2B) suggests that N-glycosylation of APP occurs rapidly after its synthesis. We then 
examined whether the conversion of the 100-kDa N-glycosylated to the 110-kDa N-
glycosylated Xenopus APP product was the result of O-glycosylation. Xenopus APP 
harbors one potential, evolutionarily conserved O-linked glycosylation site (S124; van 
den Hurk et al. [2]). Xenopus NILs were pulse labeled and subsequently chased for 60 
min in the presence or absence of benz-GalNAc that inhibits O-linked glycosylation 
[19]. Benz-GalNAc treatment inhibited the conversion of the 100- to the 110-kDa 
form of APP (Figure 3B), indicating that O-glycosylation is indeed responsible for the 
shift in molecular weight. To examine whether the N- and O-linked glycosylation of 
APP occur in the early secretory pathway, Xenopus NILs were pulse labeled with or 
without BFA which is known to block COPI-mediated transport, resulting in Golgi 
dispersion and a block in ER-to-Golgi transport [20]. BFA treatment prevented the 
formation of the N- and O-glycosylated 110-kDa form and did not result in the 
production of the 96-kDa unglycosylated form, while under these conditions only the 
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100-kDa N-glycosylated form of APP was synthesized (Figure 3C). Together, these 
results suggest that Xenopus APP is N-linked glycosylated readily after its synthesis 
in the ER, and that O-linked glycosylation takes place in a later stage of the secretory 
pathway, probably in the Golgi area where O-glycosylation is generally occurring 
[21]. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Besides glycosylation sites, the Xenopus APP sequence also contains a number of 
conserved consensus sites for phosphorylation [2]. To examine whether endogenous 
Xenopus APP is phosphorylated, NILs were incubated in the presence of radiolabeled 
orthophosphate. Following a 60-min pulse, a phosphorylated APP protein was 
produced that comigrated with the 100-kDa form of 35S-labeled APP. In contrast to 
the 100-kDa 35S-labeled APP, following 90-, 180- and even 360-min chase periods, 
Figure 3 Glycosylation of newly synthesized APP in Xenopus intermediate 
pituitary cells  
A) Following overnight preincubation in the absence (-) or presence (+) of tunicamycin
(tun), NILs were pulsed with 35S-Met/Cys for 60 min without or with the drug. The
radiolabeled proteins from the cell lysates were immunoprecipitated with the C-
terminally directed APP-antibody C87 and the immunoprecipitated proteins were
resolved by SDS-PAGE and visualized by autoradiography.  
B) Following 30 min preincubation in the absence (-) or presence (+) of benz-GalNAc,
NILs were pulsed for 60 min and subsequently chased for 60 min without or with the
drug.  
C) Following 120 min preincubation without (-) or with (+) BFA, NILs were pulsed for 60
min without or with BFA. Protein extraction, immunoprecipitation, separation and
visualization in B) and C) were performed as under A). 
A 
B 
C 
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the phosphorylated APP still migrated as a 100-kDa protein and was thus not 
converted to a 110-kDa form, and the amounts of this phosphorylated product 
remained similar during the various chase times (Figure 4A). 
Furthermore, tunicamycin treatment did not affect the migration of the phosphorylated 
APP protein (Figure 4B). These results suggest that in Xenopus intermediate pituitary 
cells a phosphorylated pool of newly synthesized APP is produced that for up to 6 h 
after synthesis does not undergo glycosylation nor proteolytic cleavage. To investigate 
whether the phosphorylation of APP was an early event, Xenopus NILs were 
incubated with radiolabeled orthophosphate in the presence or absence of BFA. BFA 
treatment did not prevent the phosphorylation of APP (Figure 4C), indicating that 
APP phosphorylation occurs in the early secretory pathway. We then examined 
whether the phosphorylated pool of APP is differentially synthesized in intermediate 
pituitary cells of Xenopus adapted to a black- or a white background. Similar amounts 
of phosphorylated 100-kDa APP were produced in NILs from black and white 
animals, indicating that, in contrast to the 35S-labeled glycosylated pool, the 
phosphorylated pool of newly synthesized APP is not induced during black-
background adaptation (Figure 4D). This notion is corroborated by the fact that the 
steady-state levels of the 100-kDa APP protein were similar in the NILs of black and 
white animals (Figure 1B). 
 
 
DISCUSSION 
In this study, we explored the biosynthesis of endogenous APP in Xenopus 
intermediate pituitary melanotrope cells. For a number of reasons, these cells 
constitute an attractive cell model system. First, the Xenopus melanotrope cells form a 
homogenous population of neuroendocrine cells, and their biosynthetic and secretory 
activity can be physiologically induced by simply placing the animal on a black 
background. Second, these cells are destined to produce large amounts of a single 
cargo molecule with a well-defined role: the prohormone POMC is synthesized, 
transported via the regulated secretory pathway and cleaved to yield α-MSH, the 
hormone responsible for skin darkening. Third, the regulatory mechanisms and 
pathways as well as many proteins (e.g the APP protein) operational in these cells are 
highly conserved between Xenopus and mammals. In general, studies on the Xenopus 
melanotrope cells have provided information that turned out to be valuable for 
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understanding the functioning of mammalian cells [22-24]. It thus appears reasonable 
to assume that the data obtained for Xenopus APP can be extrapolated to mammalian 
systems, including human. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4 Phosphorylation of newly synthesized APP in Xenopus intermediate
pituitary cells  
A) NILs were pulsed for 60 min in the presence of 32PO4 (32P) and subsequently chased for
the indicated time periods. The radiolabeled proteins from the cell lysates were
immunoprecipitated with the C-terminally directed APP-antibody C87 and the
immunoprecipitated proteins were resolved by SDS-PAGE and visualized by
autoradiography. For comparison, the analysis of APP radiolabeled with 35S-Met/Cys (35S)
and immunoprecipitated with the antibody C87 is shown.  
B) Following overnight preincubation in the absence (-) or presence (+) of tunicamycin (tun),
NILs were pulsed with 32PO4 for 60 min without or with the drug.  
C) Following 120 min preincubation in the absence (-) or presence (+) BFA, NILs were pulsed
with 32PO4 for 60 min without or with the drug.  
D) NILs from black (B) and white (W) Xenopus were pulsed for 60 min in the presence of
either 35S-Met/Cys (35S) or 32PO4 (32P). Protein extraction, immunoprecipitation, separation
and visualization in B), C) and D) were performed as under A). p-APP: phosphorylated APP.
A 
B 
C 
D 
Chapter three 
60 
Our expression studies revealed that at both the mRNA and the protein level APP is 
up-regulated in the active intermediate pituitary melanotrope cells of black-adapted 
Xenopus, whereas no changes in APP expression levels were found in the anterior 
pituitary cells. This cell-specific induction of APP expression occurs because the 
melanotrope cells are controlled by neurons of hypothalamic origin that either activate 
or inactivate the cells depending on the color of the background of the animal, while 
the anterior pituitary cells are not involved in background adaptation [25]. Also 
induced in the active melanotrope cells are a number of other gene transcripts 
encoding secretory pathway proteins that are somehow involved in POMC 
biosynthesis, such as POMC itself, the POMC-processing enzymes prohormone 
convertase 2 (PC2) and carboxypeptidase H, and the type I transmembrane protein 
p24, a putative ER-to-Golgi cargo receptor [15, 26]. Thus, APP may as well be part of 
the biosynthetic machinery in the melanotrope cells. 
Our metabolic cell labeling experiments demonstrated that in Xenopus intermediate 
pituitary cells, APP is proteolytically processed by α-secretase. In other 
neuroendocrine cells, namely PC12 and primary bovine chromaffin cells, the 
proteolytic processing of mammalian APP has been studied, showing the release of 
the large N-terminal processing product into the culture medium [27-29] and the 
formation and subsequent secretion of Aβ species [30, 31]. An Aβ-peptide is not 
formed in Xenopus intermediate pituitary cells, since in these cells APP is cleaved by 
α-secretase.  
The findings of our biosynthetic studies combined with the western blot results 
suggest the occurrence of two pools of APP in Xenopus intermediate pituitary cells 
(schematically depicted in Figure 5). In transfected mammalian cells, Ehehalt et al. 
[32] have also found two pools of APP, one of which was cleaved by β- and γ-
secretase, whereas the other underwent α-secretase cleavage. Furthermore, in rat 
hippocampus, de novo synthesized endogenous APP has been found to be cleaved by 
both α- and β-secretase [33]. While in our case one pool of endogenous Xenopus APP 
is cleaved by α-secretase, the other pool is not proteolytically processed. This 
uncleaved pool of Xenopus APP is phosphorylated. Phosphorylation of mammalian 
APP has been shown to affect its interaction with other proteins and as such is thought 
to regulate the intracellular trafficking and cleavage of APP [34, 35].  
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Thus, in Xenopus intermediate pituitary cells the phosphorylation event may prevent 
glycosylation and cleavage of the endogenous minor pool of APP. In contrast to this 
pool, the major pool of APP is up-regulated and, during its trafficking through the 
secretory pathway, becomes N-glycosylated, subsequently O-glycosylated and finally 
proteolytically cleaved. The finding that the glycosylated, but not the 
nonglycosylated, pool of Xenopus APP is cleaved, is in line with transfection studies 
in which glycosylation of mammalian APP has been found to be a prerequisite for its 
proteolytic processing [36, 37]. 
 
Figure 5 Biosynthesis and differential processing of two pools of endogenous,
newly synthesized APP 
In Xenopus intermediate pituitary cells, the major pool of APP is readily N-glycosylated in the
ER and subsequently O-glycosylated, probably in the Golgi area. The glycosylated APP is
then proteolytically processed by an α-secretase-like cleavage event, resulting in a large N-
terminal processing product (APPsα) that is secreted into the extracellular space and a small
C-terminal fragment that remains associated with the cells. Only the minor pool of APP
becomes phosphorylated and this pool does not undergo glycosylation nor proteolytic
cleavage. On the left, a schematic of the secretory pathway is depicted. SP: signal peptide;
ER: endoplasmic reticulum; CGN: cis-Golgi network; TGN: trans-Golgi network; PM: plasma
membrane; TM: transmembrane domain;  : enzymatic cleavage site; : N-linked
glycosylation; : O-linked glycosylation;  : phosphorylation. 
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The proteolytic cleavage of endogenous Xenopus APP yields two products, namely 
the large N-terminal sAPPα which is secreted, and the small C-terminal fragment C83. 
Secreted sAPPα may function as a growth factor [4] or may be involved in cell 
proliferation [38]. In transfected mammalian cells in culture, the C83-fragment 
functions as a substrate for further processing by γ-secretase, yielding the AICD that 
appears to be involved in transcriptional regulatory processes [5]. In contrast, we 
observed no further processing of endogenous C83 to an AICD in Xenopus 
intermediate pituitary cells, indicating that the formation of an AICD may occur only 
under nonphysiological conditions. Finally, prior to its proteolytic cleavage, the intact 
APP-protein itself may represent the functional molecule. In this respect, the 
hypothesis is of interest that APP could function in post-Golgi vesicular cargo 
transport as a membrane receptor for the microtubule-dependent motor protein 
kinesin-1 [3]. In the active Xenopus intermediate pituitary cells of black animals, the 
high levels of POMC biosynthesis require an efficient vesicular transport machinery. 
Thus, the up-regulation of APP in these cells may point to a role for this protein in 
post-Golgi transport of prohormone-containing vesicles.  
Together, our results show that Xenopus intermediate pituitary cells provide a useful 
model to study the biosynthesis of APP and its response to neuroendocrine cell 
activation. Since aberrant pathological processing of this precursor protein is linked to 
AD, more detailed knowledge of APP biosynthesis may eventually help in the 
understanding of the pathogenesis of this neurodegenerative disorder. 
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APPENDIX TO CHAPTER THREE 
 
In chapter three, the biosynthesis and differential processing of two pools of APP in 
the Xenopus intermediate pituitary melanotrope cell was described. We found that the 
major pool of newly-synthesized APP became N- and O-glycosylated and 
subsequently proteolytically cleaved, followed by the release of the large N-terminal 
domain into the chase medium. In this appendix, we examined whether APP is 
transported through the regulated secretory pathway of the melanotrope cells. For this 
purpose, Xenopus intermediate pituitaries were pulsed with 35S-Met/Cys for 30 min 
and subsequently chased for 180 min in the absence or presence of different 
concentrations of the dopamine D2-receptor agonist apomorphine. Apomorphine 
blocks exocytosis of secretory granules in the regulated secretory pathway [1]. Newly 
synthesized proteins were extracted from the NIL lysates and the chase media, and 
either directly subjected to SDS-PAGE or immunoprecipitated with the N-terminally 
directed APP-antibody XA12. In the non-treated lobe, a substantial amount of the 
POMC processing products (14-18 kDa POMC) and also of its processing enzyme 
prohormone convertase 2 (PC2) was secreted into the chase medium following the 
three-hour chase period (Figure A1A). In the lobes that were chased in the presence of 
apomorphine, the levels of these proteins in the chase media were significantly 
decreased in a dose-dependent manner. Using a concentration of 0.02 µM 
apomorphine, the secretion of POMC-derived peptides and PC2 was inhibited ~80%, 
whereas increasing the apomorphine concentrations to 0.1 µM and 0.5 µM completely 
blocked the secretion of POMC-derived peptides. These results show that 
apomorphine treatment (already at a final concentration of 0.1 µM) completely 
prevents the secretion of proteins that are transported through the regulated secretory 
pathway in Xenopus melanotrope cells. To study the effect of apomorphine treatment 
on the secretion of APPsα, immunoprecipitation analysis was performed using 
antibody XA12, since this antibody is able to detect the 97-kDa secreted N-terminal 
APP fragment APPsα. Following the 3-hr chase period, in the non-treated lobes, the 
majority of the 97-kDa APPsα was detected in the chase medium (Figure A1B). 
Surprisingly, in the lobes that were chased in the presence of 0.02 µM and 0.1 µM 
apomorphine, the secretion of 97-kDa APPsα into the chase medium was not inhibited. 
Only at the high concentration of 0.5 µM, apomorphine was able to block the 
secretion of APPsα (>95%). Together, the results show that APP is not co-transported 
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with POMC and PC2 in the later stages of the regulated secretory pathway of Xenopus 
melanotrope cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
An involvement of APP in the biosynthetic machinery of the melanotrope cells is  
implicated by the threefold induction of APP expression in these cells of black- vs. 
white-adapted animals. Based on these results and combined with the cargo receptor 
role in post-Golgi vesicular transport that has been suggested for APP [2], we have 
proposed a cargo receptor role for APP in the regulated secretory pathway of Xenopus 
melanotrope cells (chapter three). The data obtained in the apomorphine experiment 
however are not in line with the notion that APP and POMC are transported in the 
same secretory granules and thus would exclude the possibility that APP is a cargo 
receptor in POMC-containing vesicle transport to the plasma membrane. It therefore 
seems likely that APP is transported through another pathway, one that is less or not 
sensitive to apomorphine. In other endocrine cells, the presence of a constitutive-like 
secretory pathway has been proposed [3]. This constitutive-like pathway is thought to 
Figure A1 Effect of apomorphine on the secretion of newly synthesized proteins
from Xenopus intermediate pituitary cells  
Neurointermediate lobes (NILs) of black-adapted Xenopus were pulsed for 60 min and
subsequently chased for 3 hrs in the absence or presence of 0.02 µM, 0.1 µM or 0.5 µM
apomorphine (APO). Newly synthesized proteins were extracted from the cell lysates (c)
and chase media (m) and either loaded directly on a 12.5% SDS-PAGE gel (panel A) or
immunoprecipitated with antibody XA12 before loading on a 10% SDS-PAGE gel (panel B).
Proteins were visualized by autoradiography. 
BA 
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consist of proteins escaping from immature secretory granules within the regulated 
secretory pathway and suggested to be operational for purging these proteins either to 
the endosomal system or for constitutive-like secretion (reviewed by Arvan and 
Halban, [4]). Furthermore, a role for clathrin has been implicated within this 
constitutive-like pathway [5]. Since the cytoplasmic tail of APP contains an NPxY-
motif involved in clathrin-coated vesicle targeting [6], we hypothesize that in Xenopus 
intermediate pituitary cells APP is transported and secreted via a constitutive-like 
pathway. This possibility is further discussed in chapter seven of this thesis. 
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ABSTRACT 
The amyloid-β precursor-like protein APLP2 is structurally and functionally related to 
the amyloid-β precursor protein APP, the protein generally accepted to be involved in 
Alzheimer's disease. Since we previously observed that the levels of APP mRNA and 
protein were up-regulated threefold in the active intermediate pituitary melanotrope 
cells of black-adapted Xenopus laevis, we now decided to study the regulation of 
APLP2 in these physiologically inducible neuroendocrine cells. Interestingly, both the 
mRNA and protein levels of Xenopus APLP2 were similar in the melanotrope cells of 
black and white frogs. Newly synthesized APLP2 became glycosylated and sulphated, 
chondroitin sulphate glycosaminoglycan chains were added and eventually the protein 
was proteolytically cleaved. Unlike for APP, no phosphorylated APLP2 was 
observed. Our results show that, although APP and APLP2 are thought to be 
functionally related, their responses to neuroendocrine cell activation differ, 
suggesting distinct roles for these proteins. 
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INTRODUCTION 
The type I transmembrane amyloid-β precursor-like protein APLP2 is part of a 
superfamily that also comprises the Alzheimer’s disease (AD)-linked amyloid-β 
precursor protein APP and, in mammals, the amyloid-β precursor-like protein APLP1 
[1]. Recently, we identified the first non-mammalian APLP2 sequence in the South-
African claw-toed frog Xenopus laevis [2]. The protein sequences of APP and APLP2 
are highly conserved throughout evolution, pointing to important and overlapping 
physiological roles. Functions attributed to both APP and APLP2 range from a cargo 
receptor in axonal transport for the intact proteins [3, 4] to roles for the cleavage 
fragments derived from APP and APLP2, such as their secreted N-terminal domains 
that may act as a growth factor [5, 6] and their so-called intracellular domains (ICDs) 
that are thought to be involved in transcriptional regulation [7, 8]. Furthermore, APP-/- 
and APLP2-/- single knock-out mice are viable, while APP-/- and APLP2-/- double 
mutants show perinatal lethality, suggesting functional redundancy [9]. Also APLP1-/- 
/ APLP2-/- double mutants die within the first day of birth, whereas APP-/- / APLP1-/- 
mice are viable, indicating a key physiological role for APLP2 [10]. More recently, 
mice lacking all three APP superfamily members have been generated and these mice 
also die shortly after birth [11].  
Of the APP superfamily members, APP is the most studied one since it is directly 
associated with AD, an age-related neurodegenerative disorder. Pathological 
processing of APP, involving cleavages by enzymes named β- and γ-secretase, 
produces the neurotoxic peptide amyloid-β (Aβ), a major constituent of the senile 
plaques found in AD-brains. The third secretase enzyme family member, α-secretase, 
cleaves APP within the Aβ-sequence, thereby preventing Aβ formation. In transfected 
cells, proteolytic processing of APLP2 also involves cleavages by α-, β- and γ-
secretase-like enzymes [8, 12, 13], although the α- and β-secretase cleavage sites in 
APP and APLP2 are not conserved. Furthermore, proteolytic processing of APLP2 by 
β- and γ-secretase does not result in a neurotoxic Aβ-like peptide [1].  
We recently reported the biosynthesis of two differentially processed pools of APP in 
Xenopus intermediate pituitary melanotrope cells and found that the major pool was 
up-regulated threefold in the active melanotrope cells of black-adapted animals [14]. 
We now examined whether APLP2 is also up-regulated and what the intracellular fate 
of this APP-relative is in the Xenopus melanotrope cells. These cells form a 
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homogeneous population and their activity can be physiologically manipulated 
through adaptation of the animal to its background. When adapted to a black 
background, the melanotrope cells are highly active in producing the prohormone 
proopiomelanocortin (POMC), while following adaptation to a white background, the 
cells become in an inactive state because they are inhibited by innervating neurons of 
hypothalamic origin. During transport through the secretory pathway, newly 
synthesized POMC is post-translationally modified and proteolytically processed. One 
of the processing products is α-melanophore-stimulating hormone (α-MSH), the 
hormone that stimulates the dispersion of the black pigment melanin in skin 
melanophores causing a darkening of the animal [15].  
In this report, we show that in response to Xenopus melanotrope cell activation, the 
induction of expression of APLP2 differs from that of APP, suggesting that, although 
structurally and reportedly functionally related, these APP superfamily members have 
distinct roles in neuroendocrine cells. 
 
 
MATERIALS AND METHODS 
Animals 
South-African claw-toed frogs, Xenopus laevis, were bred and reared at the Central Animal 
Facility of the Radboud University in Nijmegen, The Netherlands. Animals were adapted to a 
black or white background under constant illumination at 22 °C for at least three weeks. All 
animal experiments were carried out in accordance with the European Communities Council 
Directive 86/609/EEC for animal welfare. 
  
Real-time quantitative RT-PCR analysis 
NILs and anterior lobes ALs of black- and white-adapted Xenopus pituitaries were dissected, 
and total RNA was isolated using the Trizol method (Gibco, BRL; standard protocol), 
redissolved in 20 µl RNase-free H2O and quantified with a GeneQuant RNA/DNA calculator 
(Pharmacia). First-strand cDNA synthesis was performed using 1 µg of total RNA in 11 µl 
H2O and 1 µl pd(N)6 (random primers, 5 mU/µl, Roche) at 70°C for 10 min, followed by 
double-strand synthesis in 20 µl strand buffer (Life Technologies, Inc.) with 10 mM DTT, 20 
U RNAsin (Promega), 0.5 mM dNTPs (Roche) and 100 U reverse transcriptase 
(SuperScriptTM II, Gibco BRL) at 37°C for 90 min. To examine which of the APLP2 mRNA 
forms were expressed in Xenopus pituitary, NIL and AL cDNA of black- and white-adapted 
animals were analyzed as described previously [2]. For real-time quantitative RT-PCR 
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analysis, samples were diluted five times in RNase-free H2O and analyzed on a 5700 
GeneAmp PCR system (PE Applied Biosystems, Wellesley, MA) as follows: 5 µl template 
cDNA was added to 20 µl SYBR green buffer (PE Applied Biosystems) with 3 mM MgCl2, 
0.2 mM dNTPs (PE Applied Biosystems), 0.6 µM of both primers and 0.625 U AmpliTaq 
gold (PE Applied Biosystems). Forward primer 5’-AGAGAAGGCTGCACAGATGAAGT-3’ and 
reverse primer 5’-GAGAAAGAAGTTGTGAACTGATCCATA-3’ were used to amplify APLP2 
cDNA, and 5’-GCCGTGTATGTGGTGGAATCT-3’ and 5’-AAGTTGTCGTTGATGACCTTTGC-3’ for 
GAPDH cDNA synthesis. PCR conditions were: 95°C for 10 min followed by 40 reaction 
cycles of 95°C for 15 sec and 60°C for 1 min in each cycle. For each reaction, the cycle 
threshold (Ct) was determined, i.e. the cycle number at which fluorescence was detected 
above an arbitrary threshold (0.5). At this threshold, Ct values are within the exponential 
phase of the amplification. To estimate the relative amounts of APLP2 mRNAs in NILs and 
ALs from black- vs. white-adapted animals, Ct values were normalized to those of the internal 
standard (GAPDH). Four independent experiments were performed. 
 
Antibodies 
Polyclonal antibodies directed against the cytoplasmic tail of human APLP2 (AP-tail; [16]), 
the cytoplasmic tail of Xenopus APP (C87; [17]) and the precursor form of Xenopus POMC 
(ST62; [18]), and monoclonal anti-tubulin antibody (E7; [19]) have been described 
previously.  
 
Western blot analysis 
For western blot analysis, tissues were lysed in lysis buffer (50 mM Hepes pH 7.3, 140 mM 
NaCl, 0.1 % Triton, 0.1 % deoxycholate, 0.5 % NP-40, 5 mM EDTA, 1 mM 
phenylmethylsulfonylfluoride (PMSF) and 1 mM soybean trypsin inhibitor) and lysates were 
centrifuged for 7 min at 13000 rpm and 4°C. Supernatants were taken and proteins were 
denatured in Laemmli sample buffer at 95°C for 5 min, separated on either a 10% or a 12.5% 
SDS-PAGE gel and transferred onto nitrocellulose membranes (Protran, Schleicher and 
Schuell). In some experiments, NIL lysates were incubated with or without N-glycosidase-F 
(Roche) for 3 hrs at 37°C. For the separation of smaller proteins (5-25 kD range), a 15% Tris-
Tricine gel was used. Blots were incubated with the anti-APLP2 antibody AP-tail, anti-APP 
antibody C87 or anti-tubulin antibody E7 and subsequently with peroxidase-conjugated 
secondary antibodies. Signals were detected using Lumilight (Roche). A BioChemi imaging 
system was used to quantify protein levels and signals were analyzed using the LabWorks 4.0 
program (UVP BioImaging systems, Cambridge, UK). 
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Cycloheximide treatment 
NILs of black-adapted animals were dissected and incubated in Ringer’s medium (112 mM 
NaCl, 2 mM KCl, 2 mM CaCl2, 15 mM Hepes pH 7.4, 0.3 mg/ml BSA and 2 mg/ml glucose) 
in the presence of 50 µg/ml cycloheximide (Sigma) for 0, 3 or 6 hrs at 22°C. Following 
cycloheximide treatment, NILs were lysed and analyzed on western blots as described above. 
 
Metabolic cell labeling and immunoprecipitation analysis 
NILs of black-adapted Xenopus were dissected and incubated in Ringer’s medium at 22°C for 
15 min. In some experiments, lobes were preincubated for 30 min in the presence or absence 
of 1 mM benz-GalNAc (Sigma) or overnight in XL15 medium with or without 10 µg/ml 
tunicamycin (Sigma). Pulse labeling of newly synthesized proteins was performed by 
incubating lobes in Ringer’s medium containing 5 mCi/ml 35S-Met/Cys (ICN) for the 
indicated time periods at 22°C (in the presence or absence of 1 mM benz-GalNAc or 10 
µg/ml tunicamycin). For pulse and pulse-chase analysis, lobes were labeled for either 15 min 
or 1 h followed either by direct homogenization or by chase incubations for the indicated time 
periods in normal Ringer’s supplemented with 5 mM cold methionine. When indicated, lobes 
were chased in the presence of 1 mM benz-GalNAc. For the phosphorylation experiments, 
lobes were labeled in the presence of 8.5 mCi/ml 32P ortho-phosphate (Amersham). In these 
experiments, phosphatase inhibitors (1 µM ocadaic acid, 20 mM pyro-phosphate, 30 mM 
NaF, 2 mM EGTA, 5 mM EDTA) were added during lysis and immunoprecipitation. For the 
sulphation experiments, NILs were labeled with 6.7 mCi/ml 35SO4 and subsequently chased in 
the presence of 1 mM cold Na2SO4 for the indicated time periods. NILs were lysed on ice in 
lysis buffer. Lysates and chase media were cleared by centrifugation (13000 rpm, 7 min, 4°C) 
and the supernatants were either directly subjected to 12.5% SDS-PAGE or 
immunoprecipitated.  In some experiments, cell lysates were incubated in the presence or 
absence of chondroitinase ABC (Sigma) for 8 hrs at 37°C prior to immunoprecipitation. For 
immunoprecipitation analysis, cell lysates and media were incubated overnight in lysis buffer 
containing 0.075% SDS at 4°C with antibody AP-tail (1:200) or C87 (1:500) under 
continuous rotation. Immunocomplexes were precipitated with 2 mg protein A Sepharose and 
analyzed on a 10% SDS-PAGE gel. The gel was exposed to an autoradiograph at –70°C or a 
phosphor-imaging screen (Biorad molecular imaging personal FX).  
 
Statistics 
Data are presented as means ± SEM. Statistical evaluation was performed using one-way 
analysis of variance (ANOVA) followed by a students t-test. Values of p < 0.05 were 
considered statistically significant. 
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RESULTS AND DISCUSSION 
 
APLP2 mRNA and protein is not differentially expressed in the pituitary of 
black- and white-adapted Xenopus 
Alternatively spliced forms of Xenopus APLP2 mRNA occur [2] and we now studied 
the distribution of the different forms in pituitary tissue. The transcript lacking exons 
7 and 14 was the predominant form expressed in both the neurointermediate lobe 
(NIL) and the anterior lobe (AL) of the pituitary (data not shown). Next, we 
determined the levels of this Xenopus APLP2 mRNA form in the NIL and AL of 
animals adapted to a black or a white background. In Xenopus, the process of 
background adaptation is regulated by the intermediate pituitary melanotrope cells 
that, depending on the color of the background of the animal, are activated or 
inhibited by neurons of hypothalamic origin. In contrast, the anterior pituitary cells 
are not involved in background adaptation [20]. Real-time quantitative RT-PCR-
analysis showed that APLP2 transcript levels were similar in NILs of black-adapted 
animals compared to those of white animals. Also in the ALs, the APLP2 mRNA 
expression levels were not significantly different (Figure 1A). To study the expression 
of the APLP2 protein, western blot analysis was performed on NIL- and AL-lysates of 
black and white animals, using the C-terminally directed anti-APLP2 antibody AP-
tail. Our analysis revealed the presence of a single APLP2 protein with an estimated 
molecular weight of ~93 kDa. The APLP2 protein levels were similar in the NILs 
from black and white animals, and also in the ALs (Figure 1B). These results show 
that (both at the mRNA and protein level) APLP2 expression is not induced in the 
active intermediate pituitary melanotrope cells of black-adapted Xenopus. In contrast, 
and as recently reported [14], the expression levels of both APP mRNA and -protein 
are up-regulated threefold in the active intermediate pituitary cells (Figure 1C), 
whereas these levels are similar in the anterior pituitary cells (data not shown). Thus, 
the expression of Xenopus APP and APLP2 is differentially regulated in response to 
neuroendocrine cell activation. 
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Biosynthesis of APLP2 in Xenopus intermediate pituitary cells 
Next, we decided to investigate the biosynthesis of newly synthesized APLP2 in 
active Xenopus intermediate pituitary cells. NILs were radiolabeled (pulsed) with 35S-
Met/Cys for 15 min and immunoprecipitation analysis using the AP-tail antibody 
revealed the presence of two products with apparent molecular weights of ~93- and 
Figure 1 APLP2-mRNA and -protein expression in the pituitary of 
black- and white-adapted Xenopus  
A) Real-time quantitative RT-PCR analysis of APLP2-mRNA levels in the NIL and 
AL of the pituitary of black (B)- and white (W)-adapted animals. The values shown 
are relative to the amounts of GAPDH mRNAs. The level of APLP2 mRNA in the
NIL of white-adapted animals was set to 100%. In each case, the values shown
represent the mean ± SEM from four independent experiments.  
B) Western blot analysis of APLP2-protein levels in the NIL and AL of black- and 
white-adapted animals, using the C-terminally directed anti-APLP2 antibody AP-
tail. Proteins were separated by SDS-PAGE. Tubulin was used to show equal 
protein loading. Shown is a representative example of three independent
experiments. Protein molecular weight markers (Mr) are indicated on the right). 
C) Quantification of the mRNA- and protein levels of APLP2 and APP in NILs of 
black- and white-adapted animals. The mRNA- and protein levels were determined 
by RT-PCR and western blot analysis, respectively. The APLP2 and APP levels in
NILs from white-adapted animals were set to 1. APP mRNA- and protein levels 
were adapted from Collin et al., 2005 [17]. The values shown represent the mean ± 
SEM from four (mRNA) or three (protein) independent experiments. 
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~100 kDa (Figure 2A). Because the western blot analysis showed only a 93-kDa 
APLP2 protein product, we considered the possibility that the AP-tail antibody might 
have immunoprecipitated a newly synthesized protein other than APLP2. Since of the 
14 amino acid residues used to raise the AP-tail antibody, 11 amino acids are 
conserved between the Xenopus APP and APLP2 proteins, in addition to APLP2, this 
antibody may have co-immunoprecipitated APP as well. To further investigate this 
possibility, immunoprecipitations were performed using both the AP-tail antibody and 
the C-terminally directed anti-APP antibody C87, showing that the upper band of 100 
kDa detected by the anti-APLP2 antibody comigrated with 100-kDa APP (Figure 2A). 
Furthermore, using the anti-APP antibody for western blot analysis of a NIL lysate 
that had been immunoprecipitated with the AP-tail antibody revealed that the APLP2 
antibody had indeed co-immunoprecipitated APP (data not shown). Thus, under the 
conditions used in the immunoprecipitation analysis, antibody C87 does not recognize 
APLP2, whereas antibody AP-tail does immunoprecipitate APP. This finding is in 
line with [16] who also found that the AP-tail antibody co-immunoprecipitates APP if 
present in high amounts. Our previous biosynthetic analysis of APP in Xenopus 
intermediate pituitary cells revealed the presence of two pools of APP. The major 
pool undergoes N- and O-linked glycosylation, proteolytic processing by α-secretase 
and subsequent secretion of the large N-terminal cleavage product, while the minor 
pool becomes phosphorylated and, once phosphorylated, does not undergo any other 
post-translational modifications nor proteolytic processing [17]. To perform a more 
detailed analysis of APLP2 biosynthesis in Xenopus intermediate pituitary cells, NILs 
were pulsed with 35S-Met/Cys for 15 or 60 min and either directly homogenized or 
subsequently chased for 90 or 180 min. During the 15- and 60- min pulse periods, two 
major APLP2 products with apparent molecular weights of ~88- and ~93-kDa were 
found. During the chase periods of 90 and 180 min, the 88-kDa newly synthesized 
form of APLP2 was converted to the 93-kDa form. The amount of this form 
subsequently decreased during the 180-min chase period (Figure 2B), a phenomenon 
also observed for the 110-kDa form of APP. Furthermore, a low-abundant, diffuse 
additional APLP2 product with an estimated molecular weight of ~190 kDa was 
detected after the 60-min pulse and following the various chase periods (Figure 2B). 
The APP antibody did not recognize this high-molecular weight product (data not 
shown). 
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Glycosylation of APLP2 in Xenopus intermediate pituitary cells 
Since in Xenopus intermediate pituitary cells APP was found to be both N- and O-
glycosylated [17], we decided to study the glycosylation status of APLP2 in these 
cells. First, NIL lysates were treated with N-glycosidase F to remove N-linked sugar 
chains. Western blot analysis revealed that the migration of APLP2 was affected by 
the N-glycosidase F treatment (Figure 3A), indicating that in Xenopus intermediate 
pituitary APLP2 is N-glycosylated. Furthermore, NILs were preincubated with or 
without tunicamycin (which prevents N-linked glycosylation of newly synthesized 
proteins). Subsequent metabolic cell labeling and immunoprecipitation analysis 
revealed that the migrations of both the 88-kDa and the 93-kDa forms of APLP2 were 
affected upon tunicamycin treatment, showing that both forms of APLP2 were N-
glycosylated and thus that the N-glycosylation of APLP2 occurred readily after its 
synthesis in Xenopus melanotrope cells (Figure 3B). Next, we decided to study 
whether APLP2 was also O-glycosylated. For this purpose, NILs were pre-incubated, 
pulsed and chased in the presence or absence of benzyl-2-acetamido-2-deoxy-a-D-
galacto-pyranoside (benz-GalNAC), which blocks O-linked glycosylation. Benz-
Figure 2 Biosynthesis of endogenous APLP2 in Xenopus
intermediate pituitary cells 
A) NILs from black-adapted Xenopus were pulsed in the presence of 35S-
Met/Cys for 15 min. Newly synthesized proteins were extracted and
immunoprecipitated from the cell lysate with either the C-terminally directed
anti-APLP2 antibody AP-tail or the C-terminally directed anti-APP antibody
C87. The radiolabeled proteins were resolved by SDS-PAGE and visualized
using autoradiography.  
B) NILs were pulsed and subsequently chased for the indicated time periods.
Newly synthesized proteins were immunoprecipitated from the cell lysates
and chase media with antibody AP-tail. The immunoprecipitates were
resolved by SDS-PAGE and the radiolabeled proteins were visualized using
autoradiography. Protein molecular weight markers (Mr) are indicated on the
right). 
A B
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GalNAc treatment caused a shift of the 93-kDa to the 88-kDa form of APLP2 (Figure 
3C), showing that APLP2 was O-glycosylated and that this post-translational 
modification was responsible for the conversion of the 88-kDa to the 93-kDa form of 
newly synthesized APLP2. In Syrian hamster retinal ganglion cells, newly 
synthesized mammalian APLP2 has also been found to undergo both N- and O-linked 
glycosylation [21]. 
Furthermore, chondroitin sulphate proteoglycan (CSPG) forms of APLP2 have been 
detected in mammalian cell lines [22, 23]. The attachment of such a high-molecular 
weight chondrotin sulphate glycosaminoglycan (CSGAG) side chain occurs at 
conserved serine residues that are part of a Ser-Gly peptide motif preceded by acidic 
amino acid residues [24, 25]. The consensus of this motif in mammalian APLP2 is 
fully conserved in the Xenopus APLP2 protein [2]. To determine whether the 190-kDa 
APLP2 product represented such a CSPG form of APLP2, newly synthesized NIL 
proteins were incubated in the presence or absence of chondroitinase ABC (which 
removes CSGAG side chains) prior to immunoprecipitation with the APLP2 antibody. 
Chondroitinase treatment caused a decrease of the 190-kDa form of APLP2, and the 
appearance of an ~ 95-kDa product, presumably representing APLP2 with the 
CSGAG side chain removed (Figure 3D).  
Together, these results show that Xenopus APLP2 undergoes N- and O-glycosylation 
as well as conversion to a CSPG form. 
 
Both APP and APLP2 are sulphated in Xenopus intermediate pituitary cells 
Besides glycosylation, secretory proteins may undergo another kind of post-
translational modification, namely sulphation. This kind of modification has been 
shown to specifically occur at the trans-Golgi network (TGN) and regulates sorting of 
proteins to their final destination [26]. Mammalian APP has previously been found to 
become sulphated prior to its proteolytic processing [27, 28]. Thus far, sulphation of 
Xenopus APP and of APLP2 has not been studied. To determine whether APP and 
APLP2 are sulphated in Xenopus intermediate pituitary cells, NILs were pulse labeled 
in the presence of 35SO4 for 15 min and subsequently chased for 0, 20 or 60 min. 
Radiolabeled proteins were immunoprecipitated with either the N-terminally directed 
anti-APP antibody XA12 or the antibody AP-tail. 
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Figure 3 Glycosylation of APLP2 in Xenopus intermediate pituitary cells 
A) Western blot analysis of NIL lysates not treated (-) or treated with (+) N-glycosidase
F using the C-terminally directed anti-APLP2 antibody AP-tail. Proteins were separated
by SDS-PAGE. 
B) Following overnight preincubation in the absence (-) or presence (+) of tunicamycin
(tun), NILs were pulsed with 35S-Met/Cys for 60 min without or with the drug. The newly
synthesized proteins from the cell lysates were immunoprecipitated with antibody AP-
tail and the immunoprecipitated proteins were resolved by SDS-PAGE and visualized
by autoradiography.  
C) Following 30 min preincubation in the absence (-) or presence (+) of benz-GalNAc,
NILs were pulsed for 60 min and subsequently chased for 60 min without or with the
drug. The newly synthesized proteins from the cell lysates were immunoprecipitated
with antibody AP-tail and the immunoprecipitated proteins were resolved by SDS-
PAGE and visualized by autoradiography. 
D) NILs were pulsed for 60 min and subsequently chased for 90 min. Newly
synthesized proteins from the cell lysates were incubated in the absence (-) or
presence (+) of chondroitinase ABC (chondr. ABC) prior to immunoprecipitation with
antibody AP-tail. The immunoprecipitates were resolved by SDS-PAGE and the
radiolabeled proteins were visualized using autoradiography. 
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Using the XA12 antibody, we found that the mature 110-kDa O-glycosylated form of 
APP was sulphated. Following the 60-min chase period, an additional sulphated 
product was detected, representing the 97-kDa large N-terminal APP cleavage product 
sAPP, both in the cell lysate and the chase medium (Figure 4A). These results show 
that in Xenopus intermediate pituitary cells APP is sulphated following its O-
glycosylation but prior to its proteolytic processing. Using the AP-tail antibody, we 
found that the 93-kDa form of APLP2 was sulphated, indicating that, like APP, 
APLP2 undergoes sulphation after its O-glycosylation (Figure 4B). Together, these 
data show that both APLP2 and APP are sulphated in the TGN and thus transported 
through the secretory pathway. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APLP2 is not phosphorylated in Xenopus intermediate pituitary cells 
Mammalian APLP2 can undergo phosphorylation at two threonine residues in the 
cytoplasmic tail [29] and both threonines have been conserved in the Xenopus APLP2 
protein sequence [2]. We recently described the presence of a small, phosphorylated 
pool of APP in Xenopus intermediate pituitary cells that, once phosphorylated, did not 
undergo any further post-translational modifications nor proteolytic cleavage [14]. To 
Figure 4 Sulphation of newly synthesized APP and APLP2 in Xenopus
intermediate pituitary cells 
NILs were pulsed for 15 min in the presence of 35SO4 and either directly 
homogenized or subsequently chased for the indicated time periods. The newly
synthesized proteins from the cell lysates and the chase media were
immunoprecipitated with either the N-terminally directed anti-APP antibody XA12 (ab 
XA12; panel A) or the C-terminally directed anti-APLP2 antibody AP-tail (ab AP-tail; 
panel B). The immunoprecipitated proteins were resolved by SDS-PAGE and 
visualized by autoradiography. For comparison, newly synthesized 35S-Met/Cys-
labeled APP and APLP2, immunoprecipitated with the antibody C87 or AP-tail, 
respectively, are shown. 
A B
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examine whether also APLP2 is phosphorylated in Xenopus intermediate pituitary 
cells, NILs were incubated in the presence of radiolabeled orthophosphate. Following 
a 60-min pulse, no phosphorylated APLP2 was immunoprecipitated, while from an 
equal amount of 32P-phospho-labeled melanotrope cell proteins, phosphorylated APP 
was immunoprecipitated with the C-terminal anti-APP antibody. For comparison, 35S-
Met/Cys-labeled immunoprecipitated APP and APLP2 were analyzed on the same gel 
(Figure 5). We conclude that, in contrast to APP, APLP2 is not phosphorylated in 
Xenopus intermediate pituitary cells. Nevertheless, the amount of phosporylated 
APLP2 may not have been sufficient for immunoprecipitation, or the C-terminal anti-
APLP2 antibody was not able to immunoprecipitate phosphorylated APLP2. 
However, our western blot analysis revealed the presence of only one glycosylated 
APLP2 protein product at the steady-state level (Figure 1B), supporting the 
hypothesis that one (glycosylated but not phosphorylated) pool of APLP2 occurs in 
Xenopus intermediate pituitary cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Proteolytic processing of APLP2 in Xenopus intermediate pituitary cells 
To study whether APLP2 is proteolytically cleaved in Xenopus intermediate pituitary 
cells, western blot analysis was performed to detect any C-terminal APLP2 processing 
products. NIL and AL lysates of both black- and white-adapted animals were 
separated on a 15% Tris-Tricine gel to separate proteins in the ~5-25-kDa range and 
Figure 5 Newly synthesized APLP2 is not phosphorylated in Xenopus
intermediate pituitary cells 
NILs were pulsed for 60 min in the presence of 32PO4 (32P). The newly synthesized 
proteins from the cell lysates were immunoprecipitated with either the C-terminally 
directed anti-APLP2 antibody AP-tail or the C-terminal anti-APP antibody C87. The 
immunoprecipitated proteins were resolved by SDS-PAGE and visualized by 
autoradiography. For comparison, newly synthesized 35S-Met/Cys-labeled APLP2 
and APP, immunoprecipitated with the antibody AP-tail or C87, respectively, are 
shown. 
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blots were incubated with the C-terminally directed anti-APLP2 antibody AP-tail. Our 
analysis revealed the presence of a protein product of about ~13 kDa in both the NIL 
and AL of black as well as white animals (Figure 6), indicating that APLP2 is indeed 
proteolytically cleaved in Xenopus pituitary cells. This notion is in line with the 
decrease in the amount of newly synthesized APLP2 during the 90- and 180-min 
chase periods (Figure 2B), although protein degradation may also be responsible for 
part of this decrease. Unfortunately, since an antibody recognizing the N-terminal part 
of Xenopus APLP2 is not available, we were not able to study the biosynthesis and 
subsequent secretion of APLP2s. The proteolytic processing of APP by α-secretase 
also resulted in a 13-kDa C-terminal fragment in Xenopus intermediate pituitary cells 
[17], suggesting that in these cells APLP2 is processed similar to APP. However, the 
levels of the C-terminal APLP2 cleavage product were similar between the lobes from 
black- and white animals, while for the C-terminal APP cleavage product the levels 
were threefold higher in lobes from black- vs white animals. These results are in line 
with the differences found in the expression levels of the APLP2 and APP 
holoproteins (Figure 1C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To determine the protein turnover of APP and APLP2 in Xenopus melanotrope cells, 
NILs were incubated for 0, 3 or 6 hrs in the presence of cycloheximide (which blocks 
translation and thus allows to study protein stability in time). Western blot analysis 
Figure 6 Production of a C-terminal cleavage fragment of APLP2 in 
Xenopus intermediate pituitary cells 
Western blot analysis of APLP2-cleavage products in NILs and ALs of black (B)- and 
white (W)-adapted animals using the C-terminally directed anti-APLP2 antibody AP-
tail. Proteins were separated on a 15% Tris-Tricine gel. Tubulin was used to show 
equal protein loading. Shown is a representative example of three independent
experiments. Protein molecular weight markers (Mr) are indicated on the right. 
APLP2-CTF: the C-terminal cleavage fragment of APLP2.
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revealed that the amount of APLP2 decreased only moderately after 3 and 6 hrs of 
cycloheximide treatment. In contrast, the amount of APP present in the cells was 
drastically reduced following 3 and 6 hrs of treatment, a finding also observed for 
POMC, the major newly synhtesized protein in Xenopus melanotropes (Figure 7). 
Quantification revealed that, relative to tubulin, 84% and only 31% of the amount of 
APLP2 and APP, respectively, remained present in the cells after 6 hrs of 
cycloheximide treatment. These results indicate that the protein turnover of APLP2 
and APP is different in Xenopus intermediate pituitary cells. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Concluding remarks 
The present study compares the characteristics of two closely related proteins, APLP2 
and APP, in a physiologically inducible neuroendocrine cell, the Xenopus 
intermediate pituitary melanotrope cell. The biosynthetic and secretory activity of this 
cell can be physiologically induced by simply adapting the animal to a black 
background. In an active state, these cells are destined to produce large amounts of a 
single cargo molecule with a well-defined role: the prohormone POMC is 
synthesized, transported via the regulated secretory pathway and cleaved to yield α-
MSH, the hormone responsible for darkening of the skin. Coordinately expressed with 
POMC are a number of other gene products that are operational in the secretory 
Figure 7 Stability of the APLP2 and APP proteins in Xenopus
intermediate pituitary cells 
NILs of black-adapted animals were incubated in the presence of cycloheximide
(cyclo) for 0, 3 or 6 hrs. NIL lysates were subjected to 10% SDS-PAGE and western 
blot analysis was performed using the C-terminally directed anti-APLP2 antibody AP-
tail, the C-terminally directed anti-APP antibody C87, the anti-POMC antibody ST62 
or the anti-tubulin antibody E7. 
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pathway, e.g. the POMC-processing enzymes PC2 and carboxypeptidase H [30]. The 
activity of the melanotrope cells is controlled by inhibitory and stimulatory neurons of 
hypothalamic origin that affect intracellular signal transduction cascades involving 
cyclic AMP- and Ca2+-dependent pathways, eventually leading to transcriptional 
regulation of a number of genes [31]. Since in an active state the melanotrope cells are 
destined to produce and process huge amounts of POMC, the genes that are 
coordinately expressed with POMC are all thought to be somehow involved in the 
biosynthesis, processing or transport of POMC. Recently, we described that the levels 
of both APP mRNA and protein were up-regulated threefold in the active melanotrope 
cells of black animals and suggested a role for APP in post-Golgi transport of 
prohormone-containing vesicles [14]. Intriguingly, we here describe that the APLP2 
mRNA and protein levels are similar in melanotrope cells of black and white animals. 
These findings show that, although structurally related, APLP2 and APP differ in their 
responses to neuroendocrine cell activation and thus may have separate roles in these 
cells. Because  both APLP2 and APP undergo post-translational modifications, such 
as N- and O-linked, glycosylation, sulphation and proteolytic processing, it is likely 
that the two proteins are transported through the secretory pathway. However, the 
occurrence of differences in post-translational modification (e.g. CSGAG side chain 
attachment to APLP2 but not to APP) and the fact that APP, but not APLP2, is 
coordinately expressed with POMC indicate that the two APP family members are 
transported through different parts of the secretory pathway. On the basis of our 
findings and together with the cargo receptor role that has been suggested for APP 
and APLPs [3, 4], we propose that both APP and APLP2 may act as cargo receptors 
but then in separate subcompartments of the secretory pathway.  
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ABSTRACT 
The amyloid-β precursor protein APP is linked to the neurodegenerative disorder 
Alzheimer’s disease via its pathological processing to the neurotoxic peptide amyloid-
β. APP is part of a superfamily that also comprises the amyloid-β precursor-like 
protein APLP2. Despite extensive research over several decades, the normal 
physiological role of APP and APLP2 are still elusive. Here, we describe the 
generation of various constructs encoding GFP-fusion proteins of wild-type or mutant 
APP and APLP2. Transient transfection studies in neuronal N2A cells combined with 
immunofluorescence and western blot analysis showed that all generated constructs 
were properly expressed, i.e. the fusion proteins had a correct size and the expected 
intracellular localization. To perform functional studies close to the in vivo situation, 
we decided to use the stable Xenopus transgenesis procedure. Using various tissue-
specific gene promoters, the generated constructs were targeted to either the 
intermediate pituitary cells, neuronal cells, muscle cells or to all cells. Remarkably, 
the GFP-APLP2 fusion proteins were found to be expressed only in muscle cells and 
not in the brain or in the intermediate pituitary cells of the generated tadpoles. Similar 
results were obtained with the constructs encoding APP fused to GFP (discussed in 
more detail in chapter six). Based on our results, we conclude that in Xenopus 
neuronal and neuroendocrine transgene expression of APP and APLP2 is prevented 
by the presence of an interfering element in the cDNA sequences of these two related 
proteins. 
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INTRODUCTION 
The amyloid-β precursor protein APP and the amyloid-β precursor-like protein 
APLP2 are two type I transmembrane proteins that are structurally and reportedly 
functionally related. APP is known for its involvement in the neurodegenerative 
disorder Alzheimer’s disease (AD), via its pathological proteolytic processing that 
results in the neurotoxic peptide amyloid-β (Aβ) [1, 2]. Despite the direct 
involvement of APP in the pathology of AD, little is known on the normal role of 
APP under physiological conditions. Extensive research over the last decades, mainly 
in transfected cells in culture, resulted in a number of proposed roles for this protein. 
Functions attributed to APP or its proteolytic processing fragments vary from a role as 
a cell-surface receptor [2] or a cargo receptor in axonal transport [3] to roles in cell 
adhesion [4], neuritic outgrowth [5] or copper homeostasis [6] or transcriptional 
regulation [7]. For APLP2, similar functions have been suggested [6, 8-10]. 
Furthermore, a role in chromosomal replication and/or segregation has been proposed 
for APLP2 but not for APP [11]. 
To address the physiological roles of APP and APLPs directly, others have previously 
generated transgenic mice, either overexpressing or lacking these proteins. Mice 
expressing wild-type or mutant forms of APP show a number of neuronal deficits, 
including neurodegenerative effects, accelerated senescence and premature death [12-
17]. Single knock-out mice lacking either APP or APLP2 are viable, while APP-/- and  
APLP2-/- double mutants show perinatal lethality, suggesting functional redundancy 
[18, 19]. Besides transgenic mice models, other vertebrates are more and more 
commonly used to study protein function, including the South-African claw-toed frog 
Xenopus laevis. This amphibian is able to adapt its skin color to its background, a 
process regulated by the intermediate pituitary melanotrope cells. When the animal is 
on a black background these cells are highly active in producing the prohormone 
proopiomelanocortin (POMC), the precursor of the α-melanophore-stimulating 
hormone (α-MSH) responsible for skin darkening, while on a white background the 
melanotrope cells are virtually inactive [20]. The stable introduction of transgenes in 
Xenopus is an easy and relatively fast procedure [21, 22]. Using a POMC gene 
promoter fragment, transgenes can be specifically targeted to the intermediate 
pituitary melanotrope cells, providing a tool to study protein function in a 
homogeneous and physiologically inducible cell population [23, 24]. Recently, we 
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described the up-regulation of endogenous APP, but not of APLP2, in response to 
Xenopus melanotrope cell activation [25, 26]. Therefore, we now decided to study the 
physiological roles of APP and APLP2 in these cells via stable Xenopus transgenesis. 
In the present study, we generated and analyzed a number of constructs encoding 
GFP-fusion proteins of either wild-type or mutant APP and APLP2. These constructs 
were then targeted either specifically to the intermediate pituitary cells using the 
POMC gene promoter or to other cell types using various tissue-specific gene 
promoters with the ultimate goal to gain more insight into the roles of APP and 
APLP2. 
 
 
MATERIALS AND METHODS 
Animals 
South-African claw-toed frogs Xenopus laevis were bred and reared at the Central Animal 
Facility of the University of Nijmegen. For transgenesis experiments, mature female Xenopus 
were obtained directly from South-Africa (Xenopus express). All animal experiments were 
carried out in accordance with the European Communities Council Directive 86/609/EEC for 
animal welfare, and permit TRC 99/15072 to generate and house transgenic X. laevis. 
 
Generation of DNA constructs encoding GFP fusion proteins of APP and APLP2 
In order to create a unique restriction site upstream of the CMV promoter sequence, the 
pCS2+ vector [27] was digested with NaeI and blunted. A double-stranded oligo containing 
an AscI site (5’-AGGCGCGCCA-3’; the AscI site is underlined) was inserted into the blunted 
NaeI site yielding pCS2+(A). The coding sequence of GFP was amplified via PCR with 
forward primer 5’-GGGGAGATCTATCGTGAGCAAGGGCGAGGA-3’ and reverse primer 5’-
GGGGAATTCCTTGTACAGCTCGTCCATGCC-3’, digested with BglII and EcoRI and fused 
downstream of the signal peptide (SP) sequence of Xenopus Ac45 cDNA in the correct 
reading frame. The SP-GFP fusion was subcloned via BamHI- and EcoRI-sites into the 
pCS2+(A) vector, thereby generating pCS2+(A) SP-GFP. AscI/HindIII fragments of tissue-
specific Xenopus gene promoters (elongation factor 1α-, neural β-tubulin-, cardiac actin- and 
POMC gene promoter) were exchanged with the AscI/HindIII fragment containing the CMV 
promoter to obtain the transgenesis vectors pEF2+(A) SP-GFP, pNtub2+(A) SP-GFP, 
pCac2+(A) SP-GFP and pPOMC2+(A) SP-GFP, respectively. The coding sequence of 
Xenopus APP (lacking the signal peptide sequence) was amplified, digested with EcoRI and 
XbaI and subcloned into the transgenesis vectors, yielding pCS2+(A) SP-GFP-APP, 
pEF2+(A) SP-GFP-APP, pNtub2+(A) SP-GFP-APP, pCac2+(A) SP-GFP-APP and 
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pPOMC2+(A) SP-GFP-APP. To generate constructs encoding amino (N)-terminal GFP-
fusion proteins of mutant APP, desired fragments of APP or the intracellular adhesion 
molecule ICAM (aa 446-502 of human ICAM [28]) were obtained via PCR using primers 
containing specific restriction sites and the fragments were subcloned into the transgenesis 
vectors described above. An overview of the primers used to amplify the various regions of 
APP is provided in table I. 
 
Table I  Overview of the primers used to generate the various constructs 
 
Mutant Amino acid 
residues 1,2 
Forward primer (5’-3’) Reverse primer (5’-3’) 
GFP-APP 18-695 gggggaattcctggaggtaccagcagat ggggtctagattagttctgcatctgctcgaagaa 
GFP-APPdelC 18-645 gggggaattcctggaggtaccagcagat ggggtctagattaagtgatgactatcaccgttgc 
GFP-APP/ICAM 18-625 gggggaattcctggaggtaccagcagat ggggactagttttgtttgatcccacttcgtc 
GFP-C99 594-695 gggggaattcgtaaagatggattccgaatata ggggtctagattagttctgcatctgctcgaagaa 
GFP-AICD 638-695 ggggagatctatagcaacggtgatagtcatc ggggtctagattagttctgcatctgctcgaagaa 
GFP-APLP2 21-705 gggggaattcggttatatcgaggcactggca ggggactagtctcaaatctgcatttgctc 
GFP-APLP2delC 21-658 ----3 ----3 
GFP-APLP2/ICAM 21-619 gggggaattcggttatatcgaggcactggca ggggactagtctcattacgcagtggtccat 
APP-GFP 1-695 gggggaattccgatcgtcggtggagccg ggggggatccgttctgcatctgctcgaagaacttg 
APPdelC-GFP 1-645 gggggaattccgatcgtcggtggagccg ggggggatccagtgatgactatcaccgttgc 
AICD-GFP 638-695 ggggaagcttaccaccatgatagcaac 
ggtgatagtcatc 
ggggggatccgttctgcatctgctcgaagaacttg 
APLP2-GFP 1-705 gggggaattcgcgcaggagagaggagtt ggggcccgggccaatctgcatttgctccaa 
1) Numbering amino acid residues APP according to APP-695: [35] 
2) Numbering amino acid residues APLP2 according to APLP2-705: [36] 
3) GFP-APLP2delC was generated by digesting GFP-APLP2 with NcoI, fill 5’-overhang with Klenow and 
ligate, hereby introducing a stop codon ~20 nt downstream of the NcoI-site 
 
 
Listed are the primer sequences used to amplify the various domains of APP and APLP2. The 
amino acid residues corresponding to the various domains are presented in the second left 
column. 
 
 
For the generation of constructs encoding carboxy(C)-terminal GFP-fusion proteins, the 
coding sequence of APP (including its own signal peptide sequence) was amplified via PCR, 
digested with EcoRI and BamHI, and subcloned into the pEGFPN3delAUG vector (Clontech 
vector, modified by us to remove the start methionine of GFP). The fragment encoding the 
SP-APP-GFP fusion protein was subsequently digested with EcoRI and XbaI and subcloned 
into the POMC transgenesis vector yielding pPOMC2+(A) SP-APP-GFP. To generate 
constructs encoding C-terminal GFP-fusion proteins of mutant APP, desired fragments of 
APP were obtained via PCR using primers containing specific restriction sites (see table I) 
and the fragments were subcloned into the transgenesis vectors described above.  
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Analogous to APP, various parts of the coding sequence of APLP2 were amplified (for primer 
sequences: see table I) and used to generate constructs encoding N- and C-terminal GFP-
fusion proteins. All generated GFP-fusion constructs were checked by cycle DNA sequencing 
using the Big Dye Ready Reaction system (Abi Prism, Perkin Elmer) and primer 5’-
AGTCCGCCCTGAGCAAAGAC-3’ reading downstream or primer 5’-TTTACGTCGCCGTCCAGCTC-
3’ reading upstream from the GFP sequence into the APP or APLP2 cDNA sequence. 
 
Transfection of the generated DNA constructs into N2A cells 
Neuronal N2A cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% Fetal Calf Serum and antibiotics at 37°C with 5.5% CO2, and grown 
until 70% confluency on coverslips or in wells. For transient expression studies, 1 µg of 
plasmid DNA was transfected using Fugene (Roche). After 24 hrs, cells were either harvested 
in lysis buffer (50 mM Hepes pH 7.3, 140 mM NaCl, 0.1 % Triton, 0.1 % deoxycholate, 0.5 
% NP-40, 5 mM EDTA, 1 mM phenylmethylsulfonylfluoride and 1 mM soybean trypsin 
inhibitor) for western blot analysis or prepared for fluorescence analysis. For the fluorescence 
analysis, cells on coverslips were fixed in 4% paraformaldehyde, washed with PBS, 
dehydrated in methanol and mounted on object slides using Mowiol (10% w/v). Digital 
images were obtained under a Leica DM RA fluorescence microscope with a Cohu High 
Performance CCD Camera using the Leica Q Fluoro software. 
 
Generation of transgenic Xenopus embryos 
The generated DNA constructs were digested with AscI and either NotI or PauI to yield a 
linear DNA fragment containing the tissue-specific promoter sequence, the fusion protein and 
the polyadenylation signal. Linearized DNA fragments were purified using Qiaex II gel 
extraction kit (Qiagen) and used for stable Xenopus transgenesis according to standard 
protocols [21, 22]. Briefly, the transgene DNA was mixed with sperm nuclei, incubated at RT 
for 15 min and injected into unfertilized eggs. Generated embryos were grown in 
0.1xMMR/6% Ficoll-400 (Sigma) and 50 µg/ml gentamycin (Gibco/BRL) until gastrulation 
and then in 0.1xMMR containing gentamycin. The presence of GFP fluorescence in living 
embryos, anaesthesized with 0.25 mg/ml MS222 (3-aminobenzoic acid ethyl ester, Sigma), 
was examined using a Leica MZ FLIII fluorescence stereomicroscope and photographs were 
taken with a Leica DC200 color camera using the Leica DCviewer software. 
 
Antibodies 
Polyclonal anti-GFP antibody has been described previously [29]. 
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Western blot analysis 
For Western blot analysis, transfected COS-1 cells or Xenopus tissues were lysed in lysis 
buffer (50 mM Hepes pH 7.3, 140 mM NaCl, 0.1 % Triton, 0.1 % deoxycholate, 0.5 % NP-
40, 5 mM EDTA, 1 mM phenylmethylsulfonylfluoride and 1 mM soybean trypsin inhibitor) 
and lysates were centrifuged for 7 min at 1300 rpm and 4°C. Supernatants were taken and 
proteins were denatured in Laemmli sample buffer at 95°C for 5 min, separated by SDS-
PAGE and transferred onto nitrocellulose membranes (Protran, Schleicher and Schuell). Blots 
were incubated with anti-GFP antibody (1:5000) and subsequently with peroxidase-
conjugated secondary antibodies. The signal was detected using Lumilight (Roche). For 
quantification, detection was performed using a BioChemi imaging system and signals were 
analyzed using the LabWorks 4.0 program (UVP BioImaging systems, Cambridge, UK). 
 
 
RESULTS AND DISCUSSION 
 
Generation of constructs encoding GFP-fusion proteins of Xenopus APP and 
APLP2 
To study the role of APP and APLP2 in transgenic Xenopi, GFP-fusion constructs 
were generated that would enable us to visualize the transgene proteins directly in 
living animals. The coding sequences of Xenopus APP and APLP2 cDNA were fused 
either downstream (N-terminal GFP-fusion proteins, e.g. GFP-APP or GFP-APLP2) 
or upstream to that of GFP (C-terminal GFP-fusion, e.g. APP-GFP or APLP2-GFP). 
Since the APP and APLP2 proteins enter the secretory pathway, for the N-terminal 
GFP-fusion proteins a signal peptide sequence (SP) was cloned upstream of GFP in 
order to allow translocation of the fusion proteins into the ER. Mutants of APP and 
APLP2 were generated by either removing certain specific domains or expressing 
such domains as GFP-fusion proteins. For instance, for both APP and APLP2, 
mutants were generated that lack their cytoplasmic tail. These domains are important 
since they harbor a number of binding sites for other proteins [30] and contain 
residues that have been reported to be phosphorylated [31, 32]. Further mutants 
contained the transmembrane domain and cytoplasmic tail of another protein, namely 
the intracellular adhesion molecule ICAM, fused to the large N-terminal domain of 
either APP or APLP2. Previously, transfection studies on a similar chimeric protein, 
consisting of the N-terminal part of the type I transmembrane protein Ac45 (a 
vacuolar ATPase accessory subunit) and the transmembrane and cytoplasmic domains 
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of ICAM, showed plasma membrane expression of the chimeric protein due to the 
presence of the ICAM domain [33]. Furthermore, mutants that express only the C-
terminal β- or γ-secretase cleavage fragments of APP (C99 and AICD, respectively) 
fused to GFP were generated. Since the γ-secretase fragment essentially corresponds 
to the cytoplasmic portion of APP, no signal peptide sequence was included in the 
construct. By expressing these mutants, we aimed to interfere with the functioning of 
the endogenous APP and APLP2 proteins. A schematic overview of the various N- 
and C-terminal GFP-fusion proteins of APP and APLP2 is presented in figure 1.  
 
 
 
Figure 1 Overview of the various GFP-APP, GFP-APLP2, APP-GFP and
APLP2-GFP fusion proteins 
N-terminal GFP-fusion proteins are presented in the upper panel, while C-terminal
GFP-fusion proteins are depicted in the lower panel. Arrows indicate the β-, α- or γ-
secretase processing sites within APP. SP: signal peptide sequence; delC: mutant
lacking the cytoplasmic tail of APP; ICAM TM/CT: mutant containing the
transmembrane domain and cytoplasmic tail of the intracellular adhesion molecule. The
transmembrane domains of APP and APLP2 are indicated by a dashed box. 
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Transient expression of the generated constructs in N2A cells 
To examine whether the fusion proteins were properly expressed, neuronal N2A cells 
were grown either in wells or on coverslips and transfected with the various constructs 
under the control of the elongation factor 1 alpha (EF1α) gene promoter. Fluorescence 
analysis showed that all fusion proteins were properly expressed in the transfected 
N2A cells (Figure 2A). The majority of the various fusion proteins was localized in 
the Golgi area, indicating that the proteins had properly entered the secretory 
pathway. The GFP-APP/ICAM and GFP-APLP2/ICAM fusion proteins were partially 
localized in the Golgi area, and partially at the plasma membrane. As excepted, the 
GFP-AICD and AICD-GFP fusion proteins were found in the cytoplasm of the 
transfected N2A cells.  
Western blot analysis using the anti-GFP antibody revealed that all fusion proteins 
migrated at the expected molecular weights, although GFP-APPdelC and GFP-
APLP2/ICAM were hardly detectable (Figure 2B), probably due to a low transfection 
efficiency. In the transfection experiment with the APP-GFP fusion protein, an 
additional product with an estimated molecular weight of ~38 kDa was observed 
(Figure 2B, lane 12), presumably representing an α-secretase cleavage product. The 
intracellular localizations and the molecular weights of the various mutants are 
summarized in Figure 2C. 
 
Tissue-specific targeting of GFP-APLP2 fusion proteins in transgenic Xenopus 
We recently reported that the expression levels of APLP2 were similar while APP 
expression was upregulated, in the melanotrope cells from black or white animals, 
suggesting distinct roles for the two family members in these cells [25, 26]. To study 
their roles in a physiological context, we decided to use the stable Xenopus 
transgenesis procedure. A schematic overview of this method is presented in figure 3. 
Briefly, first a DNA construct containing a gene promoter sequence, the coding 
sequence of the protein of interest (usually a GFP-fusion protein in order to identify 
transgenic animals and directly visualize the protein in the cell) and a poly-
adenylation signal is generated. The linear DNA fragment is then mixed with isolated 
Xenopus sperm nuclei and, following an incubation of 20 min., the DNA-nuclei 
mixture is injected into unfertilized eggs that are harvested from adult female 
Xenopus. 
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Figure 2 Transient transfection of the various generated GFP-fusion
constructs of APP and APLP2 into N2A cells  
A) Fluorescent images of N2A cells transfected with the various GFP-APP/APLP2 fusion
constructs indicated above the images.  
B) Western blot analysis lysates from N2A cells transfected with the various GFP-
APP/APLP2 fusion constructs and using the anti-GFP antibody. Lanes correspond to the
following constructs: 1) Mock; 2) GFP-APP; 3) GFP-APPdelC; 4) GFP-APP/ICAM; 5) GFP-
C99; 6) GFP-AICD; 7) GFP-APLP2; 8) GFP-APLP2delC; 9) GFP-APLP2/ICAM; 10) GFP;
11) Mock; 12) APP-GFP; 13) APPdelC-GFP; 14) AICD-GFP; 15) APLP2-GFP; 16) GFP. 
C) Overview of the results presented in A) and B) concerning the intracellular localizations
and estimated molecular weights of the various GFP-APP/APLP2 fusion proteins. PM:
plasma membrane. 
A 
B 
C 
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Fertilized embryos are selected and screened for transgene expression using a 
fluorescence microscope. In this way, dozens of transgenic animals can be generated 
within one day. Using various gene promoters, transgene expression can be targeted 
to many different tissue- or cell-types. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
With a POMC gene promoter fragment, transgenes are specifically expressed in the 
intermediate pituitary melanotrope cells [23, 24]. The neural β-tubulin (Ntub) gene 
promoter is active in neuronal cells, while the use of the EF1α gene promoter results 
in a ubiquitous expression of the transgene product. The expression of GFP driven by 
the three above-mentioned gene promoters in transgenic Xenopus tadpoles is depicted 
in figure 4A. To allow us to perform functional studies on APP and APLP2 in the 
Xenopus intermediate pituitary cells, the GFP-fusion proteins were targeted to these 
cells using the POMC gene promoter.  
 
Figure 3 The stable Xenopus transgenesis procedure
Schematic overview of the transgenesis procedure as described by Kroll and Amaya [21] 
and modified by Sparrow et al. [22].    
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Here we will only focus the results concerning the transgene expression of APLP2; 
the results of APP transgenesis are presented in chapter six. The transgenic approach 
did not result in tadpoles expressing the GFP-APLP2 fusion protein (Figure 4B, upper 
panel). Also targeting the various GFP-APLP2 mutants to the intermediate pituitary 
did not result in tadpoles showing fluorescence, indicating that in these cells, no 
Figure 4 Tissue-specific targeting of GFP and GFP-APLP2 fusion 
proteins in transgenic Xenopus 
Fluorescent images of tadpoles microinjected in the first-cell stage with the constructs 
depicted below the images. The transmembrane domain of APLP2 is indicated by a
dashed box.  
A) Expression of GFP itself driven by the intermediate pituitary specific POMC gene 
promoter (upper panel), the neural-specific β-tubulin gene promoter (middle panel) 
and the ubiquitously active EF1α gene promoter (lower panel).  
B) No fluorescence was observed when the GFP-APLP2 fusion protein were targeted 
with the POMC gene promoter (upper panel) or the neural β-tubulin gene promoter 
(middle panel). When the expression of GFP-APLP2 was driven to all cells with the 
EF1α gene promoter, fluorescence was observed only in tail muscle cells (lower
panel). SP: signal peptide sequence; pA: poly-adenylation signal. 
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transgene product was made (Table II). To further study this finding, GFP-APLP2 
expression was driven to either the neuronal cells by means of the Ntub gene 
promoter [21], or to all cells using the ubiquitously active EF1α gene promoter [34]. 
Using the Ntub promoter, again no fluorescence was observed (Figure 4B, middle 
panel). However,  with the EF1α promoter we found fluorescence only in muscle cells 
(Figure 4B, lower panel), while transgene expression in all cells was expected. Similar 
results were obtained using the APLP2-GFP fusion protein (Table II).  
 
Table II Generation and analysis of Xenopus transgenic for GFP-APLP2 and 
APLP2-GFP fusion proteins.   
Transgene Generated 
embryos 
Transgenic 
animals 
Percentage 
transgenics 
Observed 
fluorescence 
pPOMC GFP-APLP2 384 0 0 -- 
pPOMC GFP-APLP2delC 121 0 0 -- 
pPOMC GFP-APLP2/ICAM 55 0 0 -- 
pPOMC APLP2-GFP 98 0 0 -- 
pNtub GFP-APLP2 113 0 0 -- 
pNtub GFP-APLP2delC 60 0 0 -- 
pEF1α GFP-APLP2 35 5 14.2 muscle cells 
 
Listed are the various GFP-APLP2 (upper part) and APLP2-GFP (lower part) fusion 
constructs used in transgenesis, the total number of generated embryos, the number and 
percentage of transgenics and the observed fluorescence pattern in the transgenic animals. 
pPOMC: POMC gene promoter; pNtub: neural β-tubulin gene promoter; pEF1α: EF1α gene 
promoter. 
 
Thus, transgene expression of GFP-APLP2 fusion proteins in Xenopus neuronal and 
neuroendocrine cells was not established, although the same constructs were properly 
expressed in transiently transfected neuronal N2A cells. Whether this is caused by the 
possibility that neuronal expression of APLP2 is toxic to developing tadpoles or that it 
is due to an interfering element present within the coding sequence of APLP2 remains 
at present unclear. 
 
ACKNOWLEDGEMENTS 
We gratefully acknowledge Ron Engels for animal care and Ron Dirks, Eric Jansen, 
Jurjen Ruben, Denise van Strien and Tijs van Wieringen for technical assistance. We 
thank Dr B. Wieringa for the anti-GFP antibody. This research was supported by the 
Internationale Stichting Alzheimer Onderzoek (ISAO; project #00506). 
 
Stable Xenopus transgenesis to study APP and APLP2 
103 
REFERENCES 
 
1.  Glenner, G. G. & Wong, C. W. (1984) Alzheimer's disease: initial report of the purification and 
characterization of a novel cerebrovascular amyloid protein, Biochem Biophys Res Commun. 120, 885-
90. 
2.  Kang, J., Lemaire, H., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K., Multhaup, G., 
Beyreuther, K. & Müller-Hill, B. (1987) The precursor of Alzheimer's disease amyloid A4 protein 
resembles a cell-surface receptor, Nature. 325, 733-736. 
3.  Kamal, A., Stokin, G. B., Yang, Z., Xia, C. H. & Goldstein, L. S. (2000) Axonal transport of 
amyloid precursor protein is mediated by direct binding to the kinesin light chain subunit of kinesin-I, 
Neuron. 28, 449-59. 
4.  Shivers, B. D., Hilbich, C., Multhaup, G., Salbaum, M., Beyreuther, K. & Seeburg, P. H. (1988) 
Alzheimer's disease amyloidogenic glycoprotein: expression pattern in rat brain suggests a role in cell 
contact, Embo J. 7, 1365-70. 
5.  Mattson, M. P. (1997) Cellular actions of beta-amyloid precursor protein and its soluble and 
fibrillogenic derivatives, Physiol Rev. 77, 1081-132. 
6.  White, A. R., Reyes, R., Mercer, J. F., Camakaris, J., Zheng, H., Bush, A. I., Multhaup, G., 
Beyreuther, K., Masters, C. L. & Cappai, R. (1999) Copper levels are increased in the cerebral cortex 
and liver of APP and APLP2 knockout mice, Brain Res. 842, 439-44. 
7.  Cao, X. & Sudhof, T. C. (2001) A transcriptionally active complex of APP with Fe65 and histone 
acetyltransferase Tip60, Science. 293, 115-20. 
8.  Cappai, R., Mok, S. S., Galatis, D., Tucker, D. F., Henry, A., Beyreuther, K., Small, D. H. & 
Masters, C. L. (1999) Recombinant human amyloid precursor-like protein 2 (APLP2) expressed in the 
yeast Pichia pastoris can stimulate neurite outgrowth, FEBS Lett. 442, 95-8. 
9.  Muller, U. & Kins, S. (2002) APP on the move, Trends Mol Med. 8, 152-5. 
10.  Scheinfeld, M. H., Ghersi, E., Laky, K., Fowlkes, B. J. & D'Adamio, L. (2002) Processing of beta-
amyloid precursor-like protein-1 and -2 by gamma-secretase regulates transcription, J Biol Chem. 277, 
44195-201. 
11.  Rassoulzadegan, M., Yang, Y. & Cuzin, F. (1998) APLP2, a member of the Alzheimer precursor 
protein family, is required for correct genomic segregation in dividing mouse cells, Embo J. 17, 4647-
56. 
12.  Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F. & Cole, G. 
(1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice, Science. 
274, 99-102. 
13.  Hsiao, K. K., Borchelt, D. R., Olson, K., Johannsdottir, R., Kitt, C., Yunis, W., Xu, S., Eckman, C., 
Younkin, S., Price, D. & et al. (1995) Age-related CNS disorder and early death in transgenic FVB/N 
mice overexpressing Alzheimer amyloid precursor proteins, Neuron. 15, 1203-18. 
14.  Mucke, L., Masliah, E., Johnson, W. B., Ruppe, M. D., Alford, M., Rockenstein, E. M., Forss-
Petter, S., Pietropaolo, M., Mallory, M. & Abraham, C. R. (1994) Synaptotrophic effects of human 
amyloid beta protein precursors in the cortex of transgenic mice, Brain Res. 666, 151-67. 
15.  Moran, P. M., Higgins, L. S., Cordell, B. & Moser, P. C. (1995) Age-related learning deficits in 
transgenic mice expressing the 751-amino acid isoform of human beta-amyloid precursor protein, Proc 
Natl Acad Sci U S A. 92, 5341-5. 
16.  Moechars, D., Lorent, K. & Van Leuven, F. (1999) Premature death in transgenic mice that 
overexpress a mutant amyloid precursor protein is preceded by severe neurodegeneration and 
apoptosis, Neuroscience. 91, 819-30. 
17.  Moechars, D., Lorent, K., De Strooper, B., Dewachter, I. & Van Leuven, F. (1996) Expression in 
brain of amyloid precursor protein mutated in the alpha-secretase site causes disturbed behavior, 
neuronal degeneration and premature death in transgenic mice, Embo J. 15, 1265-74. 
18.  Zheng, H., Jiang, M., Trumbauer, M. E., Sirinathsinghji, D. J., Hopkins, R., Smith, D. W., 
Heavens, R. P., Dawson, G. R., Boyce, S., Conner, M. W., Stevens, K. A., Slunt, H. H., Sisoda, S. S., 
Chen, H. Y. & Van der Ploeg, L. H. (1995) beta-Amyloid precursor protein-deficient mice show 
reactive gliosis and decreased locomotor activity, Cell. 81, 525-31. 
19.  von Koch, C. S., Zheng, H., Chen, H., Trumbauer, M., Thinakaran, G., van der Ploeg, L. H., Price, 
D. L. & Sisodia, S. S. (1997) Generation of APLP2 KO mice and early postnatal lethality in 
APLP2/APP double KO mice, Neurobiol Aging. 18, 661-9. 
20.  Jenks, B. G., Leenders, H. J., Martens, G. J. & Roubos, E. W. (1993) Adaptation physiology: the 
functioning of pituitary melanotrope cells during background adaptation of the amphibian Xenopus 
laevis, Zool Sci. 10, 1-11. 
Chapter five 
104 
21.  Kroll, K. L. & Amaya, E. (1996) Transgenic Xenopus embryos from sperm nuclear 
transplantations reveal FGF signaling requirements during gastrulation, Development. 122, 3173-83. 
22.  Sparrow, D. B., Latinkic, B. & Mohun, T. J. (2000) A simplified method of generating transgenic 
Xenopus, Nucleic Acids Res. 28, E12. 
23.  Jansen, E. J., Holling, T. M., van Herp, F. & Martens, G. J. (2002) Transgene-driven protein 
expression specific to the intermediate pituitary melanotrope cells of Xenopus laevis, FEBS Lett. 516, 
201-7. 
24.  Bouw, G., Van Huizen, R., Jansen, E. J. & Martens, G. J. (2004) A cell-specific transgenic 
approach in Xenopus reveals the importance of a functional p24 system for a secretory cell, Mol Biol 
Cell. 15, 1244-53. 
25.  Collin, R. W. & Martens, G. J. (2005) The amyloid-beta precursor-like protein APLP2 and its 
relative APP are differentially regulated during neuroendocrine cell activation, Mol Cell Neurosci. in 
press. 
26.  Collin, R. W., van den Hurk, W. H. & Martens, G. J. (2005) Biosynthesis and differential 
processing of two pools of amyloid-beta precursor protein in a physiologically inducible 
neuroendocrine cell, J Neurochem. 94, 1015-24. 
27.  Turner, D. L. & Weintraub, H. (1994) Expression of achaete-scute homolog 3 in Xenopus embryos 
converts ectodermal cells to a neural fate, Genes Dev. 8, 1434-47. 
28.  Staunton, D. E., Marlin, S. D., Stratowa, C., Dustin, M. L. & Springer, T. A. (1988) Primary 
structure of ICAM-1 demonstrates interaction between members of the immunoglobulin and integrin 
supergene families, Cell. 52, 925-33. 
29.  Cuppen, E., Wijers, M., Schepens, J., Fransen, J., Wieringa, B. & Hendriks, W. (1999) A FERM 
domain governs apical confinement of PTP-BL in epithelial cells, J Cell Sci. 112 ( Pt 19), 3299-308. 
30.  Tanzi, R. E. & Bertram, L. (2005) Twenty years of the Alzheimer's disease amyloid hypothesis: a 
genetic perspective, Cell. 120, 545-55. 
31.  Suzuki, T., Nairn, A. C., Gandy, S. E. & Greengard, P. (1992) Phosphorylation of Alzheimer 
amyloid precursor protein by protein kinase C, Neuroscience. 48, 755-61. 
32.  Suzuki, T., Ando, K., Isohara, T., Oishi, M., Lim, G. S., Satoh, Y., Wasco, W., Tanzi, R. E., Nairn, 
A. C., Greengard, P., Gandy, S. E. & Kirino, Y. (1997) Phosphorylation of Alzheimer beta-amyloid 
precursor-like proteins, Biochemistry. 36, 4643-9. 
33.  Jansen, E. J., Holthuis, J. C., McGrouther, C., Burbach, J. P. & Martens, G. J. (1998) Intracellular 
trafficking of the vacuolar H+-ATPase accessory subunit Ac45, J Cell Sci. 111 ( Pt 20), 2999-3006. 
34.  Dirks, P. H., Bouw, G., Van Huizen, R., Jansen, E. J. & Martens, G. J. (2003) Functional 
Genomics in Xenopus laevis: towards transgene-driven RNA interference and cell-specific transgene 
expression, Current Genomics. 4, 699-711. 
35.  Van den Hurk, W. H., Bloemen, M. & Martens, G. J. (2001) Expression of the gene encoding the 
beta-amyloid precursor protein APP in Xenopus laevis, Brain Res Mol Brain Res. 97, 13-20. 
36.  Collin, R. W., van Strien, D., Leunissen, J. A. & Martens, G. J. (2004) Identification and 
expression of the first nonmammalian amyloid-beta precursor-like protein APLP2 in the amphibian 
Xenopus laevis, Eur J Biochem. 271, 1906-12. 
 
 
 
 
 
 
 
 
  
 
 105 
 
Chapter six 
 
 
Transgenic studies in Xenopus laevis on the amyloid-β 
precursor protein APP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter six 
106 
Transgenic studies in Xenopus laevis on the amyloid-β 
precursor protein APP  
 
Rob W.J. Collin and Gerard J.M. Martens 
 
A modified version of this chapter is currently being under consideration for 
publication in Brain Research  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Transgenic studies in Xenopus on APP 
107 
ABSTRACT 
The amyloid-β precursor protein APP is generally accepted to be involved in the 
pathology of Alzheimer’s disease. Since its physiological role is still unclear, we 
decided to study the function of APP via stable transgenesis of the amphibian 
Xenopus laevis. Constructs encoding (mutant) APP with the green fluorescent protein 
GFP N-terminally fused to it, and using either the intermediate pituitary-specific 
proopiomelanocortin (POMC) or the neural-specific β-tubulin gene promoter did not 
result in animals expressing the transgene proteins. Also when the Tet-on inducible 
gene expression system was used, no GFP-APP fusion protein expression was 
induced in neuronal cells. However, using the gene promoter of the elongation factor 
1α (EF1α) (ubiquitous expression pattern) or of cardiac actin (muscle-specific 
expression), fluorescent tadpoles were generated, although the EF1α-promoter-driven 
transgenic animals expressed GFP-APP only in muscle cells. Surprisingly, when a C-
terminal GFP-fusion protein of APP in combination with the POMC gene promoter 
was used to target transgene expression specifically to the intermediate pituitary cells, 
fluorescence throughout the whole brain of the tadpole was found. Detailed analysis 
with deletion mutants revealed the presence of a DNA element within the 3’-end of 
the Xenopus APP coding sequence that gives rise to an aberrant transcript and protein 
in the APP-GFP transgenic animals. Thus, in Xenopus targeting of APP to neuronal 
and neuroendocrine cells does not result in proper transgene expression, probably 
because Xenopus APP cDNA contains a strong neural-specific promoter element. The 
physiological significance of this internal promoter is at present unclear. 
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INTRODUCTION 
The pathological processing of the amyloid-β precursor protein APP by enzymes 
called β- and γ-secretase is a key event in the development of Alzheimer’s disease 
(AD), a neurodegenerative disorder that affects the elderly. However, the normal 
physiological role of APP is still elusive. Functions attributed to the intact protein 
range from a role as a cell-surface receptor [1], as a cargo receptor in axonal transport 
[2], in cell adhesion [3] and in copper homeostasis [4]. Also for the cleavage 
fragments derived from APP a number of functions have been suggested, e.g. its 
secreted N-terminal domain may act as a growth factor [5] and its so-called 
intracellular domain (AICD) is thought to be involved in transcriptional regulation 
[6]. 
To address the physiological role of APP, others have previously generated transgenic 
mice. Mice overexpressing wild-type or mutated forms of APP in the brain show 
cognitive deficits, decreased long-term potentiation, aggression, neophobia, 
synaptotrophic and neurodegenerative effects, accelerated senescence and premature 
death [7-12]. Single knock-out mice lacking APP show only minor abnormalities, 
such as decreased locomotor activity and reduced forelimb strength [13, 14].  
Besides transgenic mice models, other vertebrates are more and more commonly used 
to study protein function, for instance the zebrafish Danio Rerio [15] and the South-
African claw-toed frog Xenopus laevis [16]. For our transgenic studies, we used 
Xenopus laevis because of a number of experimental advantages, including large and 
easy manipulable eggs, external development and, in contrast to zebrafish, stable non-
mosaic transgenesis. Moreover, this amphibian is able to adapt its skin color to its 
background, a process regulated by the intermediate pituitary melanotrope cells. 
When the animal is on a black background these cells are highly active in producing 
the prohormone proopiomelanocortin (POMC), the precursor of the α-melanophore-
stimulating hormone (α-MSH) that is responsible for skin darkening [17]. On a white 
background the melanotropes are virtually inactive. Using a POMC gene promoter 
fragment, transgenes can be specifically targeted to the intermediate pituitary 
melanotrope cells, providing a tool to study protein function in a homogenous and 
physiologically inducible cell population [18, 19]. Furthermore, we have detailed 
knowledge of the biosynthesis of POMC and the functioning of the secretory pathway 
in the Xenopus melanotrope cells [20-22]. 
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Recently, we have reported that APP is up-regulated in response to Xenopus 
melanotrope cell activation [23] and proposed a cargo receptor role for APP within 
the secretory pathway of these cells. We now combine the unique Xenopus 
melanotrope cell model with stable Xenopus melanotrope cell-specific transgene 
expression to explore the physiological role of APP. 
 
 
MATERIALS AND METHODS 
Animals 
South-African claw-toed frogs Xenopus laevis were bred and reared at the Central Animal 
Facility of the University of Nijmegen. For transgenesis experiments, mature female Xenopus 
were obtained directly from South-Africa. All animal experiments were carried out in 
accordance with the European Communities Council Directive 86/609/EEC for animal 
welfare, and permit TRC 99/15072 to generate and house transgenic X. laevis. 
 
Generation of DNA constructs encoding N- and C-terminal APP-GFP fusion proteins 
In order to create a unique restriction site upstream of the CMV promoter sequence, the 
pCS2+ vector [24] was digested with NaeI and blunted. A double-stranded oligo containing 
an AscI site (5’-AGGCGCGCCA-3’; the AscI site is underlined) was inserted into the blunted 
NaeI site yielding pCS2+(A). The coding sequence of GFP was amplified via PCR with 
forward primer 5’-GGGGAGATCTATCGTGAGCAAGGGCGAGGA-3’ and reverse primer 5’-
GGGGAATTCCTTGTACAGCTCGTCCATGCC-3’, digested with BglII and EcoRI and fused 
downstream of the signal peptide (SP) sequence of Xenopus Ac45 cDNA in the correct 
reading frame. The SP-GFP fragment was subcloned via BamHI- and EcoRI-sites into the 
pCS2+(A) vector, thereby generating pCS2+(A) SP-GFP. AscI/HindIII fragments of tissue-
specific Xenopus gene promoters (elongation factor 1α-, neural β-tubulin-, cardiac actin- and 
POMC gene promoter) were exchanged with the AscI/HindIII fragment containing the CMV 
promoter to obtain the transgenesis vectors pEF2+(A) SP-GFP, pNtub2+(A) SP-GFP, 
pCac2+(A) SP-GFP and pPOMC2+(A) SP-GFP, respectively. The coding sequence of 
Xenopus APP (lacking the signal peptide sequence) was amplified with primers 5’-
GGGGGAATTCCTGGAGGTACCAGCAGAT-3’ and 5’-
GGGGTCTAGATTAGTTCTGCATCTGCTCGAAGAA-3’, digested with EcoRI and XbaI and 
subcloned into the transgenesis vectors, yielding pCS2+(A) SP-GFP-APP, pEF2+(A) SP-
GFP-APP, pNtub2+(A) SP-GFP-APP, pCac2+(A) SP-GFP-APP and pPOMC2+(A) SP-GFP-
APP. To generate constructs encoding N-terminal GFP-fusion proteins of mutant APP, 
desired fragments of APP (corresponding to amino acid residues (aa) 1-647, 597-695 or 640-
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695; numbering according to APP695: Van den Hurk et al. [25]) or the intracellular adhesion 
molecule ICAM (aa 446-502 of human ICAM; numbering according to Staunton et al. [26]) 
were obtained via PCR using primers containing specific restriction sites and the fragments 
were subcloned into the transgenesis vectors described above.  
For the generation of constructs encoding C-terminal GFP-fusion proteins, the coding 
sequence of APP (including its own signal peptide sequence) was amplified via PCR using 
forward primer 5’-GGGGGAATTCCGATCGTCGGTGGAGCCG-3’ and reverse primer 5’-
GGGGGGATCCGTTCTGCATCTGCTCGAAGAACTTG-3’, digested with EcoRI and BamHI, and 
subcloned into the pEGFPN3delAUG vector (Clontech vector, modified by us to remove the 
start methionine of GFP). The fragment encoding the SP-APP-GFP fusion protein was 
subsequently digested with EcoRI and XbaI and subcloned into the POMC transgenesis vector 
yielding pPOMC2+(A) SP-APP-GFP. To generate constructs encoding C-terminal GFP-
fusion proteins of mutant APP, desired fragments of APP (aa 1-647 or 640-695; numbering 
according to APP695: Van den Hurk et al. [25]) were obtained via PCR using primers 
containing specific restriction sites and the fragments were subcloned into the transgenesis 
vectors described above. For the use of the Tet-on inducible gene expression system, the 
portion encoding the SP-GFP-APP fusion protein was removed from the pPOMC2+(A) SP-
GFP-APP construct with HindIII and NotI, and subcloned into pCS2+(tetO), yielding 
pCS2+(tetO) SP-GFP-APP. The plasmids pCS2+(tetO) GFP and pNtub/rtTA2S-M2 were 
kind gifts of B. Das [27]. All generated GFP-APP fusion constructs were checked by cycle 
DNA sequencing using the Big Dye Ready Reaction system (Abi Prism, Perkin Elmer, 
Wellesley, MA, USA) and primer 5’-AGTCCGCCCTGAGCAAAGAC-3’ reading downstream or 
primer 5’-TTTACGTCGCCGTCCAGCTC-3’ reading upstream from the GFP sequence into the 
APP cDNA sequence. 
 
Transfection of the generated DNA constructs into N2A cells 
Neuronal N2A cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% Fetal Calf Serum and antibiotics at 37°C with 5.5% CO2, and grown 
until 70% confluency on coverslips or in wells. For transient expression studies, 1 µg of 
plasmid DNA was transfected using Fugene (Roche, Indianapolis, IN, USA). After 24 hrs, 
cells were either harvested in lysis buffer (50 mM Hepes pH 7.3, 140 mM NaCl, 0.1 % Triton, 
0.1 % deoxycholate, 0.5 % NP-40, 5 mM EDTA, 1 mM phenylmethylsulfonylfluoride and 1 
mM soybean trypsin inhibitor) for western blot analysis or prepared for fluorescence analysis. 
For the fluorescence analysis, cells on coverslips were fixed in 4% paraformaldehyde, washed 
with PBS, dehydrated in methanol and mounted on object slides using Mowiol (10% w/v). 
Digital images were obtained under a Leica DM RA fluorescence microscope with a Cohu 
High Performance CCD Camera using the Leica Q Fluoro software. 
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Generation of transgenic Xenopus embryos 
The generated DNA constructs were digested with AscI and either NotI or PauI to yield a 
linear DNA fragment containing the tissue-specific promoter sequence, the fusion protein and 
the polyadenylation signal. For the 5’-deletion analysis, the construct encoding APP-GFP was 
digested with PauI and either EcoRI, SalI, NaeI, PstI or BamHI. These linear DNA fragments 
were purified using Qiaex II gel extraction kit (Qiagen, Hilden, Germany) and used for stable 
Xenopus transgenesis according to standard protocols [16, 28]. Briefly, the transgene DNA 
was mixed with sperm nuclei, incubated at RT for 15 min and injected into unfertilized eggs. 
Generated embryos were grown in 0.1xMMR/6% Ficoll-400 (Sigma) and 50 µg/ml 
gentamycin (Gibco/BRL, Grand Island, NY, USA) until gastrulation and then in 0.1xMMR 
containing gentamycin. The presence of GFP fluorescence in living embryos, anaesthesized 
with 0.25 mg/ml MS222 (3-aminobenzoic acid ethyl ester, Sigma), was examined using a 
Leica MZ FLIII fluorescence stereomicroscope and photographs were taken with a Leica 
DC200 color camera using the Leica DCviewer software. 
 
Doxycyclin treatment 
For the induction of gene expression in animals transgenic for the Tet-on constructs, stage 45 
embryos (numbering according to [29] were grown in 0.1 x MMR containing 5 µg/ml or 50 
µg/ml doxycycline hyclate (Sigma) for the indicated time periods. 
 
Antibodies 
Polyclonal anti-APP antibody C87 [23] and the anti-GFP antibody [30] have been described 
previously. 
 
Western blot analysis 
For Western blot analysis, transfected COS-1 cells or Xenopus tissues were lysed in lysis 
buffer (50 mM Hepes pH 7.3, 140 mM NaCl, 0.1 % Triton, 0.1 % deoxycholate, 0.5 % NP-
40, 5 mM EDTA, 1 mM phenylmethylsulfonylfluoride and 1 mM soybean trypsin inhibitor) 
and lysates were centrifuged for 7 min at 1300 rpm and 4°C. Supernatants were taken and 
proteins were denatured in Laemmli sample buffer at 95°C for 5 min, separated by SDS-
PAGE and transferred onto nitrocellulose membranes (Protran, Schleicher and Schuell). Blots 
were incubated with anti-APP antibody C87 (1:3000) or anti-GFP antibody (1:5000) and 
subsequently with peroxidase-conjugated secondary antibodies. The signal was detected using 
Lumilight (Roche). For quantification, detection was performed using a BioChemi imaging 
system and signals were analyzed using the LabWorks 4.0 program (UVP BioImaging 
systems, Cambridge, UK). 
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Rapid amplification of 5’-cDNA ends (5’-RACE) 
For this purpose, tadpoles transgenic for one of the APP-GFP deletion mutants (embryos that 
were microinjected with the APP-GFP construct digested with NaeI and BssHII). To generate 
a pool of adaptor-ligated double-stranded cDNAs, brain total RNA from transgenic tadpoles 
was isolated using a total RNA isolation kit (Promega, Madison, WI, USA). Subsequently, 
polyA+ RNA was isolated (polyA+ RNA isolation kit, Promega) and 1 µg polyA+ RNA was 
used to generate this pool, according to the protocol of the manufacturer (MarathonTM cDNA 
amplification kit, Clontech, Mountain View, CA, USA). 5’-RACE was performed using 
adaptor primer 5’-CCATCCTAATACGACTCACTATAGGGC-3’ and gene-specific reverse primer 
5’- CGTCCAGCTCGACCAGGATGGGCA-3’ (corresponding to the coding sequence of GFP). 
Subsequently, RE-PCR was performed using nested adapter primer 5’-
ACTCACTATAGGGCTCGAGCGGC-3’ and nested gene-specific reverse primer 5’-
CTCGCCCTTGCTCACGATGGATC-3’. The generated PCR products were subcloned into 
pGemTeasy vector (Promega) and inserts were sequenced from both strands (ABI prism, 
Perkin Elmer, Wellesley, MA, USA) with T7- and SP6 sequencing primers. 
 
Computer analysis 
For the identification of transcription factor binding sites, the nucleotide sequences of 
Xenopus and human APP cDNA were analyzed with the Genomatix MatInspector program 
[31]. 
 
 
RESULTS 
 
Generation of constructs encoding GFP-fusion proteins of (mutant) Xenopus 
APP 
To study the role of APP in transgenic Xenopi, APP-GFP fusion constructs were 
generated that would enable us to visualize the transgene proteins directly in living 
animals. The coding sequence of Xenopus APP cDNA was fused either downstream 
(N-terminal GFP-fusion: GFP-APP) or upstream to that of GFP (C-terminal GFP-
fusion: APP-GFP). Since APP is a protein that enters the secretory pathway, for the 
GFP-APP fusion proteins a signal peptide (SP) sequence was cloned upstream of GFP 
in order to allow translocation of the fusion proteins into the ER. In addition, mutants 
of APP were generated that either lack the cytoplasmic tail (delC) or contain the 
transmembrane domain and cytoplasmic tail of another protein, namely the 
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intracellular adhesion molecule ICAM (ICAM TM/CT). Furthermore, mutants 
consisting of only the C-terminal β- or γ-secretase cleavage fragments of APP were 
made (C99 and AICD, respectively). Since the latter represents only the cytoplasmic 
tail of APP, no signal peptide sequence was included in this construct. By expressing 
mutants that lack or only contain certain domains of APP, we aimed to interfere with 
the role of endogenous APP. An overview of the generated mutants is depicted in 
figure 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Transient expression of the generated constructs in N2A cells 
To examine whether the fusion proteins were properly expressed, neuronal N2A cells 
were grown either in wells or on coverslips and transfected with the constructs under 
the control of the elongation factor 1 alpha (EF1α) gene promoter. Western blot 
analysis showed that all fusion proteins migrated at the calculated molecular weights 
(see chapter five). 
 
Figure 1 Overview of the generated GFP-APP and APP-GFP fusion
constructs 
Overview of the constructs encoding N-terminal or C-terminal GFP-fusion proteins of
wild-type and mutant APP. Arrows indicate the β-, α- or γ-secretase processing sites
within APP. SP: signal peptide sequence; delC: mutant lacking the cytoplasmic tail of
APP; ICAM TM/CT: mutant containing the transmembrane domain and cytoplasmic tail
of the intracellular adhesion molecule. C99: mutant containing only the C-terminal part
of APP remaining after β-secretase cleavage; AICD: mutant containing only the C-
terminal part of APP remaining after γ-secretase cleavage. The transmembrane domain
of APP is indicated by a dashed box. 
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Tissue-specific targeting of GFP-APP fusion proteins in transgenic Xenopus 
Recently, we reported on the coordinate expression of APP with that of POMC and 
other components of the regulated secretory pathway, i.e. the expression levels were 
higher in melanotrope cells from black compared to white animals [23]. We therefore 
decided to explore in the present study the role of APP in these cells by targeting 
GFP-fusion proteins of (mutant) APP specifically to the melanotrope cells using a 
POMC gene promoter fragment. Targeted expression of GFP itself driven by this 
promoter fragment showed a somewhat broader fluorescence pattern observed at 
embryonic stage 25 (numbering according to [29], but a clearly specific fluorescent 
signal in the pituitary region from stage 40 onwards [18]. However, using the various 
GFP-APP fusion constructs, in all cases no fluorescence was observed in the 
pituitaries of the generated embryos, indicating that in these animals no transgene 
fusion protein was produced. An overview of the number of embryos generated with 
the various constructs and the percentage of transgene expressing animals is presented 
in table 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B
Figure 2 Tissue-specific targeting of GFP-APP fusion proteins in transgenic
Xenopus 
A) Fluorescent images of tadpoles microinjected in the first-cell stage with the constructs
depicted below the images. No fluorescence was observed using the neural tubulin gene
promoter (pNtub: upper panel), while tail muscle fluorescence was found when the EF1α
gene promoter (pEF1α: middle panel) was used and tail and jaw muscle fluorescence using
the cardiac actin  promoter (pCac: lower panel).  
B) Western blot analysis of tail lysates of wild-type tadpoles and tadpoles transgenic for
GFP-APP and expressing the fusion protein in muscle cells. Proteins were resolved on a
10% SDS-PAGE gel and the anti-APP antibody C87 was used. Molecular weight markers
(Mr) are indicated on the right. SP: signal peptide sequence; TM: transmembrane domain;
pA: poly-adenylation signal. 
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To further investigate these unexpected findings, we targeted some of the fusion 
proteins either to neuronal cells by means of the neural β-tubulin (Ntub) gene 
promoter [16], or to all cells with the ubiquitously active EF1α gene promoter [32]. 
Using the Ntub promoter, again no fluorescence was found. However, with the EF1α 
promoter fluorescence was observed, but only in muscle cells, while transgene 
expression was expected in all cells. Furthermore, targeting GFP-APP only to muscle 
cells using the cardiac actin (Cac) gene promoter [16] did result in transgenic animals 
with the expected expression pattern (of the injected embryos, ~25% was transgenic; 
Table I), showing different levels of fluorescence in the tail, jaw and some muscles in 
the head (Figure 2A). To study whether the observed fluorescence in the Cac-driven 
transgenic animals corresponded to an intact GFP-APP fusion protein, protein lysates 
of the tails of GFP-positive (showing different fluorescence intensity) and wild-type 
tadpoles were analyzed on western blot. Besides the 110-kDa endogenous APP, this 
analysis showed an immunoreactive product of ~140 kDa in the transgenic but not in 
the wild-type animals, indicating that the observed fluorescence was produced by the 
entire GFP-APP fusion protein (Figure 2B). In the transgenic animals, the levels of 
endogenous APP were comparable to those in the wild-type animals, suggesting that 
in Xenopus muscle cells the expression of the fusion protein did not affect the 
endogenous levels of APP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Inducible expression of GFP-APP in transgenic Xenopus 
Fluorescent images of tadpoles microinjected in the first-cell stage with the two constructs
depicted on the left of the images. Gene expression was induced by incubating the
animals in the presence of doxycyclin for 12 hrs. No fluorescence was observed after
doxycyclin treatment using the construct encoding GFP-APP (upper right panel). Using
the construct encoding GFP alone, fluorescence was observed in neuronal cells of the
transgenic tadpoles after doxycyclin treatment (lower right panel). The transmembrane
domain of APP is indicated by a dashed box. Tet: Tet activator protein; pTRE: promoter
containing Tet responsive elements. SP: signal peptide sequence;  pA: poly-adenylation
signal. 
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Together, these results suggest that targeting GFP-APP fusion proteins to intermediate 
pituitary or neuronal cells does not result in transgene protein expression, while the 
transgene GFP-APP fusion product was properly expressed when a muscle-specific 
gene promoter was used.Tet-on inducible transgene expression of GFP-APP in 
Xenopus. 
One of the explanations for the above-mentioned results is that neuronal transgene 
expression of APP is toxic during early development of Xenopus embryos. To study 
this possibility, we decided to use an inducible gene expression system, the Tet-on 
system. With this system transgenic animals can be generated that do not express the 
transgene product until a desired time point. The Tet-on system has been previously 
successfully used to induce by doxycyclin expression of a protein at any desired time 
point during Xenopus embryonic development and in a tissue-specific manner [27]. 
For our purpose, we performed transgenesis with a mixture of two different DNA 
constructs, one encoding the Tet activator protein under the control of the Ntub 
promoter, and a second construct encoding either GFP itself or the GFP-APP fusion 
protein under the control of the Tet responsive element (TRE). Upon addition of 
doxycyclin, the Tet activator protein will undergo a conformational change and 
subsequently interact with the TRE, resulting in transcription of either GFP itself or 
GFP-APP. The generated embryos were grown until stage >45 in the absence of 
doxycyclin and were subsequently induced for 12 hrs in doxycyclin-containing 
medium. In the embryos injected with the construct containing GFP itself and 
following induction, a strong fluorescent signal was detected throughout the brain 
(Figure 3, lower right panel). Of the 75 animals that were induced, 33 animals 
expressed GFP (i.e. 44% of the animals were transgenic). In 75 animals injected with 
the construct encoding the GFP-APP fusion protein, no fluorescence was observed 
after induction with doxycyclin (Figure 3, upper right panel). Also a tenfold increase 
in the concentration of doxycyclin did not result in the expression of the fusion 
protein in these animals, while none of the animals died after the doxycyclin 
treatment. These results show that again no transgene expression of GFP-APP could 
be accomplished in neuronal cells, even not when the fusion protein was not 
expressed during the first two weeks of embryonic development. 
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Table 1 Generation and analysis of Xenopus transgenic for GFP-APP and APP-
GFP fusion proteins. 
 
Transgene Generated  
embryos 
Transgenic 
animals 
Percentage 
transgenics 
Observed 
fluorescence 
pPOMC GFP-APP 383 0 0 -- 
pPOMC GFP-APPdelC 157 0 0 -- 
pPOMC GFP-APP/ICAM 64 0 0 -- 
pPOMC GFP-C99 98 0 0 -- 
pPOMC GFP-AICD 211 0 0 -- 
pNtub GFP-APP 117 0 0 -- 
pNtub GFP-APPdelC 79 0 0 -- 
pEF1α GFP-APP 30 6 20 tail muscle 
pEF1α GFP-APPdelC 171 21 12.3 tail muscle 
pCac GFP-APP 216 53 24.5 muscle cells 
 
pPOMC APP-GFP 212 77 36.3 neuronal cells 
pPOMC APPdelC-GFP 156 0 0 -- 
pPOMC AICD-GFP 96 2 2.0 pituitary 
 
Listed are the various amino-terminal (upper part) and carboxy-terminal (lower part) GFP-
fusion constructs of (mutant) APP used in transgenesis, the total number of generated 
embryos, the number and percentage of transgenics and the observed fluorescence pattern 
in the transgenic animals. pPOMC: POMC gene promoter; pNtub: neural β-tubulin gene 
promoter; pEF1α: EF1α gene promoter; pCac: cardiac actin gene promoter. 
 
 
 
Tissue-specific targeting of APP-GFP fusion proteins 
Since the GFP-APP constructs did not result in neuroendocrine transgene expression, 
we next targeted APP-GFP fusion proteins (APP-GFP, APPdelC-GFP and AICD-
GFP) to the intermediate pituitary cells using the POMC gene promoter. With the 
APPdelC-GFP fusion protein construct, again no animals showing pituitary 
fluorescence were generated (Table 1). For the AICD-GFP construct, however, 
embryos were produced that showed fluorescence specifically in the pituitary region 
(Figure 4A, upper panel), although the percentage of transgenic embryos was only 2% 
(Table 1). Normally, a construct expressing GFP alone under the control of the POMC 
gene promoter yields ~ 5-10% transgenic animals. Intriguingly, using the construct 
encoding the APP-GFP fusion protein and containing the POMC gene promoter, 
fluorescence throughout the brains of the tadpoles was found (Figure 4A, middle 
panel). The observed fluorescence was reminiscent of the expression of GFP itself 
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driven by the neural-specific Ntub promoter, although the Ntub-driven fluorescence 
was more intense (Figure 4A, lower panel). Since the POMC gene promoter is 
normally active only in the intermediate pituitary cells, we reasoned that the 
unexpected fluorescence might have been caused by an element in the coding 
sequence of Xenopus APP cDNA. To study the possibility of an internal promoter 
activity, a construct encoding the APP-GFP fusion protein but lacking the POMC 
gene promoter was used to perform transgenesis. Again, tadpoles were generated that 
showed fluorescence throughout the whole brain.  
 
 
 
Figure 4 Tissue-specific targeting of APP-GFP fusion proteins in transgenic 
Xenopus 
Fluorescent images of tadpoles microinjected in the first cell-stage with the constructs
depicted below the respective images. Fluorescence in the intermediate pituitary (IP) was
observed when the AICD-GFP construct was targeted with the POMC gene promoter
(pPOMC; upper panel), while fluorescence in neuronal cells was found when the pPOMC
APP-GFP construct was used (middle panel). For comparison, GFP expression driven by
the neural tubulin gene promoter (pNtub: lower panel) is shown. The transmembrane
domain of APP is indicated by a dashed box. AICD: APP intracellular domain; SP: signal
peptide sequence; pA: poly-adenylation signal. 
B 
A 
C 
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Interestingly, similar results were obtained with a promoterless construct encoding 
GFP fused C-terminally to human APP (data not shown). The fluorescence in the 
brains of the tadpoles transgenic for APP-GFP was not present anymore in the brains 
of the adult frogs. These results suggest the presence of a neural-specific promoter 
element within the coding sequence of both Xenopus and human APP cDNA that is 
active only during early Xenopus embryonic development. 
 
 
 
B 
CA 
Figure 5 Identification of the region within Xenopus APP cDNA responsible
for its aberrant promoter activity 
A) 5’-end deletion mutants of the APP-GFP construct were used in transgenesis and the
generated animals were screened for fluorescence (fluo) in the brain (+: fluorescence, -:
no fluorescence). The linear fragments depicted were produced via digestions with the
indicated restriction enzymes. The region within APP cDNA encoding the transmembrane
domain is indicated by a dashed box. pA: poly-adenylation signal. 
B) Sequence analysis of the 5’-RACE PCR products to determine the start site of the
aberrant transcript (indicated by an asterisk). The sequence of the nested adapter oligo
used to perform the 5’-RACE PCR is underlined.  
C) Western blot analysis of brain lysates of wild-type tadpoles (lane 1; background bands),
tadpoles transgenic for 5’-deleted (microinjected with NaeI/PauI digested APP-GFP
construct) ∆APP-GFP (lane 2; presence of a 32-kDa product not present in lane 1) or
animals expressing GFP alone (lane 3; 30-kDa GFP-product). Proteins were separated on
a 12.5% SDS-PAGE gel and an anti-GFP antibody was used. Molecular weight markers
(Mr) are indicated on the left. 
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Identification of the region within APP cDNA responsible for the internal 
promoter activity  
To identify the region within Xenopus APP cDNA responsible for the aberrant 
promoter activity, linear DNA fragments representing 5’-deletion mutants of the APP-
GFP construct were generated. Except for GFP alone (with its start Met-residue 
removed), all of these fragments led to fluorescence in the brains of the generated 
embryos (Figure 5A), showing that the region responsible for the aberrant promoter 
activity is located within the 3’-end of Xenopus APP cDNA. Next, rapid amplification 
of 5’-cDNA ends (5’-RACE) was performed to determine the transcription start site 
of the produced aberrant RNA. For this purpose, total RNA was isolated from the 
brains of tadpoles that displayed fluorescence due to the aberrant promoter activity 
(designated ∆APP-GFP animals) and the RNA was used to generate a cDNA pool. 
Sequence analysis of the 5’-RACE PCR product of ~120 base pairs revealed the start 
site of the aberrant APP-derived transcript (Figure 5B). 
To study the molecular weight of the protein produced by the aberrant transcript, a 
brain lysate of embryos transgenic for ∆APP-GFP was subjected to western blot 
analysis with an anti-GFP antibody. For comparison, brain lysates of animals 
expressing GFP itself or of wild-type embryos were analyzed on the same gel. This 
analysis revealed the presence of an ~32-kDa protein product in the ∆APP-GFP 
transgenics (Figure 5C, lane 2). The difference in molecular weight between this 
protein and GFP is ~2 kDa (Figure 5C), corresponding to ~20 amino acids of the C-
terminal region of the APP protein. The 32-kDa protein produced in the ∆APP-GFP 
transgenic animals therefore likely starts at methionine residue 677 encoded by 
nucleotides 2031-2033, i.e. the first AUG present in the aberrant transcript (Figure 
5B; numbering according to APP695) [25]. Furthermore, the nucleotide sequence 
surrounding this methionine-coding region is fully conserved in the human cDNA 
sequence. Together, these data suggest that Xenopus and human APP cDNA contain a 
transcriptionally active DNA element in its 3’-end region, generating only in neuronal 
cells an aberrant transcript that is subsequently translated into a protein from 
methionine-residue 677 onwards (numbering according to APP695) [25]. 
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Our 5’-deletion analysis and the identification of the transcription start site restricted 
the region containing the transcriptionally active DNA element to 289 base pairs (bp). 
Because the human APP cDNA also showed the aberrant promoter activity, the DNA 
element within Xenopus APP cDNA is likely also present in the human sequence 
(Figure 6A). In order to identify a putative transcription factor binding site within 
these 289 bp of the Xenopus and human APP cDNA sequences, we performed a 
computer analysis that revealed the presence of two regions that conform to the 
glucocorticoid responsive element (GRE) consensus sequence [33].  
A 
B 
Figure 6 Analysis of the DNA element within APP cDNA responsible for the
aberrant promoter activity 
A) Comparative analysis of the region in the Xenopus and human APP cDNAs surrounding the
start site of the aberrant transcript. Identical nucleotides are white on a black background. The
putative glucocorticoid responsive elements (GRE and GRE1/2) within Xenopus and human APP
are indicated by open boxes. The transcription start site in Xenopus APP cDNA is indicated by
an asterisk and the direction of transcription by an arrow. The codon representing the start
methionine is underlined. The N-terminal region of the aberrant APP-GFP protein fragment is
presented below the alignment. The positions of exons 16, 17 and 18 of the APP gene are
indicated by vertical lines. 
B) Comparative analysis of the putative GREs present within Xenopus and human APP cDNA,
and the GRE in the Xenopus POMC gene promoter. The positions of the various GREs relative
to the start sites of the corresponding transcripts are indicated on the right. The consensus of
the GRE half-site (GRE1/2) is indicated above the GRE consensus. Nucleotides that conform to
the GRE consensus are in capitals. 
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One of these regions corresponds to the complete GRE, whereas the other represents a 
so-called GRE half-site (GRE1/2) [34]. The locations of these putative GREs within 
APP cDNA are indicated in Figure 6A and the degree of similarity with the GRE 
consensus is shown in Figure 6B. The Xenopus POMC gene promoter also contains a 
GRE [35] (Figure 6B) and therefore, glucocorticoid receptors may well be present in 
the intermediate pituitary cells. Thus, the GREs within the APP sequence and the 
POMC promoter may compete for the available glucocorticoid receptor molecules. 
Reasoning along this line, the presence of a GRE in the APP sequence may not only 
result in the aberrant promoter activity, but may also be responsible for the fact that 
proper transgene expression of GFP-APP fusion proteins was not observed in the 
Xenopus intermediate pituitary cells. A similar mechanism may have prevented Ntub-
driven transgene expression of APP in neuronal cells.  
 
 
DISCUSSION 
Although the pathological processing of APP is clearly involved in AD, the normal 
role of this protein is still elusive. One of the proposed functions for APP is a cargo 
receptor role in post-Golgi/vesicular transport [2]. Recently, we suggested a similar 
role for APP within the secretory pathway of physiologically activated Xenopus 
intermediate pituitary melanotrope cells on the basis of a threefold up-regulation of 
APP expression in the active melanotrope cells [23]. In the present study, we decided 
to generate and analyze transgenic Xenopus to explore the physiological role of APP 
close to the in vivo situation. Remarkably, with transgenes encoding GFP-fusion 
proteins of wild-type and mutant APP, and under the control of a Xenopus POMC 
promoter fragment, no embryos were generated that expressed the transgene product 
in the intermediate pituitary. To further study this finding, Ntub promoter-driven 
transgenes were used, but again no embryos expressing GFP-APP in the brain were 
produced. With the EF1α or the Cac promoter, however, transgenic tadpoles that 
expressed the correct GFP-APP fusion protein in muscle cells were generated, while 
with the EF1α promoter a ubiquitous expression pattern was expected. Thus, 
transgene expression of GFP-APP fusion proteins was found only in Xenopus muscle 
cells, but not in neuronal or neuroendocrine cells.  
A number of explanations for these observations should be considered. First, an 
incorrect conformation of the generated GFP-APP fusion proteins might have resulted 
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in a lack of fluorescence in Xenopus neuronal cells. This however seems unlikely, 
since we found that in transfected neuronal N2A cells the same constructs did give 
fluorescent cells. Furthermore, in rat hippocampal neurons an APP-YFP fusion 
protein has been properly expressed [36]. A second explanation for our findings is 
that the APP transgene product is toxic when expressed in Xenopus neuronal cells, 
causing early embryonic death. To test this hypothesis, the Tet-on inducible gene 
expression system with the Ntub promoter was used to generate transgenic Xenopus 
embryos in which the expression of GFP-APP could be induced at any desired time-
point during embryonic development and only in neuronal cells. Nevertheless, 
induction of GFP-APP expression in stage-45 embryos did not result in animals that 
showed fluorescence in the brain and the induction was not lethal. In contrast, 
induction of Tet-embryos transgenic for GFP alone gave many embryos clearly 
showing fluorescence in neuronal cells. Based on these results, a toxic effect of 
neuronal APP overexpression during early Xenopus embryonic development is not 
likely. Also, neuronal overexpression of APP is not lethal in the fruit fly Drosophila 
melanogaster [37] and the mouse [38]. Since GFP fusions to other type I 
transmembrane proteins are properly expressed in Xenopus neuronal and 
neuroendocrine cells ([19] and unpublished observations), the inability to generate 
animals showing fluorescence in these cells seems to be specific for APP. A third 
explanation for our results is therefore that the coding sequence of APP may contain a 
transcriptionally active DNA element that prevents or overrules the transcription of 
the transgene specifically in neuronal cells. This possibility is corroborated by the fact 
that the promoterless construct containing GFP C-terminally linked to APP gave 
fluorescence throughout the tadpole brain, suggesting the presence of a DNA element 
within Xenopus APP cDNA that contains neural-specific promoter activity. Computer 
analysis to identify the promoter element within the 289 bp of the 3’-end of both 
Xenopus and human APP cDNA responsible for this aberrant activity revealed the 
presence of nucleotide stretches conforming to the GRE consensus [33]. Thus, 
binding of the glucocorticoid receptor to these GREs within APP cDNA may be 
responsible for the transcriptional activity observed in the APP-GFP transgenic 
animals. 
Our results have shown that APP cDNA contains a DNA element that in transgenic 
Xenopus is transcriptionally active only in neuronal cells. In view of these results and 
since the targeting of the GFP-APP fusion protein to neuronal/neuroendocrine cells 
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did also not result in Xenopus embryos expressing the transgene protein, we suggest 
that the same transcriptionally active DNA element in APP cDNA is as well involved 
in the silencing of both the Ntub- and the POMC gene promoters. The silencing 
mechanism could involve the interaction of the internal DNA element with neural-
specific transcription factors that are required for the proper activity of these gene 
promoters. Another possibility is that the transcriptional activity within the 3’-end of 
APP cDNA not only results in an aberrant transcript but also sterically hinders the 
proper POMC- or Ntub-driven transcriptional machinery. Binding of glucocorticoid 
receptors to the GREs present within APP cDNA may then be the cause of both the 
aberrant transcriptional activity as well as the prevention of proper transgene 
expression driven by the POMC and Ntub gene promoters. Since the mechanisms that 
regulate glucocorticoid signaling  are complex (activating or repressing transcriptional 
activity) and often require additional transcription factors (reviewed by Schoneveld et 
al. [39]), other factors may play a role in these signaling mechanisms as well.   
The DNA element that causes aberrant transcriptional activity observed in the 
transgenic animals is present in the APP cDNA sequence. To speculate on a possible 
physiological significance of this finding, one has to realize that in the genome, 
mRNA/cDNA sequences are encoded by exons that are interrupted by introns. The 
transcription start site of the aberrant transcript corresponds to a region within exon 
18, while the GREs are located in exon 17 (Figure 6). Therefore, if the GREs are 
responsible for the observed activity, it is unlikely that this phenomenon also occurs 
in vivo and thus the corresponding aberrant transcript will probably not be produced in 
wild-type animals (because of the presence of the intron sequence between exons 17 
and 18 of the endogenous Xenopus APP gene). However, other transcription factors 
binding in the exon 18-region may be responsible for our observations. 
In conclusion, targeting constructs encoding APP-GFP fusion proteins to 
neuroendocrine and neuronal cells via the stable Xenopus transgenesis procedure did 
not result in proper transgene expression of the fusion proteins, probably due to the 
presence of a neural-specific internal promoter activity within the 3’-end of APP 
cDNA. It is not expected that the observed internal promoter element is also active in 
the APP gene of wild-type animals (Xenopus or mammals), and thus under 
physiological conditions, but this remains to be investigated.  
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GENERAL DISCUSSION 
 
As the population gets older and older, age-related diseases are becoming more and 
more a threat to public health. One example of an age-related disease is the 
neurodegenerative disorder Alzheimer’s disease (AD) that causes memory loss. 
Currently, an estimated $156 billion a year is spent on medical care for the 28 million 
people suffering form this disease worldwide. AD is characterized by two 
morphological features, namely neurofibrilary tangles and senile plaques. The 
neurofibrilary tangles are intracellular lesions that consist of a hyperphosphorylated 
form of the protein tau, whereas the senile plaques are extracellular protein deposits of 
which the Aβ-peptide is a major component. Aβ is generated through proteolytic 
processing of the amyloid-β precursor protein APP, a type I transmembrane protein of 
unknown function. In order to develop drugs to treat, or even better, to prevent AD, 
detailed knowledge of the molecular mechanisms that cause AD is required. 
Extensive research over the last decade has resulted in a better understanding of the 
pathological processing of APP and the enzymes involved in these processes. 
Nevertheless, the normal physiological role of APP is still not understood. The 
research described in this thesis focuses on molecular and cell biological aspects of 
APP and its relative, the amyloid-β precursor-like protein APLP2, in the intermediate 
pituitary cells of the amphibian Xenopus laevis. Furthermore, stable Xenopus 
transgenesis was used to gain more insight into the physiological roles of APP and 
APLP2. In this final chapter, the results obtained are discussed and put in a broader 
perspective.  
 
Evolutionary aspects of the APP superfamily 
APP has been identified in many vertebrate species, including human [1], mouse [2], 
rat [3], monkey [4], chicken [5], Xenopus laevis [6] and zebrafish [7]. The APP 
superfamily is further comprised of APLP1 and APLP2 that were identified only in 
human, mouse and rat [8-12]. In the invertebrate species C.elegans and Drosophila 
melanogaster, only one APP-related protein occurs, named APL-1 and APPL, 
respectively [13, 14]. These proteins are thought to represent the ancestral forms of 
the APP superfamily members known in mammals. Phylogenetic analysis using 
various invertebrate and vertebrate APP-like sequences has suggested that two gene 
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duplication events have occurred in the evolution of the APP superfamily. The first 
duplication would have given rise to an APLP1 and a preAPP/APLP2 lineage, 
whereas the second event would have resulted in the APP and APLP2 genes [5]. In 
chapter two, we describe the identification of the first non-mammalian APLP2 protein 
in the amphibian Xenopus laevis. The availability of the Xenopus APLP2 sequence 
allowed us to perform a new phylogenetic analysis of the APP superfamily. In 
contrast to Coulson et al. [5], we concluded that during evolution a first gene 
duplication event has resulted in an APP and a preAPLP lineage. Subsequently, a 
second gene duplication event gave rise to the APLP1 and APLP2 genes. Given that 
both APP and APLP2 have been identified in Xenopus and mammals, the first gene 
duplication event which separates the APP and preAPLP lineages predates the 
amphibian-mammalian split. Since our research has now shown that APLP2 is present 
in Xenopus, it is likely that APLP2 is also present in other non-mammalian vertebrate 
species. We recently performed a protein blast with the part of Xenopus APLP2 
representing the highly conserved cytoplasmic tail and found highly similar sequences 
in two fish species, Tetraodon nigerviridis and Danio rerio, indicating that APLP2 
proteins also occur in fish. In a similar blast using a part of the human APLP1 protein 
sequence, the only matches that were found represented mammalian APLP1 
sequences, suggesting that APLP1 is present exclusively in mammals and not in other 
vertebrate species.  
The overall amino acid sequence identity between Xenopus and human APLP2 is ~ 
75%, while in some regions the degree of conservation was even higher. Furthermore, 
all residues known to be post-translationally modified in mammalian APLP2 are 
conserved in Xenopus APLP2. Our comparative sequence analysis has thus revealed 
evolutionarily conserved, and thus potentially important, domains and the high degree 
of conservation between the Xenopus and mammalian APLP2 proteins suggests an 
important role for this protein. 
The fact that the members of the APP superfamily are highly conserved throughout 
evolution suggests that these proteins have important physiological roles. A number 
of functions have been proposed for APP, including a role as cell-surface receptor [1], 
in cell adhesion [3], as a growth factor [15], in transcriptional regulation [16] or as 
cargo receptor in axonal transport [17]. For APLP1 and -2, similar roles have been 
suggested [18-20]. Furthermore, studies in knock-out mice have revealed that APP 
and the APLPs have, at least partially, overlapping roles [21-25]. Yet, the 
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physiological roles of the APP superfamily members are still elusive. Therefore, we 
decided to use Xenopus laevis, namely the Xenopus intermediate pituitary cell model 
combined with a transgenic approach, to gain more insight into the functions of APP 
and APLP2. 
 
Functioning of the Xenopus intermediate pituitary cells 
The South-African claw-toed frog Xenopus laevis has the ability to adapt its skin color 
to its background. This process of background adaptation is regulated by the 
melanotrope cells of the intermediate pituitary gland. When the animal is on a white 
background, the melanotrope cells are virtually inactive, whereas on a black 
background, they are highly active in producing huge amounts of the prohormone 
proopiomelanocortin (POMC). Newly synthesized POMC is transported through the 
regulated secretory pathway of these cells and during this transport it undergoes a 
number of post-translational modifications, such as N-linked glycosylation, sulphation 
and proteolytic processing. One of the processing products of POMC is the α-
melanophore stimulating hormone (α-MSH) that is secreted and via the bloodstream 
transported to the skin melanophores, where it disperses the pigment melanin, causing 
the skin to become black. The amount of POMC, both at the steady-state as well as 
the newly synthesized protein level, is >30 times higher in melanotrope cells from a 
black-adapted compared to a white-adapted animal. A differential screening approach 
aimed at the identification of gene products that were coordinately expressed with 
POMC resulted in a number of other transcripts that were more abundantly present in 
intermediate pituitary cells of black- vs. white animals. Among these were the 
POMC-processing enzymes prohormone convertase 2 (PC2) and carboxypeptidase H, 
some members of the p24 family of putative ER-to-Golgi cargo receptors, the acidic 
neuroendocrine-specific proteins secretogranin II and –III, the V-ATPase accessory 
subunit Ac45 and the PC2-chaperone 7B2 [26-29]. All of these proteins are somehow 
involved in the transport or processing of POMC in the regulated secretory pathway 
of these prohormone-producing cells. The activation of the biosynthetic machinery is 
accompanied by a number of morphological changes in the melanotrope cells, such as 
an increased cell size, a larger nucleus, and a highly developed ER and Golgi [30]. 
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APP in Xenopus intermediate pituitary cells 
Since APP has been implicated to play an intracellular role in vesicular transport, we 
decided to use the Xenopus intermediate pituitary melanotrope cell model to study its 
biosynthesis and expression. Real-time quantitative PCR- and western blot analysis 
showed that, both at the mRNA- and protein level, APP is threefold up-regulated in 
the melanotrope cells of black compared to white animals. These results indicate that 
APP is somehow involved in the biosynthetic machinery of the active melanotrope 
cells, since the only purpose of these cells is to produce and process vast amounts of 
POMC. Next, we studied the biosynthesis of APP using metabolic pulse-chase cell 
labeling and immunoprecipitation analysis, and found two pools of APP that were 
differentially processed. The major pool of APP (>95%) is N-glycosylated readily 
after its synthesis in the ER, O-glycosylated in the Golgi area, subsequently sulphated 
in the TGN and finally proteolytically processed by an α-secretase-like enzyme 
followed by the release of the large N-terminal processing product APPsα into the 
extracellular space (chapters three and four). Since in Xenopus melanotrope cells APP 
is transported through the secretory pathway, we wondered whether APP is 
cotransported in the same vesicles as POMC. For this purpose, Xenopus intermediate 
pituitaries were incubated in the absence or presence of the dopamine receptor agonist 
apomorphine that specifically blocks secretion of proteins in the regulated secretory 
pathway. Remarkably, when using an apomorphine concentration that clearly 
inhibited the secretion of POMC-derived peptides and mature PC2, the secretion of 
APPsα was not affected (appendix to chapter three). These results indicate that the 
final step of APP transport does not occur via the regulated secretory pathway and 
thus that APP is not cotransported with POMC in the same exocytotic vesicles. 
 
The role of APP in Xenopus intermediate pituitary cells: a model 
Together with the cargo receptor role that has been proposed for APP in vesicular 
transport, the findings of our expression and biosynthetic studies on APP now allow 
us to speculate on the role of APP in the active Xenopus intermediate pituitary cells of 
black-adapted animals. After its synthesis in the ER, immature APP is transported to 
the Golgi apparatus. This first step of APP transport probably occurs via the coatomer 
protein COPII, since the cytoplasmic tail of APP contains the di-phenylalanine 
COPII-binding motif required for the proper ER exit of a number of membrane 
proteins [31]. Probably APP does not play a cargo receptor role in COPII-mediated 
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ER-to-Golgi transport, since, unlike for instance the putative ER-to-Golgi receptors 
ERGIC-53 [32] and the p24 family of proteins [28, 29, 33], APP is not cycling 
between the ER and Golgi. Following its O-glycosylation in the Golgi, APP 
undergoes sulphation in the TGN, the cellular compartment that plays a key role in the 
sorting of lysosomal, plasma membrane and secretory proteins into membrane 
vesicles for transport to their final destination [34]. In the regulated secretory 
pathway, small cargo-containing vesicular structures called immature secretory 
granules (ISG) bud off from the TGN. Subsequently, these ISG fuse to form larger 
granules called mature secretory granules (MSG), of which other vesicular structures 
are again budding off. This latter process is thought to be mediated by clathrin and the 
vesicles formed are thought to contain proteins that are either transported back to the 
TGN, targeted to the lysosomal pathway via early endosomes or destined for 
‘constitutive-like’ secretion (reviewed by Tooze et al. [35] and Arvan and Halban 
[36]). Based on these assumptions, we present a model of the various ways in which 
secretory proteins may be transported through different compartments of the secretory 
pathway in Xenopus intermediate pituitary cells (Figure 1, upper left panel).  
Upon black-background adaptation, the regulated secretory pathway is highly 
activated to be able to produce, process and transport the huge amounts of POMC that 
are required. In our model, the constitutive-like pathway is derived from the regulated 
pathway and it is therefore likely that its components are also induced upon black-
background adaptation. Since APP is threefold induced in the active intermediate 
pituitary cells, but not co-secreted with POMC-derived peptides and other 
components of the regulated secretory pathway, we propose that eventually APP 
becomes not part of the final stages of the regulated but rather of the constitutive-like 
secretory pathway. In this respect, APP might serve as a receptor transporting 
vesicular cargo that is part of the constitutive-like pathway (Figure 1, right panel). The 
cytoplasmic tail of APP contains the NPxY motif involved in clathrin-coated vesicle 
targeting [37] and APP might therefore be sorted into the constitutive-like vesicles 
that bud off from the immature secretory granules in a clathrin-dependent fashion. 
After this budding, APP could interact with the light chain of the kinesin-1 
microtubule motor protein and in this way allow transport of the constitutive-like 
vesicles. 
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Figure 1 Model of the putative roles of APP and APLP2 in the secretory
pathway of Xenopus intermediate pituitary cells 
In the upper left panel, a schematic representation of the various compartments of the
secretory pathway is shown. Sections (1) and (2) are enlarged in the right and lower-left
panel, respectively. (1) During the maturation of immature secretory granules (ISG) to
mature secretory granules (MSG), constitutive-like granules containing APP bud off, a
process that involves clathrin. Following the budding, APP interacts with kinesin, functions
as a kinesin cargo receptor for constitutive-like vesicle transport along microtubules, and is
subsequently proteolytically cleaved. Furthermore, the secreted N-terminal domain of APP
(APPsα) may have an extracellular role. (2) Similar to APP, APLP2 may function as a
kinesin cargo receptor, but then in the constitutive secretory pathway. ER: endoplasmic
reticulum; CGN: cis-Golgi network; TGN: trans-Golgi network; EE: early endosomes; ISG:
immature secretory granules; MSG: mature secretory granules; PM: plasma membrane. 
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Once the cytoplasmic tail of APP is attached to kinesin and the constitutive-like 
vesicle is formed, the large luminal domain of APP is cleaved by α-secretase and the 
vesicle undergoes exocytosis, allowing APPsα to be secreted along with the other 
constitutive-like cargo molecules. The nature of the interaction between APP and 
kinesin light chain is still subject to debate. Whereas some groups have reported a 
direct interaction of APP with the tetra-trico peptide repeat of kinesin light chain [17], 
others concluded that this interaction is mediated by JIP-1, a Jun N-terminal kinase 
(JNK) scaffold protein [38, 39]. JIP-1 has been found to interact with both APP [40] 
and kinesin [41]. Furthermore, studies in Drosophila and C.elegans have shown that 
homologs of JIP-1 and JNK are required for proper vesicular transport [42, 43]. Thus, 
JIP-1 and JNK may also play a role in APP-mediated vesicular transport. 
In addition to the role of APP proposed above or alternatively, the fragments 
generated by the proteolytic processing of APP may represent the functional 
molecules. The large secreted N-terminal APP cleavage product APPsα has been 
reported to function as a growth factor (reviewed by Mattson [15]). Thus, APPsα 
might also function as a growth factor in Xenopus, stimulating processes in cells 
surrounding the pituitary. However, if APP would solely function as a precursor for a 
growth factor for other cells, one would not expect the ubiquitously expressed APP to 
be threefold upregulated in the highly specialized intermediate pituitary cells of black-
adapted animals. Besides APPsα, the proteolytic processing of APP by α-secretase 
results in a stable cell-associated C-terminal fragment called C83, which can serve as 
a substrate for further processing by γ-secretase yielding the APP intracellular domain 
AICD. In our experiments, we did not detect a C-terminal fragment corresponding to 
AICD. This might be due to the fact that AICD is an unstable fragment [44] or 
because it is known to form a complex with Fe65 and might therefore not be 
accessible to the antibody used. 
In Xenopus intermediate pituitary cells, a small fraction (<5%) of newly synthesized 
APP becomes phosphorylated. Once phosphorylated, this pool undergoes no other 
post-translational modifications nor proteolytic processing and remains stable for at 
least 6 hrs. The cytoplasmic tail of APP harbors a number of evolutionarily conserved 
threonine and tyrosine residues that have been reported to be phosphorylated in vivo 
[45-47]. The phosphorylation event plays a role in the interaction of APP with a 
number of other proteins, including X11, Fe65 and JIP-1 [20, 48, 49]. These 
interactions may have different effects on the proteolytic processing and the 
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functioning of APP. For example, the binding of APP to X11 stabilizes APP and 
prevents its processing by β- and γ-secretase, and thereby formation of Aβ [50]. On 
the other hand, its interaction with Fe65 is required for γ-secretase cleavage, the 
production of AICD and the subsequent translocation of this domain to the nucleus for 
the regulation of transcriptional activity [16]. Of special interest is the interaction of 
APP with JIP-1, the aforementioned JNK signaling scaffold protein thought to be 
involved in vesicular cargo transport. Since JNK has been found to phosphorylate 
APP in vitro [38, 51], APP phosphorylation may also be important for its functioning 
as a cargo receptor, although this post-translational modification is not per se required 
for the APP-kinesin interaction [38]. Taken together, phosphorylation of APP may 
mediate the association with different binding partners and thus contribute to many 
different cellular processes. The physiological importance of the phosphorylated pool 
of APP in Xenopus intermediate pituitary cells is questionable, especially since this 
pool represents only a very small portion of the total amount of APP in these cells. 
Because the levels of the phosphorylated pool of APP are similar in intermediate 
pituitary cells derived from either black- or white adapted Xenopus, this pool of APP 
is probably not involved in the transport or processing of POMC. 
 
APLP2 in Xenopus intermediate pituitary cells 
After having identified the APLP2 protein in Xenopus laevis, we decided to study its 
expression in Xenopus intermediate pituitary (chapter four). Surprisingly, and in 
contrast to what was found for APP, in the Xenopus melanotrope cells we identified 
only one pool of APLP2 that was not induced upon black-background adaptation, 
indicating that APLP2 is not directly involved in POMC biosynthesis. These results 
also imply that, although structurally and functionally related, APP and APLP2 have 
different roles in these cells. Next, we studied the biosynthesis of newly synthesized 
APLP2 and found that, like APP, APLP2 is N- and O-glycosylated and sulphated. 
Besides these post-translational modifications, chondroitin sulphate 
glycosaminoglycan (CSGAG) side chains are attached to a small portion of APLP2 
but not to APP. Finally, APLP2 is proteolytically processed in an α-secretase-like 
manner. Whether the large N-terminal processing product of APLP2 is secreted could 
not be determined since a proper antibody against the N-terminal domain of APLP2 
was not available. By using cycloheximide, we were able to show that APLP2 has a 
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slower protein turnover rate when compared to that of APP (chapter four). The 
differences in the induction of expression and in some of the post-translational 
modifications suggest that APP and APLP2 are transported through separate 
compartments of the secretory pathway. Based on our results, we propose that APP 
and APLP2 have similar, but spatially distinct roles. Like APP, APLP2 interacts with 
kinesin light chain and may function as a cargo receptor in vesicular transport [19]. 
Whereas APP might be involved in vesicle formation or transport in the constitutive-
like secretory pathway, APLP2 may fulfill a comparable role within another, e.g. the 
constitutive, secretory pathway in Xenopus intermediate pituitary cells (Figure 1, 
lower left panel). 
As suggested for APP, the N-terminal cleavage product of APLP2 may have a 
function extracellularly, since this APLP2 fragment has been reported to stimulate 
neuritic outgrowth [18]. Likewise, the C-terminal fragment of APLP2 might have an 
intracellular role since it may be further processed to an AICD-like fragment involved 
in transcriptional regulation [20]. However, we found no evidence that the generation 
of such a AICD-like APLP2 fragment occurs in Xenopus intermediate pituitary cells. 
In contrast to APP, a phosphorylated pool of APLP2 was not detected in Xenopus 
intermediate pituitary cells (chapter four),  but the amount of phosphorylated APLP2 
may have been below the detection limit of our experimental conditions. 
Nevertheless, it seems unlikely that a phosphorylated pool of APLP2, if present at all, 
plays a significant role in these prohormone-producing cells. 
Taken together, the results from the biosynthetic studies have shown that in Xenopus 
intermediate pituitary cells most, but not all, post-translational modifications of APP 
and APLP2 are similar. However, the expression data suggest that these two 
structurally related proteins have different roles in the melanotrope cells. APP is 
coordinately expressed with POMC and other components of the regulated secretory 
pathway, and is thus probably somehow involved in the biosynthetic machinery, 
although in the later stages of the secretory pathway APP and POMC are not 
cotransported in the same vesicles. In contrast to APP, APLP2 is not upregulated in 
the active melanotrope cells and therefore not directly linked to POMC biosynthesis 
in these cells. 
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Functional studies on APP and APLP2 using stable Xenopus transgenesis 
As mentioned above, APP and APLP2 likely have different roles in Xenopus 
intermediate pituitary cells, and APP may somehow be linked to POMC biosynthesis. 
To gain more insight into the physiological roles of APP and APLP2 in these cells, we 
decided to generate Xenopus transgenic for these proteins. By using an ~500-bp 
fragment of the POMC gene promoter, in general transgene products can be 
specifically targeted to the intermediate pituitary melanotrope cells [52]. First, we 
generated a number of constructs encoding N-terminal GFP-fusion proteins of either 
wild-type APP, wild-type APLP2 or a number of mutants of these proteins (chapter 
five). Although all of these constructs were properly expressed in transiently 
transfected N2A cells and despite many efforts (e.g. many injection rounds, injecting 
different amounts of transgene DNA and using unfertilized eggs from several 
different females), no animals expressing the transgene fusion protein were generated 
when the constructs were targeted to the intermediate pituitary. We then decided to 
target some of the fusion proteins to other tissues by using the neural-specific β-
tubulin (Ntub), the ubiquitously active elongation factor 1α (EF1α) or the muscle-
specific cardiac actin (Cac) gene promoter. With the Ntub promoter, again no animals 
expressing the APP or the APLP2 transgene were generated. Also in combination 
with the Tet-on inducible gene expression system, no transgene expression of GFP-
APP was found, making it unlikely that neuronal overexpression of GFP-APP would 
be toxic during early embryonic development of Xenopus. However, driving GFP-
APP or GFP-APLP2 expression with the EF1α- or Cac promoter did result in animals 
expressing the transgene product in muscle cells. Nevertheless, one would expect a 
ubiquitous expression pattern for the EF1α promoter. One possibility to explain these 
results is that within the coding sequences of APP and APLP2, a DNA element would 
be present that in Xenopus prevents neuronal and neuroendocrine transgene 
expression of these proteins (chapters five and six). 
Next, the POMC promoter was used to target APP-GFP fusion proteins specifically to 
the intermediate pituitary, but surprisingly, this approach resulted in tadpoles that 
showed fluorescence in the whole brain. Further analysis revealed the presence of a 
DNA element within the 3’-end of Xenopus APP cDNA that acts as an internal 
promoter and is specifically active in neuronal cells during embryonic development, 
but not in the adult stages of Xenopus. The fact that transgene expression of the 
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various GFP-APP fusion proteins could not be accomplished in neuronal or 
neuroendocrine cells together with the presence of the DNA promoter element within 
APP cDNA indeed suggests that this element not only results in transcription and 
subsequent translation of an aberrant product, but may also prevent proper POMC-
promoter-driven transcription and translation of the desired transgene product (i.e. 
intact GFP-APP fusion proteins). Since a human APP-GFP transgene also gave brain 
fluorescence in tadpoles, the element that causes the aberrant activity is apparently 
also present in the human APP sequence. It would be very interesting to see whether 
this phenomenon also occurs in vivo, e.g. whether this DNA element is present and 
active in the Xenopus genome (or that it occurs and is functional only in APP cDNA 
because intron sequences are absent). Computer analysis of the internal promoter 
region resulted in the identification of glucocorticoid responsive elements (GREs) 
present in the APP sequence and binding of the glucocorticoid receptor (GR) to these 
GREs may be responsible for the aberrant transcriptional activity observed in the 
transgenic tadpoles (chapter six). Often in combination with a number of other 
transcription factors, glucocorticoid signaling can both activate and repress 
transcriptional activity (reviewed by Schoneveld et al. [53]). Therefore, the GREs 
within APP cDNA may also be responsible for the prevention of proper transgene 
expression driven by the POMC- and Ntub promoters. In this model, binding of GR 
molecules to the GRE within APP cDNA results in the generation of a transcript that 
causes the aberrant fluorescence observed in the APP-GFP transgenic animals. 
Furthemore, GR binding may also sterically hinder the POMC- or Ntub-driven 
transcriptional machinery, causing the production of a transcript lacking a polyA tail 
that may thus be prone to degradation (Figure 2). A question that remains is whether 
this DNA element within APP cDNA is also active in the brains of other species, 
including human. To further study this, primer-extension or northern blot analysis 
may be performed. At present, the physiological relevance, if any, of this remarkable 
finding remains unclear. 
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Since the targeting of APLP2 did also not result in transgene expression in Xenopus 
brain or pituitary cells, similar to APP cDNA, APLP2 cDNA may contain a 
transcriptionally active DNA element that prevents proper POMC- or Ntub-driven 
transgene expression. The consensus for the GRE is only partially conserved in the 
APLP2 cDNA sequence (TGgcCT in APLP2; consensus TGTTCT). Unlike for APP, 
no aberrant brain fluorescence was observed in the tadpoles when an APLP2-GFP 
fusion construct was used (chapter five). Thus, if the putative GRE element within 
APLP2 is capable of recruiting GR molecules, GR binding apparently does not result 
in an aberrant transcript as observed for APP (Figure 2). One explanation for this may 
be the involvement of other DNA elements that are present in the APP, but not in the 
APLP2 sequence. Thus, the mystery concerning the mechanisms that prevent proper 
transgene expression of APP and APLP2 in Xenopus neuroendocrine and neuronal 
cells is not yet solved. 
Taken together, unfortunately we have not been able to generate transgenic animals 
expressing either APP or APLP2 fusion proteins in Xenopus intermediate pituitary 
cells. The transgenic approach has therefore not led to more insight into the 
physiological roles of these two related proteins in neuroendocrine cells. 
Figure 2 Model of the mechanism by which in Xenopus transgene
expression of APP and APLP2 may be prevented 
Upon binding of the glucocorticoid receptor (GR; indicated by a gray balloon) to the
glucocorticoid responsive elements (GREs) present within APP and APLP2 cDNA, the
normal transcriptional machinery driven by either the POMC or Ntub gene promoter is
blocked (1). Furthermore, in the APP transgenic animals an aberrant transcript is
generated, resulting in the observed fluorescence in the brains of the tadpoles (2). The
aberrant activity may be mediated by the interaction of GR with the GREs present within
APP cDNA. Alternatively or in addition, other transcription factors that may bind to DNA
elements present in the APP but not in the APLP2 cDNA sequence may play a role in this
process. 
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Future prospects 
Although over the last decades much progress has been made in understanding the 
molecular mechanisms that play a role in the pathology of AD, in particular the 
pathological processing of APP to Aβ, the physiological role of APP still remains 
obscure. In order to be able to develop drugs to treat AD, more knowledge is required 
on the role of APP and the processes that determine its intracellular transport and its 
proteolytic processing by the various secretase enzymes in a physiological context. 
One of the normal functions that have been proposed for APP is a cargo-receptor role 
in post-Golgi/vesicular transport [17]. The threefold up-regulation of APP in the 
intermediate pituitary cells of black-adapted vs. white-adapted Xenopus suggests a 
role for this protein in the biosynthesis or transport of POMC. Nevertheless, regarding 
a cargo-receptor function of APP in Xenopus melanotrope cells, a number of 
questions remain unanswered: 1) what is the nature of the vesicles that contain APP? - 
2) what type of cargo is co-transported in APP-containing vesicles? - 3) does APP 
interact with kinesin in these cells? - 4) what is the effect of over- or underexpressed 
APP on the biosynthesis of POMC and other cargo molecules in these cells, or if 
dominant-negative mutants are present that interfere with the role of endogenous 
APP? To address the first question, immuno-EM studies using the C-terminally 
directed anti-APP antibody could provide detailed information on the size of the 
vesicles in which APP is transported through the late stages of the secretory pathway, 
especially when co-labeling studies with anti-POMC antibodies will be able to 
distinguish the granules in the regulated secretory pathway from the vesicles in the 
constitutive-like pathway. Preliminary immuno-EM studies using the anti-APP 
antibody have thus far not been successful.  
The second question may be answered by isolating intact APP-containing vesicles, 
separate the contents of these vesicles via 2D-gel electrophoresis and analyze the 
various proteins via mass-spectrometry. Whether these proteins indeed occur within 
the constitutive-like secretory pathway could subsequently be examined by metabolic 
cell labeling in the presence or absence of apomorphine to determine whether their 
secretion is affected by this agent. For this, specific antibodies directed against the 
constitutive-like proteins are required. To study the third question, regarding a 
possible interaction between APP and the kinesin motor protein in Xenopus 
intermediate pituitary cells, co-immunoprecipitation analysis using anti-APP and anti-
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kinesin antibodies has to be performed under the proper conditions. Unfortunately, 
efforts to detect Xenopus kinesin light chain using antibodies directed against the 
murine orthologue of this protein (a kind gift from dr. Larry Goldstein) have not been 
successful. Therefore, we have not yet been able to confirm an interaction between 
APP and the kinesin motor protein in Xenopus intermediate pituitary cells. Finally, 
answering the fourth question would be most informative for establishing the 
physiological role of APP. In itself, the physiologically inducible melanotrope cell 
model combined with the tissue-specific targeting of transgene products to these cells 
provides an intriguing model to study the in vivo function of proteins operational in 
the secretory pathway. It is therefore unfortunate that we have not been able to 
express APP transgenes in Xenopus intermediate pituitary cells. Although many 
efforts have been made to accomplish this, a few additional options are worthwhile to 
consider. One approach may be the inclusion of insulator sequences in the transgene 
DNA to protect it from neighboring influences within the Xenopus genome. However, 
since we have repeatedly observed the phenomenon of aberrant promoter activity, it 
seems unlikely that in all of these cases the region in the vicinity of the integration site 
of the transgene in the Xenopus genome contained the proper DNA elements to elicit 
this activity. Insulator sequences will therefore probably not silence the activity of the 
internal promoter element within APP cDNA. Secondly, the identification of the 
precise DNA element within APP cDNA that causes the aberrant transcription and as 
such prevents the proper transgene expression of APP, will be of great interest. As 
aforementioned, one of these elements may be the GRE.  
Silent mutations can thus be made within the GREs in Xenopus APP cDNA, thereby 
changing the DNA sequence without affecting the amino acid sequence. This may 
eliminate the internal promoter element, resulting in proper transgene expression of 
the GFP-APP or APP-GFP fusion proteins. Proper transgene expression of these 
fusion proteins will pave the way to the elucidation of the physiological role of APP 
in the Xenopus intermediate pituitary cells. For the p24δ2 putative ER-to-Golgi cargo 
receptor, transgene expression of the p24δ2-GFP fusion protein in Xenopus 
intermediate pituitary cells completely displaced the endogenous p24 proteins [33]. If 
such a displacement would also occur in melanotrope cells expressing the GFP-APP 
transgene, establishing the effect of expressing various APP mutants could be 
informative. For example, APP mutants in which glycosylation, phosphorylation or 
proteolytic processing sites have been changed might not be transported properly 
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through the secretory pathway and may thus cause a phenotype. Furthermore, APP 
mutants that lack the cytoplasmic tail may cause an effect since this domain harbors 
the binding sites for e.g. kinesin and clathrin. Besides overexpressing (dominant-
negative mutants of) APP, knocking down the expression of APP in Xenopus 
intermediate pituitary cells might also be of interest. The RNA interference (RNAi) 
technique is more and more commonly used to knock-down the expression of any 
desired target [54]. Thus far, efforts to use the RNAi procedure in combination with 
Xenopus transgenesis has resulted in only the knock-down of exogenous (GFP) but 
not of endogenous targets, including APP [55]. However, new approaches may be 
used in the future to successfully use RNAi in Xenopus, or introduce siRNAs in 
primary melanotrope cell cultures. Since we know in detail the normal functioning of 
the Xenopus intermediate pituitary cells, generating and analyzing Xenopus that 
overexpress or lack APP in these cells could eventually result in a better 
understanding of the role of APP. With respect to APLP2, similar approaches may be 
applied to gain more insight into its role in Xenopus intermediate pituitary cells. Since 
our biosynthetic and expression data indicate that in these cells APP and APLP2 have 
different functions, the generation of frogs transgenic for APLP2 would enable us to 
study these differences in more detail. 
 
In conclusion, the research described in this thesis illustrates that the Xenopus 
intermediate pituitary cell is an attractive model system to study the role of proteins 
that are operational in the secretory pathway. The fact that APP, but not APLP2, is 
threefold up-regulated in the active melanotrope cells of black-adapted animals shows 
that these two proteins have distinct roles in these cells and indicates that APP is 
somehow involved in POMC biosynthesis or transport. Unfortunately, our efforts to 
further clarify the physiological roles of APP and APLP2 in these neuroendocrine 
cells via stable Xenopus transgenesis were unsuccessful. Yet, more knowledge of the 
function of APP under physiological conditions will help our understanding of the 
pathological processes that contribute to the development of AD, and will increase the 
chances of developing drugs against this neurodegenerative disorder. Since the 
population ages more and more, this will be of great importance to our society. 
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SUMMARY 
 
Alzheimer’s disease (AD) is a neurodegenerative disorder that affects a large part of 
the elderly population and causes memory loss. AD is characterized by two 
morphological features in the brain, namely the presence of intracellular 
neurofibrilary tangles and extracellular protein deposits, known as senile plaques. One 
of the major constituents of the senile plaques is the amyloid-β peptide (Aβ) that is 
generated by the proteolytic processing of the amyloid-β precursor protein APP by 
two enzymes called β- and γ-secretase. Under physiological conditions, APP is 
processed by another enzyme, α-secretase, which prevents the formation of Aβ. 
Although APP is directly involved in the pathology of AD, the normal physiological 
role of APP is still elusive. APP is part of a superfamily that besides APP comprises 
the amyloid-β precursor-like proteins APLP1 and APLP2. Whereas APP has been 
identified in many vertebrate species, including fish, amphibians, reptiles and birds, 
APLPs have been identified only in mammalian species. The goal of the research 
described in this thesis was to explore the physiological role of the APP superfamily 
members APP and APLP2, using the South-African claw-toed frog Xenopus laevis as 
a model organism.  
Chapter one provides an introduction to the various topics dealt with in this thesis, 
including recent literature on AD, the cell biology of APP and the APLPs, and the use 
of Xenopus laevis as an animal model to perform functional studies. 
In chapter two, we describe the identification of the first non-mammalian APLP2. 
Subsequent phylogenetic analysis of the APP superfamily, now including Xenopus 
APLP2, revealed that during evolution two gene duplication events have occurred. In 
contrast to what was previously thought, the first event gave rise to an APP and a 
preAPLP lineage, whereas the second duplication event resulted in the APLP1 and 
APLP2 lineages. In addition, the identification of Xenopus APLP2 has revealed 
evolutionarily conserved regions that helps to delineate functionally important 
domains in the protein. We further observed that Xenopus APLP2 mRNA was 
alternatively spliced in a manner comparable with its mammalian orthologues.  
In chapter three, we study the biosynthesis and expression of APP in the Xenopus 
intermediate pituitary cells. These cells are involved in the adaptation of the animals 
skin color to its background. When the animals are on a black background, these 
Summary 
 
150 
neuroendocrine cells are dedicated to produce huge amounts of the prohormone 
proopiomelanocortin (POMC). Newly synthesized POMC is processed to a number of 
bioactive peptides in the regulated secretory pathway and one of these peptides is the 
α-melanophore stimulating hormone α-MSH that causes dispersion of the pigment 
melanin in the skin melanophores, causing the animals to become black. In contrast, 
on a white background the melanotrope cells are virtually inactive. A number of other 
proteins operational in the regulated secretory pathway are coordinately expressed 
with POMC. We found that APP mRNA- and protein levels were also up-regulated in 
the active melanotrope cells of black-adapted Xenopus. Metabolic cell labeling studies 
revealed the presence of two pools of newly synthesized APP, only one of which was 
up-regulated. The major, up-regulated pool of APP became N- and O-glycosylated, 
sulphated and subsequently proteolytically processed by α-secretase. The large N-
terminal processing product was then secreted into the extracellular space. In contrast, 
the minor pool of APP was phosphorylated and did not undergo any other post-
translational modifications nor proteolytic processing. The fact that APP expression is 
induced in the active melanotrope cells indicates that APP is somehow involved in the 
biosynthesis, transport or processing of POMC. Nonetheless, experiments with an 
agent that selectively inhibits the secretion of regulated proteins revealed that APP 
and POMC are not cotransported in the final stages of the secretory pathway 
(appendix to chapter three). 
In chapter four, the biosynthesis of APLP2 in Xenopus intermediate pituitary is 
studied. Unlike for APP, the mRNA- and protein levels of APLP2 were similar in the 
melanotrope cells of black- and white-adapted animals. Like APP, newly-synthesized 
APLP2 became N- and O-glycosylated, sulphated and proteolytically processed in an 
α-secretase-like manner, while chondroitin sulphate glycosaminoglycan side chains 
were added to APLP2, but not to APP. The fact that APLP2 is not induced upon 
black- background adaptation and that some of its post-translational modifications 
differ from those of APP suggests that these APP superfamily members are 
transported through different subcompartments of the secretory pathway. Thus, these 
two structurally related proteins appear to have separate roles in neuroendocrine cells.  
Together with their high evolutionary conservations, our biosynthetic studies on APP 
and APLP2 suggested an important function for these proteins, and we therefore 
decided to further study their physiological roles via stable Xenopus transgenesis 
(chapters five and six). By using the POMC gene promoter, transgene expression of a 
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protein of interest can be targeted specifically to the intermediate pituitary cells. 
However, targeting GFP-APP as well as GFP-APLP2 fusion proteins in this way did 
not result in animals expressing the transgene. When we used other tissue-specific 
gene promoters, transgene expression was found in Xenopus muscle cells, but not in 
neuronal or neuroendocrine cells. Targeting the APLP2-GFP fusion protein to the 
Xenopus intermediate pituitary again did not result in proper transgene expression. 
Surprisingly, however, targeting the APP-GFP fusion construct specifically to the 
intermediate pituitary cells gave fluorescence throughout the brains of the transgenic 
tadpoles. Detailed analysis of this remarkable observation revealed the presence of an 
internal promoter element within the 3’-end of both the Xenopus and human APP 
cDNA sequence. In the animals transgenic for APP-GFP, this promoter activity 
resulted in an aberrant transcript that was subsequently translated. Computer analysis 
of the region within APP cDNA responsible for the promoter activity revealed the 
presence of putative glucocorticoid responsive elements (GREs) that, perhaps in 
combination with other transcription factors, may cause the aberrant activity observed 
in the transgenic tadpoles. Moreover, since we have not been able to generate animals 
expressing the APP transgene in neuroendocrine and neuronal cells, this promoter 
element may also be responsible for preventing such transgene expression. Like for 
APP, no transgene expression of APLP2 was observed in the intermediate pituitary or 
brain cells. Thus, the coding sequence of APLP2 cDNA may also contain an 
interfering DNA element (for instance a GRE), preventing proper transgene 
expression in Xenopus neuroendocrine cells, although the APLP2-GFP fusion 
construct did not result in an aberrant brain fluorescence as found in the APP-GFP 
transgenic tadpoles. 
Finally, in chapter seven the results described in this thesis are discussed and put in a 
broader perspective. Based on our biosynthetic studies and together with the cargo 
receptor function that has been proposed for both APP and APLP2, we hypothesize 
that in Xenopus intermediate pituitary cells APP fulfills such a cargo receptor role 
within the constitutive-like secretory pathway, whereas APLP2 has a similar role but 
then in a separate subcompartment, e.g. the constitutive secretory pathway. This 
hypothesis is illustrated in a model presented in this chapter. Furthermore, 
recommendations for future research are provided. 
In conclusion, the research described in this thesis suggests that in neuroendocrine 
cells APP plays an important role within the secretory pathway. Furthermore, the 
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different biosynthetic properties of APP and APLP2 indicate that these two 
structurally related proteins have similar, but spatially distinct, roles in these cells. 
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SAMENVATTING 
 
De ziekte van Alzheimer is een hersenaandoening die geheugenverlies veroorzaakt en 
een groot deel van de oudere bevolking treft. De ziekte wordt gekenmerkt door twee 
morfologische aspecten, namelijk de aanwezigheid van intracellulaire fibrilachtige 
structuren, tangles genoemd, en extracellulaire eiwitophopingen, seniele plaques 
genoemd. Eén van de hoofdbestanddelen van deze plaques is het amyloid-β peptide, 
dat ontstaat door de pathologische klieving van het amyloid-β precursor eiwit APP 
door de enzymen β- en γ-secretase. Onder fysiologische condities wordt APP gekliefd 
door een ander enzym dat α-secretase heet en kan er geen amyloid-β ontstaan. 
Alhoewel APP direct betrokken is bij de ziekte van Alzheimer, is er maar weinig 
bekend over de normale functie van het eiwit. Naast APP bestaan er twee gerelateerde 
eiwitten, de amyloid-β precursor-gelijkende eiwitten APLP1 en APLP2. Daar waar 
APP voorkomt in vele gewervelde diersoorten, onder meer in vissen, amfibieën, 
reptielen en vogels, zijn APLP1 en -2 tot dusver alleen in zoogdieren geidentificeerd. 
Het doel van het onderzoek beschreven in dit proefschrift was om de normale, 
fysiologische rol van APP en APLP2 te bestuderen, waarbij de Zuid-Afrikaanse 
klauwpad Xenopus laevis als diermodel gebruikt is. 
In hoofdstuk één wordt een uitgebreide introductie gegeven van de verschillende 
onderwerpen die in dit proefschrift behandeld worden, waaronder de ziekte van 
Alzheimer, celbiologische aspecten van APP, APLP1 en APLP2, en het gebruik van 
Xenopus laevis als diermodel.  
In hoofdstuk twee wordt de identificatie van APLP2 in Xenopus beschreven, de eerste 
niet-zoogdier soort waarin dit eiwit wordt aangetroffen. Een fylogenetische analyse 
van de APP familie, nu inclusief Xenopus APLP2, wees uit dat gedurende de evolutie 
twee genduplicaties hebben plaatsgevonden. In tegenstelling tot wat eerder is 
beschreven, bleek dat de eerste duplicatie een APP-tak en een pre-APLP tak heeft 
voortgebracht, waarna tijdens de tweede duplicatie uit deze laatste tak APLP1 en 
APLP2 zijn ontstaan. Verder heeft de identificatie van APLP2 in Xenopus 
geresulteerd in het vinden van evolutionair geconserveerde regio’s in het eiwit, die op 
hun beurt weer kunnen helpen functioneel belangrijke domeinen te karakteriseren. 
Bovendien hebben we gevonden dat het messenger-RNA (mRNA) van APLP2 in 
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Xenopus op een soortgelijke manier door de cellen wordt verwerkt, vergeleken met 
het mRNA van APLP2 in zoogdieren.  
Hoofdstuk drie beschrijft de bestudering van de biosynthese van APP in de 
melanotrope cellen gelegen in de hypofyse-middenkwab van Xenopus. Deze cellen 
zijn betrokken bij het proces van achtergrondadaptatie van de huid. Wanneer de 
klauwpad zich op een zwarte achtergrond bevindt, gaan deze neuroendocriene cellen 
grote hoeveelheden van het prohormoon proopiomelanocortine (POMC) aanmaken. 
Nieuw-gemaakt POMC wordt in de gereguleerde secretieroute gekliefd tot een aantal 
kleinere bioactieve peptiden. Eén van deze peptiden is het α-melanofoor-stimulerende 
hormoon α-MSH, dat zorgt voor de dispersie van het pigment melanine in de 
huidcellen met als gevolg dat de huid van de dieren zwart wordt. Echter wanneer de 
dieren zich op een witte achtergrond bevinden, zijn de melanotrope cellen nauwelijks 
actief. Naast POMC komen er een aantal andere eiwitten in de gereguleerde 
secretieroute verhoogd voor in de melanotrope cellen van de zwarte dieren vergeleken 
met die van witte dieren. Wij hebben gevonden dat ook APP, zowel op mRNA- als op 
eiwitniveau, verhoogd tot expressie kwam in de actieve melanotrope cellen van zwart-
geadapteerde Xenopus. Door de cellen radio-actief gelabelde eiwitten te laten 
aanmaken, kwamen we erachter dat er twee typen APP gesynthetiseerd worden in 
deze cel, waarvan er slechts één verhoogd tot expressie komt in zwarte dieren. Dit 
type APP, tevens het meest voorkomende, wordt na de aanmaak N- en O-
geglycosyleerd, gesulfateerd en uiteindelijk gekliefd door het enzym α-secretase, 
waarna het N-terminale klievingsproduct door de cellen wordt uitgescheiden in het 
extracellulaire medium. 
In tegenstelling tot het meest voorkomende type APP, wordt de andere, kleine 
hoeveelheid APP alleen gefosforyleerd en ondergaat het verder geen post-
translationele modificaties en ook geen proteolytische klieving. Het gegeven dat APP 
verhoogd voorkomt in actieve melanotrope cellen wijst erop dat APP op de één of 
andere manier betrokken is bij de biosynthese, het transport of de verwerking van 
POMC. Desalniettemin hebben experimenten waarbij de secretie van gereguleerde 
eiwitten specifiek geremd werd, uitgewezen dat APP en POMC niét samen 
getransporteerd worden in de laatste fase van de secretieroute (appendix van 
hoofdstuk drie). 
In hoofdstuk vier wordt de biosynthese van APLP2 in de hypofyse-middenkwab 
cellen beschreven. In tegenstelling tot APP, waren de mRNA –en eiwitniveaus van 
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APLP2 gelijk in melanotrope cellen van zwart- en wit geadapteerde dieren. Net als 
APP werd ook nieuw gemaakt APLP2 N- en O-geglycosyleerd, gesulfateerd en 
gekliefd door een soort α-secretase enzym, terwijl chondroitine sulfaat 
glycosaminoglycaan ketens werden toegevoegd aan APLP2, maar niet aan APP. Het 
feit dat APLP2 niet verhoogd wordt tijdens de adaptatie naar een zwarte achtergrond 
en dat APP en APLP2 niet exact dezelfde post-translationele modificaties ondergaan, 
doet vermoeden dat deze twee familieleden door verschillende subcompartimenten 
van de secretieroute getransporteerd worden. Het lijkt er dus op dat deze twee 
structureel gerelateerde eiwitten verschillende functies uitoefenen in neuroendocriene 
cellen. 
Samen met hun hoge evolutionaire conservering hebben onze biosynthetische studies 
aan APP en APLP2 uitgewezen dat deze eiwitten wellicht een belangrijke functie 
vervullen. Daarom hebben we besloten hun fysiologische rol verder te bestuderen met 
behulp van de Xenopus transgenese methode (hoofdstukken vijf en zes). Door de 
promoter van het POMC-gen te gebruiken kunnen eiwitten op deze manier specifiek 
tot expressie worden gebracht in de melanotrope cellen van de hypofyse middenkwab. 
In een poging GFP-APP en GFP-APLP2  fusie-eiwitten naar deze cellen te ‘sturen’, 
zijn we er helaas niet in geslaagd dieren te genereren die het transgen tot expressie 
brachten. Wanneer andere weefselspecifieke genpromoters werden gebruikt, kwam 
het transgen wel tot expressie in spiercellen van de klauwpad, maar niet in hersen- of 
neuro-endocriene cellen. Ook een APLP2-GFP fusie-eiwit kwam niet tot expressie in 
de melanotrope cellen van Xenopus. Verrassend genoeg resulteerde het specifiek 
sturen van het APP-GFP fusie-construct enkel en alleen naar de melanotrope cellen, in 
fluorescentie (en dus transgen-expressie) in alle hersencellen van de kikkervis. Een 
gedetaileerde analyse van deze opmerkelijke waarneming leidde tot de identificatie 
van een intern promoter element aanwezig in het 3’-uiteinde van het coderende-DNA 
(cDNA) van zowel Xenopus als humaan APP. In de dieren die transgene waren voor 
het APP-GFP construct zorgde deze promoteractiviteit ervoor dat er een afwijkend 
transcript ontstond, dat vervolgens getransleerd werd naar een eiwit. Computeranalyse 
van de regio in APP cDNA die verantwoordelijk is voor de promoteractiviteit, 
resulteerde in de aanwezigheid van vermoedelijke glucocorticoid responsive elements 
(GREs) die, wellicht tesamen met andere transcriptiefactoren, de afwijkende activiteit 
in de transgene kikkervissen veroorzaken. Bovendien zou dit element, aangezien we 
er niet in geslaagd zijn het APP transgen tot expressie te brengen in neuro-endocriene 
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en hersencellen, ook verantwoordelijk kunnen zijn voor de preventie van deze 
transgene expressie. Net als voor APP, werd er geen transgene expressie van APLP2 
waargenomen in de melanotrope en de hersencellen van Xenopus. Daarom zou ook 
het cDNA van APLP2 een storend element (bijvoorbeeld een GRE) kunnen bevatten 
dat de correcte transgen expressie verhindert, alhoewel een afwijkend transcript zoals 
aangetroffen in dieren transgeen voor het APP-GFP construct, niet waargenomen 
werd bij het APLP2-GFP construct.   
Tot slot worden in hoofdstuk zeven de resultaten beschreven in dit proefschrift 
bediscussieerd en in een wat breder perspectief geplaatst. Naar aanleiding van onze 
biosynthetische studies tesamen met de cargo-receptor rol die is voorgesteld voor 
zowel APP als APLP2, hebben we een hypothese opgesteld waarin we 
veronderstellen dat in de melanotrope cellen van de hypofyse middenkwab, APP een 
cargo-receptor rol vervult in de constitutief-afgeleide secretieroute, terwijl APLP2 een 
soortgelijke functie heeft, maar dan in de constitutieve secretieroute. Deze aanname 
wordt verder geillustreerd in een model. Verder worden er nog aanbevelingen gedaan 
voor eventuele vervolgstudies.   
Samengevat veronderstelt het onderzoek beschreven in dit proefschrift dat APP in de 
secretieroute van neuroendocriene cellen een belangrijke rol vervult. Verder  wijzen 
de verschillen in biosynthetische eigenschappen van APP en APLP2 erop dat deze 
structureel gerelateerde eiwitten soortgelijke functies vervullen, maar op een andere 
plaats in deze cellen. 
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